Document:

EX-10.9

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

Exhibit 10.9 
 EXECUTION
VERSION 
 EXCLUSIVE LICENSE AGREEMENT 

by and between 
 AMGEN
INC. 
 and 

VIGIL NEUROSCIENCE, INC. 

Dated as of July 9, 2020 
 Amgen
Proprietary – Confidential 
 Amgen Proprietary – Confidential/Vigil Proprietary & Confidential 

Amgen Contract No. 2020044836 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1. DEFINITIONS
	  	 	1	 
	 ARTICLE 2. LICENSE GRANT
	  	 	13	 
	 Section 2.1
	 	Grant	  	 	13	 
	 Section 2.2
	 	Sublicenses	  	 	14	 
	 Section 2.3
	 	Retained Rights and Limitations	  	 	14	 
	 Section 2.4
	 	[***]	  	 	14	 
	 Section 2.5
	 	Transfer of Licensed Know-How and Licensed Materials	  	 	15	 
	 Section 2.6
	 	Covenant Not to Sue	  	 	20	 
	 Section 2.7
	 	No Other Rights	  	 	21	 
	 Section 2.8
	 	Restrictions	  	 	21	 
	 ARTICLE 3. EQUITY, MILESTONES, ROYALTIES AND PAYMENTS
	  	 	21	 
	 Section 3.1
	 	Equity in VIGIL	  	 	21	 
	 Section 3.2
	 	Upfront and Milestone Payments	  	 	21	 
	 Section 3.3
	 	Royalties	  	 	22	 
	 Section 3.4
	 	Method of Payment	  	 	24	 
	 Section 3.5
	 	Royalty Reports	  	 	24	 
	 Section 3.6
	 	Currency Conversion	  	 	24	 
	 Section 3.7
	 	Late Payments	  	 	25	 
	 Section 3.8
	 	Records and Audits	  	 	25	 
	 Section 3.9
	 	Taxes	  	 	25	 
	 ARTICLE 4. PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT
	  	 	27	 
	 Section 4.1
	 	Intellectual Property Ownership	  	 	27	 
	 Section 4.2
	 	Prosecution and Maintenance	  	 	28	 
	 Section 4.3
	 	Enforcement	  	 	29	 
	 Section 4.4
	 	Defense of Third Party Claims	  	 	30	 
	 Section 4.5
	 	Recovery	  	 	30	 
	 Section 4.6
	 	Patent Term Extensions and Filings for Regulatory Exclusivity Periods	  	 	30	 
	 Section 4.7
	 	Patent Marking	  	 	30	 
	 ARTICLE 5. OBLIGATIONS OF THE PARTIES
	  	 	31	 
	 Section 5.1
	 	Responsibility	  	 	31	 
	 Section 5.2
	 	Diligence	  	 	31	 
	 Section 5.3
	 	Reports	  	 	31	 
	 Section 5.4
	 	Distracting Programs	  	 	31	 
	 Section 5.5
	 	Amgen Restrictions	  	 	33	 
	 Section 5.6
	 	Reasonable Restrictions	  	 	33	 
	 ARTICLE 6. REPRESENTATIONS
	  	 	33	 
	 Section 6.1
	 	Mutual Representations and Warranties	  	 	33	 
	 Section 6.2
	 	Additional AMGEN Warranties	  	 	34	 
	 Section 6.3
	 	Disclaimer	  	 	35	 
	 Section 6.4
	 	Additional VIGIL Warranties	  	 	35	 
	 Section 6.5
	 	VIGIL Covenants	  	 	36	 
	 Section 6.6
	 	AMGEN Covenants	  	 	39	 
	 ARTICLE 7. INDEMNIFICATION
	  	 	39	 
	 Section 7.1
	 	Indemnity	  	 	39	 
	 Section 7.2
	 	LIMITATION OF DAMAGES	  	 	40	 

  

  
 i 

							
	 Section 7.3
	 	Insurance	  	 	40	 
	 ARTICLE 8. CONFIDENTIALITY
	  	 	41	 
	 Section 8.1
	 	Confidential Information	  	 	41	 
	 Section 8.2
	 	Terms of this Agreement; Publicity	  	 	42	 
	 Section 8.3
	 	Publications	  	 	43	 
	 Section 8.4
	 	Relationship to the Confidentiality Agreement	  	 	44	 
	 Section 8.5
	 	Attorney-Client Privilege	  	 	44	 
	 ARTICLE 9. TERM & TERMINATION
	  	 	44	 
	 Section 9.1
	 	Term	  	 	44	 
	 Section 9.2
	 	Termination by AMGEN	  	 	44	 
	 Section 9.3
	 	Termination by VIGIL	  	 	46	 
	 Section 9.4
	 	Termination Upon Bankruptcy	  	 	47	 
	 Section 9.5
	 	Effects of Termination	  	 	47	 
	 Section 9.6
	 	Survival	  	 	50	 
	 ARTICLE 10. MISCELLANEOUS
	  	 	51	 
	 Section 10.1
	 	Entire Agreement; Amendment	  	 	51	 
	 Section 10.2
	 	Section 365(n) of the Bankruptcy Code	  	 	51	 
	 Section 10.3
	 	Independent Contractors	  	 	51	 
	 Section 10.4
	 	Dispute Resolution; Governing Law; Jurisdiction	  	 	52	 
	 Section 10.5
	 	Notice	  	 	52	 
	 Section 10.6
	 	Compliance With Law; Severability	  	 	53	 
	 Section 10.7
	 	Non-Use of Names	  	 	53	 
	 Section 10.8
	 	Successors and Assigns	  	 	53	 
	 Section 10.9
	 	Sale Transaction or AMGEN Acquisition	  	 	53	 
	 Section 10.10
	 	Waivers	  	 	54	 
	 Section 10.11
	 	No Third Party Beneficiaries	  	 	54	 
	 Section 10.12
	 	Headings; Exhibits	  	 	54	 
	 Section 10.13
	 	Interpretation	  	 	54	 
	 Section 10.14
	 	Equitable Relief	  	 	54	 
	 Section 10.15
	 	Force Majeure	  	 	55	 
	 Section 10.16
	 	Further Assurances	  	 	55	 
	 Section 10.17
	 	Counterparts	  	 	55	 

 Exhibit List 
  

			
	Exhibit A	  	Licensed Know-How & Licensed Materials
	Exhibit B	  	Licensed Patents
	Exhibit C	  	Permitted CMOs/CROs
	Exhibit D	  	Licensed Compounds
	Exhibit E	  	Supplemental Confidentiality Agreement
	Exhibit F	  	Reservation Agreement
	Exhibit G	  	Ongoing Studies
	Exhibit H	  	[***] Order Summary

  
 ii 

 EXCLUSIVE LICENSE AGREEMENT 

This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of July 9, 2020 (the “Effective
Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“AMGEN”), and VIGIL NEUROSCIENCE, INC., a Delaware corporation having an address at 400
Technology Square, 10th Floor, Cambridge, MA 02139 (“VIGIL”). VIGIL and AMGEN are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 
 WHEREAS,
AMGEN possesses certain rights to patents and other intellectual property related to compounds binding to TREM2 (as hereinafter defined); and 

WHEREAS, VIGIL desires to license from AMGEN such patents and intellectual property rights, and to commercially develop, manufacture,
use and distribute products containing compounds that bind to TREM2, and AMGEN desires to grant such a license to VIGIL in accordance with the terms and conditions of this Agreement; and 

WHEREAS, simultaneous with the execution of this Agreement, AMGEN and Atlas Venture Life Science Advisors LLC
(“Atlas”) have executed that certain Guarantee pursuant to which Atlas has guaranteed the performance of VIGIL’s payment obligations under Section 2.5.3; and 

WHEREAS, simultaneous with the execution of this Agreement, Amgen and VIGIL have executed that certain Side Letter (the “Equity
Side Letter”), pursuant to which, VIGIL has committed to issue to AMGEN equity of VIGIL and Amgen has been further granted certain rights with respect to [***], as partial consideration for the licenses and covenants granted in this
Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual promises and covenants contained in this Agreement, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

ARTICLE 1. DEFINITIONS 
 All references to
particular Exhibits, Articles or Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have
the following meanings: 
  

			
		
	Section 1.1	  	“Abandoned Patent Right” has the meaning set forth in 4.2.2(AMGEN Step-In Right).
		
	Section 1.2	  	“Acquisition Transaction” has the meaning set forth in Section 2.4 [***].
		
	Section 1.3	  	“Agreement” has the meaning set forth in the Preamble.

  
 -1- 

			
		
	Section 1.4	  	“Affiliate” means, with respect to any Person, any other Person that, directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, for as long
as such control exists. For purposes of this Section, “control” means the direct or indirect ownership of more than fifty percent (50%) of the voting or economic interest of a Person, or the power, whether pursuant to contract, ownership
of securities or otherwise, to direct the management and policies of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and
sublicense rights, under this Agreement by reason of being an Affiliate of such Party.
		
	Section 1.5	  	“AMGEN” has the meaning set forth in the Preamble.
		
	Section 1.6	  	“AMGEN Acquiree” has the meaning set forth in Section 10.9 (Sale Transaction or AMGEN Acquisition).
		
	Section 1.7	  	“AMGEN Acquisition” has the meaning set forth in Section 10.9 (Sale Transaction or AMGEN Acquisition).
		
	Section 1.8	  	“AMGEN Cell Line” means the [***].
		
	Section 1.9	  	“AMGEN Indemnified Parties” has the meaning set forth in Section 7.1.2 (By VIGIL).
		
	Section 1.10	  	“AMGEN Shares” has the meaning set forth in Section 3.1.
		
	Section 1.11	  	“Anti-Corruption Laws” means Laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant
function, including without limitation, the U.S. Foreign Corrupt Practices Act (FCPA) as amended, the UK Bribery Act 2010, as amended, and any other applicable laws, rules and regulations relating to or concerning public or commercial bribery or
corruption.
		
	Section 1.12	  	“Audited Party” has the meaning set forth in Section 3.8 (Records and Audits).
		
	Section 1.13	  	“Calendar Quarter” means a three-month period beginning on January, April, July or October 1st.
		
	Section 1.14	  	“Calendar Year” means a one-year period beginning on January 1st and ending on December 31st.
		
	Section 1.15	  	“Change of Control” means (a) the closing of the sale, transfer, exclusive license or other disposition of all or substantially all of VIGIL’s assets or intellectual property, (b) the consummation of
the merger or consolidation of VIGIL with or into another entity (except a merger or consolidation in which the holders of capital stock of VIGIL immediately prior to such merger or consolidation continue to hold at least fifty percent (50%) of the
voting power of the capital stock of VIGIL or the surviving or acquiring entity), (c) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of
affiliated persons (other than an underwriter of VIGIL’s securities), of VIGIL’s securities if, after such closing, such person or group of affiliated persons would hold fifty percent (50%) or more of the outstanding voting stock of VIGIL
(or the surviving or acquiring entity) or (d) a liquidation, dissolution or winding up of VIGIL.

  
 -2- 

			
		
	Section 1.16	  	“CNS Field” means diseases of the central nervous system.
		
	Section 1.17	  	“Commercially Reasonable Efforts” means those efforts and resources commensurate with those efforts commonly used in the pharmaceutical industry by [***] in connection with the development or commercialization of
pharmaceutical products that are of similar status, taking into account the proprietary position of the product (including intellectual property scope, subject matter and coverage), safety and efficacy, product profile, competitiveness of the
marketplace, the regulatory status and approval process, anticipated or approved labeling, present and future market potential, the probable profitability of the applicable product (including pricing and reimbursement status achieved or likely to be
achieved) and other relevant factors such as technical, legal, scientific or medical factors. In determining the level of efforts constituting “Commercially Reasonable Efforts,” the following shall not be taken into account:
(a) any other pharmaceutical product VIGIL or any of its Affiliates is then researching, developing or commercializing, alone or with one or more collaborators or (b) any payment required to be made to AMGEN hereunder.
		
	Section 1.18	  	“Confidential Information” has the meaning set forth in Section 8.1.1 (Confidential Information).
		
	Section 1.19	  	“Consulting Support” means any work or services to be performed by AMGEN and is requested by VIGIL and agreed upon by Amgen that is related to the Exploitation of the Licensed Materials and Licensed Know
How.
		
	Section 1.20	  	“Control” or “Controlled” means, with respect to any Know-How, material, Patent Right, or other intellectual property right, the possession (whether by
ownership or license) by a Party or its Affiliate of the ability to grant to the other Party a license, sublicense or access as provided herein to such Know-How, material, Patent Right, or other intellectual
property right, without violating Laws or the terms of any agreement or other arrangement with any Third Party, or being obligated to pay any royalties or other consideration therefor, in existence as of the time such Party or its Affiliates would
first be required hereunder to grant the other Party such license, sublicense or access.
		
	Section 1.21	  	“Cover” means (a) with respect to Know-How, such Know-How was used in the Exploitation of the product, and (b) with respect
to a Patent Right, (1) a Valid Claim would (absent a license thereunder or ownership thereof) be Infringed by the Exploitation of the product or (2) such Patent Right includes generic or specific disclosure of the product or use thereof
wherein such disclosure is not claimed but a claim to such disclosure would be a Valid Claim; provided, however, that in determining whether a Valid Claim that is a claim of a pending application would be Infringed, it
shall be treated as if issued as then currently being prosecuted. Cognates of the word “Cover” shall have correlative meanings.
		
	Section 1.22	  	“Covered Individuals and Entities” (or, in the singular, “Covered Individual and Entity”) means any one or more of an HCP, HCI, Payor, Purchaser, Healthcare Industry Professional Society and Trade
Association, and entities owned or operated by any one or more of an HCP, HCI, Payor, Purchaser, or Healthcare Industry Professional Societies or Trade Association.

  
 -3- 

			
		
	Section 1.23	  	“Defending Party” has the meaning set forth in Section 4.4.1.
		
	Section 1.24	  	“De Novo Compound” means any and all [***] that are discovered, researched, developed or otherwise Exploited by VIGIL, its Affiliates or Sublicensees that [***], but specifically excludes all Licensed Compounds and
Program Compounds.
		
	Section 1.25	  	“De Novo Product” means any pharmaceutical or biopharmaceutical product containing a De Novo Compound in any form or formulation, and optionally in combination with one or more other active agents, provided that if
a product includes any Licensed Compound or Program Compound, such product constitutes a “Licensed Product” not a De Novo Product.
		
	Section 1.26	  	“Disclosing Party” has the meaning set forth in Section 8.1.1 (Confidential Information).
		
	Section 1.27	  	“Distracting Product” means any compound or product (but excluding any Licensed Product) that binds to TREM2 [***] (specifically including a De Novo Product) unless and until VIGIL has elected to treat such compound
or product as a “Newly Added Product” pursuant to Section 5.4.2.
		
	Section 1.28	  	“Distracting Program” means the clinical development, commercialization or manufacture of any Distracting Product.
		
	Section 1.29	  	“Distracting Transaction” means any transaction entered into by VIGIL or its Affiliates after the Effective Date whereby a Third Party that is engaged in a Distracting Program becomes an Affiliate of
VIGIL.
		
	Section 1.30	  	“Distracting Transaction Affiliates” means those entities that are or would become Affiliates of VIGIL by virtue of a Distracting Transaction.
		
	Section 1.31	  	“Divest” means, with respect to any Distracting Program, the sale, exclusive license or other transfer of substantially all of the right, title and interest in and to such Distracting Program, including technology, Know-How, intellectual property and other assets materially relating thereto, to an independent Third Party, without the retention or reservation of any rights or interest (other than an economic interest) in such
Distracting Program by the relevant Party or its Affiliates.
		
	Section 1.32	  	“Dollars” or “$” means U.S. Dollars.
		
	Section 1.33	  	“Effective Date” has the meaning set forth in the Preamble.
		
	Section 1.34	  	“EMA” means the European Medicines Agency or any successor entity thereto.
		
	Section 1.35	  	“Enforcing Party” has the meaning set forth in Section 4.3.3 (Progress Reports).
		
	Section 1.36	  	“Exclusively Licensed Know-How” means the Licensed Non-Manufacturing Know-How set forth on
Exhibit A under the heading “Exclusively Licensed Know-How”.
		
	Section 1.37	  	“Exploit” means to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, a product. Cognates of the word
“Exploit” shall have correlative meanings.

  
 -4- 

			
		
	Section 1.38	  	“FDA” means the United States Food and Drug Administration or any successor entity thereto.
		
	Section 1.39	  	“Financing Agreements” means those agreements by and among VIGIL, AMGEN and the various investors to effect the Series A Financing.
		
	Section 1.40	  	“First Commercial Sale” means, with respect to a product in any country, the first sale for end use or consumption of such product in such country after Marketing Approval has been granted in such country. First
Commercial Sale excludes any sale or other distribution of such product for use in a clinical trial or other development activity, promotional use (including samples) prior to Marketing Approval or for compassionate use or on a named patient
basis.
		
	Section 1.41	  	“FTE Rate” means $[***] per hour. The FTE Rate shall be increased by [***] percent ([***]%) each calendar year, beginning with the [***] calendar year.
		
	Section 1.42	  	[***]
		
	Section 1.43	  	“GAAP” means the then current generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as
having the right to establish such principles in the United States, in each case consistently applied.
		
	Section 1.44	  	“Generic Product” means, with respect to a Small Molecule Product in a particular regulatory jurisdiction, on a Small Molecule
Product-by- Small Molecule Product and country-by-country basis, any pharmaceutical
product (other than a Small Molecule Product under this Agreement) that (a) is approved by the Regulatory Authority in such country for at least one indication for which such Small Molecule Product obtained Regulatory Approval from the
applicable Regulatory Authority in such jurisdiction through an abbreviated new drug application as defined in 21 U.S.C. 355(j) (or equivalent outside the United States) and (b) is sold in such jurisdiction by a Third Party that is not a
Sublicensee and did not purchase such product in a chain of distribution that included any of VIGIL or its Affiliates or Sublicensees.
		
	Section 1.45	  	“Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision.
		
	Section 1.46	  	“Government Official” means (i) any Person employed by or acting on behalf of a Governmental Authority; (ii) any political party, party official or candidate; (iii) any Person who holds or performs
the duties of an appointment, office or position created by custom or convention; and (iv) any Person who holds himself out to be the authorized intermediary of any of the foregoing.
		
	Section 1.47	  	“Healthcare Industry Professional Society and Trade Association” means a non-profit or tax exempt healthcare industry organization seeking to further a particular profession,
the interests of individuals engaged in that profession, or the public interest (examples of such include without limitation the American Society of Hematology, the North American Society for Dialysis and Transplantation, the American Society of
Hypertension, the American Cancer Society and the American Society of Clinical Oncology).

  
 -5- 

			
		
	Section 1.48	  	“Healthcare Institution” or “HCI” means a facility that provides health maintenance, or treats illness and injury, and can include without limitation any hospital, convalescent hospital, dialysis
center, health clinic, nursing home, extended care facility, or other institution devoted to the care of sick, infirm, or aged persons, and is in a position to purchase or influence a purchasing decision for any human therapeutic product marketed,
distributed, or sold or any service related thereto provided by or on behalf of Amgen or any of its Affiliates (each an “Amgen Therapeutic Product”).
		
	Section 1.49	  	“Healthcare Professional” or “HCP” means any person licensed to prescribe an Amgen Therapeutic Product, as well as anyone working for a person licensed to prescribe an Amgen Therapeutic Product
and/or in a position to influence a purchasing decision, including without limitation physicians and other providers (e.g., nurses, pharmacists), dialysis providers, and other office personnel.
		
	Section 1.50	  	“Infringe” or “Infringement” means any infringement as determined by Law, including, without limitation, direct infringement, contributory infringement or any inducement to infringe.
		
	Section 1.51	  	“Initiation” means, with respect to a human clinical trial, the first dosing in the first patient in such clinical trial.
		
	Section 1.52	  	“International Trade Laws” means all applicable United States laws, regulations, and orders pertaining to trade and economic sanctions, export controls, and customs, including, such laws, regulations, and orders
administered and enforced by the U.S. Department of the Treasury, the U.S. Department of Commerce, the U.S. Department of State and the U.S. Customs and Border Protection agency, including but not limited to the sanctions administered and enforced
by the Office of Foreign Assets Control (OFAC), the United States Export Administration Act of 1979, as amended, and the Export Control Reform Act of 2018, and implementing Export Administration Regulations (EAR); the Arms Export Control Act and
implementing International Traffic in Arms Regulations (ITAR); and all comparable applicable export and import Laws outside the United States for each country where the Parties or their agents and representatives conduct business.
		
	Section 1.53	  	“IPO” means VIGIL’s initial public offering or another transaction, including a reverse merger, pursuant to which VIGIL (or its successor) first has its equity securities listed on a recognized stock exchange
or trading system (e.g., NYSE or NASDAQ).
		
	Section 1.54	  	“Issuing Party” has the meaning set forth in Section 8.2.2 (Review).
		
	Section 1.55	  	“Know-How” means techniques, technology, trade secrets, inventions (whether patentable or not), methods, data (both primary and summary), reports and results (including
pharmacological, toxicological and clinical data and results), analytical and quality control data and results, regulatory documents, cell line technology and development information, manufacturing process information and other
information.

  
 -6- 

			
		
	Section 1.56	  	“Law” means, individually and collectively, any and all laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable
jurisdiction, including, but not limited to, Anti-Corruption Laws, International Trade Laws, those concerning data privacy and protection, and healthcare compliance.
		
	Section 1.57	  	“Licensed Compound” means any compound that: (a) is Controlled by AMGEN or its Affiliates; (b)(1) for a monoclonal antibody, binds to TREM2 [***] and (2) for a small molecule, binds to TREM2 and has
agonist activity on TREM2 [***]; and (c) was discovered, researched or developed in the conduct of the Licensed MAB Program or the Licensed Small Molecule Program by AMGEN or its Affiliates prior to the Effective Date. The Licensed Compounds
are listed or referenced on Exhibit D.
		
	Section 1.58	  	“Licensed Field” means any and all uses.
		
	Section 1.59	  	“Licensed Non-Manufacturing Know-How” means all proprietary Know-How that both (a) is
Controlled by AMGEN or its Affiliates and (b) [***] in the Licensed MAB Program and Licensed Small Molecule Program, in each case (a) and (b) prior to the Effective Date, as set forth on Exhibit A; provided, however,
“Licensed Non-Manufacturing Know-How” excludes (1) any Know-How relating to AMGEN’s or its Affiliates
manufacturing platform or activities, including, specifically, the Licensed Manufacturing Know-How and (2) any Know-How solely relating to the research,
development, manufacture or use of [***].
		
	Section 1.60	  	“Licensed Know-How” means the Licensed Non-Manufacturing Know-How together with the Licensed
Manufacturing Know-How, in each case, as set forth on Exhibit A.
		
	Section 1.61	  	“Licensed Lead Antibody Compound” means the Licensed Compound known as [***] or [***].
		
	Section 1.62	  	“Licensed Manufacturing Know-How” means all proprietary manufacturing process-related Know-How directly relating to the manufacture of
the Licensed Lead Antibody Compound that both (i) is Controlled by AMGEN or its Affiliates and (ii) [***], in each case (i) and (ii) prior to the Effective Date, as set forth on Exhibit A; provided, however, that
“Licensed Manufacturing Know-How” excludes (1) any Know-How relating to AMGEN’s or its Affiliates commercial manufacturing platform and (2) any Know-How solely relating to the research, development or manufacture of [***].
		
	Section 1.63	  	“Licensed Materials” means those certain materials set forth on Table 1 of Exhibit A, all to the extent Controlled by AMGEN or its Affiliates as of the Effective Date.
		
	Section 1.64	  	“Licensed MAB Program” means AMGEN’s research and development activities prior to the Effective Date with respect to monospecific monoclonal antibody agonists of TREM2.
		
	Section 1.65	  	“Licensed Patents” means the Patent Rights Controlled by AMGEN or its Affiliates as of the Effective Date and set forth on Exhibit B.
		
	Section 1.66	  	“Licensed Product” means any pharmaceutical or biopharmaceutical product containing a Licensed Compound or Program Compound in any form or formulation, and optionally in combination with one or more other active
agents.

  
 -7- 

			
		
	Section 1.67	  	“Licensed Small Molecule Program” means AMGEN’s research and development activities prior to the Effective Date with respect to small molecule agonists of TREM2.
		
	Section 1.68	  	“Losses” has the meaning set forth in Section 7.1.1 (By AMGEN).
		
	Section 1.69	  	“MAB Product” means a Product that contains a monoclonal antibody agonist of TREM2.
		
	Section 1.70	  	“Marketing Approval” means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country, necessary for the manufacture, use, storage, import, marketing and sale of the Product in
such country.
		
	Section 1.71	  	“MPA” means that certain Amended and Restated Master Purchase Agreement dated [***] by and between [***] and [***].
		
	Section 1.72	  	“[***] Period” has the meaning set forth in Section 2.4 [***].
		
	Section 1.73	  	“Net Sales” means, with respect to a certain time period, the gross invoiced sales prices charged for Products sold by or for VIGIL, its Affiliates and Sublicensees (the “Selling Party”) in
arm’s length transactions to Third Parties during such time period, less the total of the following charges or expenses as determined in accordance with GAAP:
		
		  	 (a)   [***]

		
		  	 (b)   [***]

		
		  	 (c)   [***]

		
		  	 (d)   [***]

		
		  	 (e)   [***]

		
		  	 (f)   [***]

		
		  	 (g)   [***]

		
		  	Any disposal of Products for, or use of Products in, clinical or pre-clinical trials, given as free samples, or distributed for indigent programs shall not be included in Net Sales.
		
		  	Upon any sale or other disposal of any Product that should be included within Net Sales for any consideration other than an exclusively monetary consideration on bona fide arm’s length terms, then for purposes of calculating
the Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for money at the average sales price during the applicable reporting period generally achieved for such Product in the country in which such sale or other
disposal occurred when such Product is sold alone and not with other products.

  
 -8- 

			
		
		  	Where a Product is sold together with another pharmaceutically active ingredient for a single price (including any combination product including the Product) (a “Bundle”), then for the purposes of calculating the
Net Sales under this Agreement, such Product shall be deemed to be sold for an amount equal to (X/(X+Y)) * Z, where: X is the average sales price during the applicable reporting period for such Product being sold alone (in the same dosage form) (or,
should more than one Product be included in a Bundle with a product other than a Product, the sum of such average sales prices for the included Products) in the particular country of sale; Y is the sum of the average sales price during the
applicable reporting period in the particular country of sale, when sold alone, of each pharmaceutical (other than the included Product(s)) included in the Bundle (in the same dosage form); and Z equals the Net Sales of such Bundle. In the event
that a Product or one or more of the other pharmaceuticals in the Bundle are not sold separately (in the same dosage form), the Parties will discuss in good faith to determine an equitable fair market price to apply to such Product or other
pharmaceutical in the Bundle.
		
	Section 1.74	  	“Order” means a statement of work or work order under the MPA pursuant to which [***] related to the manufacture of the Licensed Lead Antibody Compound drug substance.
		
	Section 1.75	  	“Ongoing Studies” means those preclinical research studies conducted by AMGEN and [***] and ongoing as of the Effective Date, as listed on Exhibit G.
		
	Section 1.76	  	“Ongoing Studies Agreement” means that certain Preclinical Research Program Agreement by and between AMGEN and [***] effective [***].
		
	Section 1.77	  	“Patent Rights” means any provisional and non-provisional patents and patent applications, together with all additions, divisions, continuations, continuations-in- part, substitutions, and reissues claiming priority thereto, as well as any reexaminations, extensions, registrations, patent term extensions, supplemental
protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof.
		
	Section 1.78	  	“Party” has the meaning set forth in the Preamble.
		
	Section 1.79	  	“Payor” means an organization, including without limitation its directors, officers, employees, contractors and agents, whether private or governmental (e.g., Centers for Medicare and Medicaid Services, Veterans
Administration), that provides medical and/or pharmacy plans for covering and reimbursing patients and/or Healthcare Professionals from medical expenses incurred, including without limitation managed care organizations, pharmacy benefit managers,
health maintenance organizations, other healthcare coverage providers, and any similar such organization.
		
	Section 1.80	  	“Permitted CMO/CRO” means (a) [***] or (b) any other party deemed to be a Permitted CMO/CRO pursuant to the terms of Section 2.5.3.
		
	Section 1.81	  	“Permitted CMO/CRO Agreement” has the meaning set forth in Section 2.5.3(b).
		
	Section 1.82	  	“Permitted CMO/CRO Request” has the meaning set forth in Section 2.5.3(g).
		
	Section 1.83	  	“Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body,
or an individual.

  
 -9- 

			
		
	Section 1.84	  	“Product” means any (1) Licensed Product, or (2) any Distracting Product (including, for clarity, a De Novo Product) that Vigil has elected to treat as a Newly Added Product pursuant to Section 5.4.2
on and after the date of such election.
		
	Section 1.85	  	“Program Compound” means any and all compounds (including both small molecule and monoclonal antibodies) that are discovered, researched or developed by VIGIL, its Affiliates or Sublicensees that [***] and
(a) the discovery, research, development, manufacture or commercialization of which incorporates or uses any (i) Exclusively Licensed Know-How, (ii) Licensed Compound (other than use as
described in (z) below (i.e., any such Licensed Compound was not known to VIGIL to be included in a library of compounds used for screening)), or (iii) any improvement, modification, variant, derivative, salt, prodrug, polymorph or
stereoisomer of any of the foregoing (i) - (ii), or (b) is Covered by a Licensed Patent. For clarification, a small molecule compound shall not be considered a Program Compound (and would instead be considered a De Novo Compound) if such small
molecule (x) is not Covered by any Licensed Patent; (y) [***]; and (z) results from and/or is identified by screening a library of compounds [***], and, conversely, a small molecule compound would be considered a Program Compound if any of
clauses (x), (y), or (z) were untrue. For further clarification, a monoclonal antibody shall not be considered a Program Compound (and would instead be considered a De Novo Compound) if such antibody (1) is produced with [***], (2) [***],
and (3) has a lineage that is not derived from a Licensed Compound and, conversely, a monoclonal antibody would be considered a Program Compound if any of clauses (1), (2), or (3) were untrue.
		
	Section 1.86	  	“Program Patent” means Patent Rights (excluding the Licensed Patents) owned or licensed by VIGIL, its Affiliates or Sublicensees, as of the Effective Date or thereafter, that Cover [***].
		
	Section 1.87	  	“Proper Conduct Practices” means, in relation to any Person, such Person and each of its Representatives, not, directly or indirectly, (a) making, offering, authorizing, providing or paying anything of value in
any form, whether in money, property, services or otherwise to any Governmental Authority, Government Official, or other Person charged with similar public or quasi-public duties, or to any customer, supplier, or any other Person, or to any employee
thereof, or failing to disclose fully any such payments in violation of the laws of any relevant jurisdiction to (i) obtain favorable treatment in obtaining or retaining business for it or any of its Affiliates, (ii) pay for favorable
treatment for business secured, (iii) obtain special concessions or for special concessions already obtained, for or in respect of it or any of its Affiliates, in each case which would have been in violation of any Law, (iv) influence an
act or decision of the recipient (including a decision not to act) in connection with the Person’s or its Affiliate’s business, (v) induce the recipient to use his or her influence to affect any government act or decision in
connection with the Person’s or its Affiliate’s business, or (vi) induce the recipient to violate his or her duty of loyalty to his or her organization, or as a reward for having done so; (b) engaging in any transactions,
establishing or maintaining any fund or assets in which it or any of its Affiliates shall have proprietary rights that have not been recorded in the books and records of it or any

  
 -10- 

			
		  	of its Affiliates; (c) making any unlawful payment to any agent, employee, officer or director of any Person with which it or any of its Affiliates does business for the purpose of influencing such agent, employee, officer or
director to do business with it or any of its Affiliates; (d) violating any provision of applicable Anti-Corruption Laws; (e) making any payment in the nature of bribery, fraud, or any other unlawful payment under the Law of any
jurisdiction where it or any of its Affiliates conducts business or is registered; or (f) if such Person or any of its Representatives is a Government Official, improperly using his or her position as a Government Official to influence the
award of business or regulatory approvals to or for the benefit of such Person, its Representatives or any of their business operations, or failing to recuse himself or herself from any participation as a Government Official in decisions relating to
such Person, its Representatives or any of their business operations.
		
	Section 1.88	  	“Purchaser” means an individual or entity, including without limitation wholesalers, pharmacies, and group purchasing organizations, that purchase an Amgen Therapeutic Product to sell to members of the healthcare
community or that are authorized to act as a purchasing agent for a group of individuals or entities who furnish healthcare services.
		
	Section 1.89	  	“Transaction Notice” has the meaning set forth in Section 2.4 [***].
		
	Section 1.90	  	“Receiving Party” has the meaning set forth in Section 8.1.1 (Confidential Information).
		
	Section 1.91	  	“Regulatory Authority” means any Governmental Authority or other authority responsible for granting Marketing Approvals for the Product, including the FDA, European Commission/EMA and any corresponding national or
regional regulatory authorities.
		
	Section 1.92	  	“Regulatory Exclusivity” means, with respect to the Product, any exclusive marketing rights or data exclusivity rights conferred by the applicable Regulatory Authority with respect to the Product other than a Patent
Right.
		
	Section 1.93	  	“Regulatory Filing” means any all (a) submissions, material correspondence, notifications, registrations, licenses, authorizations, applications and other filings with any Governmental Authority with respect to
the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of the Product and (b) Marketing Approvals for the Product.
		
	Section 1.94	  	“Release” has the meaning set forth in Section 8.2.2 (Review).
		
	Section 1.95	  	“Representatives” means, as to any Person, such Person’s Affiliates and its and their successors, owners, controlling Persons, directors, officers, employees, agents, representatives, subcontractors, or other
third party acting for or on its behalf.
		
	Section 1.96	  	“Reservation Agreement” means that certain [***], in the form substantially similar to that attached as Exhibit E.
		
	Section 1.97	  	“Reservation Fee” has the meaning set forth in the Reservation Agreement.
		
	Section 1.98	  	“Reservation Agreement Process Consumables Fees” means those amounts payable by [***] under the Reservation Agreement in connection with [***].

  
 -11- 

			
		
	Section 1.99	  	“Reviewing Party” has the meaning set forth in Section 8.2.2 (Review).
		
	Section 1.100	  	“Royalty Term” has the meaning set forth in Section 3.3.1 (Royalty Rate; Royalty Term).
		
	Section 1.101	  	“Sale Transaction” has the meaning set forth in Section 10.8 (Successors and Assigns).
		
	Section 1.102	  	“Sanctioned Country” means Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine, and any other country or region subject to comprehensive sanctions under applicable Law.
		
	Section 1.103	  	“Sanctioned Person” means any natural or legal person (i) identified on the Specially Designated Nationals and Blocked Persons List administered by the U.S. Department of Treasury Office of Foreign Assets
Control (OFAC), on the Entity List, the Unverified List, or the Denied Persons List administered by the U.S. Department of Commerce Bureau of Industry and Security (BIS), or on any equivalent lists maintained by the United Nations; (ii) fifty
percent (50%) or greater owned, directly or indirectly, in the aggregate, or otherwise controlled by a person or persons described in clause (i); or (iii) that is organized, resident, or located in a Sanctioned Country.
		
	Section 1.104	  	“Sensitive Manufacturing Know-How” means highly confidential Licensed Manufacturing Know-How [***].
		
	Section 1.105	  	“Series A Financing” means the funding of VIGIL through the sale of Series A Preferred Shares (as defined in the Financing Agreements) raising not less than [***].
		
	Section 1.106	  	“Significant Territorial Rights” means rights to develop or commercialize a Product in (a) the [***], (b) [***] or (c) at least three (3) of the [***].
		
	Section 1.107	  	“Small Molecule Product” means a Product that contains a small molecule agonist of TREM2.
		
	Section 1.108	  	“Sublicensee(s)” means any Person other than an Affiliate of VIGIL to which VIGIL has granted a sublicense under this Agreement.
		
	Section 1.109	  	“Term” has the meaning set forth in Section 9.1 (Term).
		
	Section 1.110	  	“Territory” means the entire world.
		
	Section 1.111	  	“Third Party” means a Person other than (a) AMGEN or any of its Affiliates and (b) VIGIL or any of its Affiliates.
		
	Section 1.112	  	“Third Party Acquirer” has the meaning set forth in Section 10.9 (Sale Transaction or AMGEN Acquisition).
		
	Section 1.113	  	“TREM2” means triggering receptor expressed on myeloid cells 2 (TREM2)
		
	Section 1.114	  	“United States” or “U.S.” means the United States of America, including its territories and possessions (including the District of Columbia and Puerto Rico).

  
 -12- 

			
		
	Section 1.115	  	“Valid Claim” means a claim of any issued and unexpired patent or patent application within the Licensed Patents or Program Patents and that has not been held invalid or unenforceable by a final decision of a court
or governmental agency of competent jurisdiction, which decision can no longer be appealed or was not appealed within the time allowed; provided, however, that if a claim of a pending patent application within the Licensed Patents or
Program Patents shall not have issued within [***] years after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a Patent Right issues
with such claim (from and after which time the same would be deemed a Valid Claim).
		
	Section 1.116	  	“VAT” has the meaning set forth in Section 3.9.3 (VAT).
		
	Section 1.117	  	“VIGIL” has the meaning set forth in the Preamble.
		
	Section 1.118	  	“VIGIL Indemnified Parties” has the meaning set forth in Section 7.1.1 (By AMGEN).

 ARTICLE 2. LICENSE GRANT 

Section 2.1 Grant. Subject to the terms and conditions of this Agreement, AMGEN hereby grants to VIGIL: 

(a) an exclusive (even as to AMGEN, but subject to Section 2.3), royalty bearing, sublicensable (but only in accordance with Section 2.2
(Sublicenses)), license under AMGEN’s rights in and to the Licensed Patents and 
 (b) a non-exclusive, royalty bearing, sublicensable
(but only in accordance with Section 2.2 (Sublicenses)) license under AMGEN’s rights in and to the Licensed Know-How and 

(c) an exclusive, (even as to AMGEN, but subject to Section 2.3), royalty bearing sublicensable (but only in accordance with Section 2.2
(Sublicenses)) license under AMGEN’s rights in and to the Exclusively Licensed Know-How, 
 in each case (a),
(b) and (c), solely to Exploit Products in the Licensed Field in the Territory during the Term. 
 Notwithstanding the foregoing, the Licensed Know-How shall be sublicensable only in connection with the rights of VIGIL with respect to Products and not with respect to any other products or services. During the Term, neither AMGEN nor any of its Affiliates
will enter into any agreement or otherwise license, grant, assign, transfer, convey, or otherwise encumber or dispose any right, title, or interest in or to any of the Licensed Patents or Licensed Know-How,
which agreement, license, grant, assignment, transfer, conveyance, encumbrance, or disposition would conflict with the rights granted to VIGIL hereunder. 
  

  
 -13- 

 Section 2.2 Sublicenses. VIGIL shall be entitled, without the prior
consent of AMGEN, to grant one or more sublicenses, in full or in part, by a written agreement to Third Parties (with the right to sublicense through multiple tiers), provided, however, that as a condition precedent to
and requirement of any such sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and conditions of this Agreement; and (b) VIGIL will continue to be responsible for full performance of
VIGIL’s obligations under the Agreement and will be responsible for all actions of such Sublicensee as if such Sublicensee were VIGIL hereunder. Notwithstanding the foregoing, (i) VIGIL shall have no right to grant any such sublicenses to
research, develop or commercialize the Product prior to the expiration of [***] without AMGEN’s prior written consent, except to contractors acting in support of VIGIL’s development efforts as described in Section 5.2 (Diligence); and
(ii) VIGIL shall have no right to grant any such sublicenses, without AMGEN’s prior written consent in its sole discretion, under any Licensed Manufacturing Know-How (except to a Permitted CMO/CRO in
accordance with Section 2.5.3). For clarification, a Sublicensee shall not be obligated to comply with Section 2.4 [***]. 

Section 2.3 Retained Rights and Limitations. Notwithstanding the licenses granted to VIGIL in this Article 2 (License
Grant), AMGEN retains (1) a research-only right under AMGEN’s rights in and to the Licensed Patents and Exclusively Licensed Know-How solely for AMGEN’s research use as tool molecules, but
expressly excluding any right for AMGEN to use Licensed Compounds or Exclusively Licensed Know-How to [***], in each case for purposes of identifying therapeutic candidates, clinically develop, interact with
any regulatory authority with respect to, or commercialize, any Licensed Compound or Program Compound; (2) all rights necessary for AMGEN (a) to continue collaboration with [***] in accordance with the Ongoing Studies Agreement, (b) to
complete activities contemplated by the Ongoing Studies Agreement and (c) to collaborate with [***] to publish the results of the Ongoing Studies in accordance with Section 8.3; (3) all rights necessary for AMGEN to [***] and license [***]
to conduct the Licensed Lead Antibody Compound manufacturing and related activities under the Order in accordance with Section 2.5.3; and (4) all rights necessary for AMGEN to [***] and license [***] to complete [***] in accordance with
Section 2.5.3(j) and for AMGEN to conduct [***] as contemplated in Section 2.5.3(k). 
 Section 2.4 [***]. 

2.4.1 If VIGIL (or any assignee or surviving party) elects to [***] for a Product with a Third Party (a “Proposed
Transaction”), VIGIL will provide AMGEN with prompt written notice of such Proposed Transaction with appropriate detail of the structure and material details of such Proposed Transaction (the “Transaction Notice”). 

2.4.2 If AMGEN desires to engage on the Proposed Transaction (e.g. to [***]), then AMGEN will notify VIGIL thereof (the “AMGEN
Election Notice”) within [***] of AMGEN’s receipt of the Transaction Notice. If Amgen provides the AMGEN Election Notice within such time period, for [***] following AMGEN’s receipt of the Transaction Notice (the “[***]
Period”), AMGEN will have an exclusive right to [***] such a Proposed Transaction. During the [***] Period, VIGIL shall [***] for such Proposed Transaction or related transaction between the Parties (an “Acquisition
Transaction”) and shall not [***] from any Third Party that would interfere with such [***]. If either (a) Amgen declines the opportunity to [***] or fails to respond to the Transaction Notice with [***] of receipt or (b) [***], then
VIGIL will be free to negotiate such Proposed Transaction for such Product with any Third Party and, provided a definitive agreement for such Proposed Transaction is executed within [***] of the Transaction Notice (or, if AMGEN provides an AMGEN
Election Notice, VIGIL will have a period of [***]), VIGIL will have no 

  
 -14- 

 
further obligations to Amgen under this Section 2.4 (subject to the terms of Section 2.2 (Sublicenses), as applicable) with respect to such Proposed Transaction. In the event VIGIL
fails to enter into a definitive agreement for any Proposed Transaction in such [***] period, Amgen’s rights and VIGIL’s obligations under Sections 2.4.1 and 2.4.2 will continue with respect to such Proposed Transaction. 

2.4.3 AMGEN’s rights under Sections 2.4.1 and 2.4.2 will terminate upon an IPO or Change of Control of VIGIL. 

2.4.4 For the sake of clarity, the foregoing provision shall not apply to the grant of a sublicense to a contract manufacturer or a
contract research organization solely for the purpose of manufacturing or developing a Product for VIGIL or to a Third Party distributor selling finished Product purchased from or on behalf of VIGIL. 

Section 2.5 Transfer of Licensed Know-How and Licensed Materials. 

2.5.1 Licensed Non-Manufacturing Know-How and
Licensed Materials. AMGEN shall transfer to VIGIL the Licensed Non-Manufacturing Know-How and Licensed Materials (other than [***]) listed on Exhibit A, in
accordance with a schedule specified on Exhibit A or as mutually agreed by the Parties (provided, the Parties will use reasonable efforts to ensure such transfer is completed within [***] after the Effective Date). The Parties
acknowledge that there are extensive documents, materials and information related to the Licensed Compounds, and that it is the intent of the Parties that the transfer of documents, materials and information hereunder be limited to that information
within the Licensed Non-Manufacturing Know-How that are necessary or reasonably useful to VIGIL’s Exploitation of Licensed Compounds. Accordingly, AMGEN shall not
have any obligation to transfer to VIGIL any Licensed Non-Manufacturing Know-How or Licensed Materials other than those set forth on Exhibit A. AMGEN will provide notice
to VIGIL when AMGEN has completed the transfer of all Licensed Non-Manufacturing Know-How and Licensed Materials listed in Exhibit A. Within ten (10) days of
receipt of such notice VIGIL will confirm that such transfer is complete or will provide written notice to AMGEN of any remaining Licensed Non-Manufacturing Know-How or
Licensed Materials that have not been transferred. In the event that VIGIL is unable to accept any Licensed Materials in such [***] transfer period, AMGEN reserves the right to charge VIGIL for any further storage of such Licensed Materials at a
rate reflecting AMGEN’s costs and expenses with respect to such continued storage. In the event that VIGIL determines in good faith that any Licensed Non-Manufacturing
Know-How or Licensed Materials other than those set forth on Exhibit A is [***], [***] or is [***], the Parties shall in good faith discuss such necessity, and, if unable to agree, the issue will be escalated
to each Party’s designated representative for further discussion. If the Parties agree on the necessity of such Licensed Non-Manufacturing Know-How or Licensed
Materials, AMGEN shall [***], with such support subject to Section 2.5.2. 
 2.5.2 Consulting Support. AMGEN shall
provide, [***], Consulting Support with respect to the matters described in 2.5.1 in connection with [***] until the earlier of (a) AMGEN has provided [***] total of Consulting Support or (b) the [***] ([***])-month anniversary of the
Effective Date. Without limiting the generality of the foregoing, Consulting Support will include [***]. If VIGIL requires additional Consulting Support in excess of [***], then VIGIL may request such additional Consulting Support in writing. AMGEN
shall notify VIGIL within [***] ([***]) days after receipt of such request whether it, in its sole discretion, is willing to provide such additional Consulting Support, which shall be at VIGIL’s expense, at the FTE Rate for the relevant AMGEN
employees. 

  
 -15- 

 2.5.3 AMGEN Cell Line and Licensed Manufacturing
Know-How. With respect to AMGEN’s transfer of the AMGEN Cell Line and Licensed Manufacturing Know-How, the Parties agree that the following procedures shall
apply: 
 (a) [***]. 

(i) Concurrent with the execution of this Agreement, Amgen [***]. In connection with the execution of the [***], VIGIL shall
pay to [***] the [***], in each case in the time frames contemplated in the [***]. Subject to AMGEN’s receipt of the [***] from VIGIL in such timeframes, AMGEN will [***] to [***] in accordance with the [***]. 

(ii) Promptly following the Effective Date, [***] will [***] draft, review and align upon the contents of the Order outlining
the specific activities to be undertaken by [***] in connection with [***], together with the applicable standards and specifications for the manufacture, testing, release and delivery such cGMP batch, to allow [***] and [***] to execute the Order
no later than [***]. The Order will include those items set forth in Exhibit H and such other items, if applicable, as may be agreed by the Parties and [***]. 

(iii) Promptly following the execution of the Order, AMGEN shall undertake the transfer of the AMGEN Cell Line, related
Licensed Manufacturing Know-How and related Licensed Materials to [***] in connection with activities to take place under the Order. Amgen will [***], in no instance will Amgen be obligated to [***] ([***]) in
connection with activities under or related to the Order. The Parties anticipate that [***]; provided, however, Amgen does not bear responsibility for the success or failure of [***]. AMGEN shall continue to [***] (both before and after the [***]
through [***] until [***] of such Licensed Lead Antibody Compound. VIGIL will use its Commercially Reasonable Efforts to support the activities under the Order and shall [***] under the Order. Amgen has no further [***] obligations after [***] under
the Order. 
 (iv) VIGIL shall be responsible for all fees and expenses of [***] in connection with the Order, including for
all activities described in Exhibit H and separately any fees resulting from additional items included in the Order and subsequent amendments or modifications to the Order. The Parties expect [***] fees and expenses for the Order (for the activities
described on Exhibit H) to be approximately $[***] (inclusive of [***]). [***] represents and warrants that the estimate set forth in Exhibit H reflects [***] the costs of the activities described therein and [***]. The Parties expect that until the
Contractual Transition Date, [***] in a time frame consistent with the payment terms of the Order and [***]; provided, the Parties may mutually agree on an [***] and that after the Contractual Transition Date, [***]. 

  
 -16- 

 (v) VIGIL shall use Commercially Reasonable Efforts to, as soon as
reasonably practicable after the Effective Date, negotiate and enter into a binding agreement with [***] (including a quality agreement) (the “[***] Agreement”) to allow VIGIL to [***] (such time point, the “Operational
Transition Date”). After VIGIL [***] with respect to such activities under [***], Amgen will continue to [***]; however, VIGIL will thereafter take lead responsibility for the [***] under [***]. The Parties expect, and [***], such GMP
documentation activities to take place in [***]. Once the [***] Agreement has been executed, [***] (the “Contractual Transition Date”). 

(vi) Each Party will bear its own internal costs and expenses in connection with performing activities under this
Section 2.5.3(a), including for clarity, all activities each Party undertakes to support [***] activities under the Order (such costs and expenses, the “[***] Support Costs”); provide, however, in the event [***]. 

(b) VIGIL must employ a Permitted CMO/CRO for any manufacturing or research related activities that require access to the AMGEN Cell Line or
other Sensitive Manufacturing Know-How. The [***] Agreement and VIGIL’s agreements with any other Permitted CMO/CRO that will have access to the AMGEN Cell Line or Sensitive Licensed Manufacturing Know-How shall provide for, among other things, (i) [***]; provided, (ii) [***], except as otherwise expressly contemplated in this Agreement and (iii) such additional provisions as are required to comply with
the manufacturing and other limitations set forth in this Section 2.5.3 (such agreement, the “Permitted CMO/CRO Agreement”). Upon AMGEN’s reasonable request, VIGIL shall [***]. For clarification, the requirement that VIGIL
employ a Permitted CMO/CRO and enter into a Permitted CMO/CRO Agreement apply with respect to the use of the AMGEN Cell Line or other Sensitive Manufacturing Know-How (including the manufacture of drug
substance) but does not apply with respect to other contract manufacturing or contract research activities that do not involve the use [***]. For clarity, without Amgen’s express written approval, VIGIL is not authorized to and shall [***] and
all VIGIL use and access to [***] will be pursuant to a confidentiality agreement pursuant to clause (e) of this section. For further clarification, VIGIL may arrange for storage of the AMGEN Cell Line at such Third Party storage facility as
VIGIL may determine and that is approved by Amgen in writing as a Permitted CMO/CRO. 
 (c) VIGIL acknowledges that the transfer of the [***]
to the Permitted CMO/CRO is solely to [***]. Notwithstanding the foregoing or anything to the contrary, except as contemplated below, Amgen shall not be required to transfer any Manufacturing Know-How relating
to [***]; however, (1) AMGEN expressly permits VIGIL to engage [***] to perform the [***] and other contract research organizations that are Permitted CMO/CROs for any [***] that may be necessary to support any Regulatory Filings with respect
to the Licensed Product containing Licensed Lead Antibody Compound and (2) AMGEN agrees to provide reasonable samples of [***] directly to any such Permitted CMO/CRO to facilitate such assays or tests. VIGIL shall receive the data and reports
from such assays or tests conducted by such Permitted CMO/CROs and, without Amgen’s express written approval, VIGIL is not authorized to and shall not [***]. 

  
 -17- 

 (d) VIGIL agrees that it shall not, and it shall use Commercially Reasonable Efforts to
cause the Permitted CMO/CRO not to: (i) reverse engineer or otherwise deconstruct the [***], or to determine or to seek to determine [***], other than as expressly required to manufacture the Licensed Lead Antibody Compound or a Licensed
Product containing the Licensed Lead Antibody Compound; (ii) [***], other than as expressly permitted under this Agreement or as may be expressly required to conduct the assays and tests contemplated in clause (c); (iii) notwithstanding anything to
the contrary in Section 8.3.1 (Right to Publish), publish or otherwise publicly disclose the [***]; or (iv) permit [***] to a Third Party or any of its Affiliates, other than as expressly required to manufacture the Licensed Lead Antibody
Compound or a Licensed Product containing the Licensed Lead Antibody Compound or [***] (provided such access or transfer is in accordance with this Agreement). AMGEN agrees to provide VIGIL with [***] by a Permitted CMO/CRO in accordance with this
Agreement from AMGEN or from an AMGEN-approved vendor on reasonable and customary commercial terms. 
 (e) Upon VIGIL’s written request
(and in any event prior to Amgen providing to VIGIL [***]), the Parties shall enter into the supplemental confidentiality agreement in the form attached hereto on Exhibit E to ensure that [***] provided to VIGIL shall be limited to [***], each of
whom need such information for purposes of [***] for the Licensed Product containing the Licensed Lead Antibody Compound and [***] (such [***], the “Clean Team,” and such purpose, the “Manufacturing Know-How Purpose”) and that such [***] shall be used solely for the Manufacturing Know-How Purpose. Prior to providing [***] to [***] of the Clean Team, the identity
of such [***] shall be provided to Amgen, and VIGIL shall enter into written agreements with such [***] containing confidentiality and non-use provisions no less restrictive than those contained in
Section 8.1 (Confidential Information) (“[***] Confidentiality Agreement”). Any act or omission of any such [***] that would be a breach of its [***] Confidentiality Agreement shall be deemed a breach of this Agreement by VIGIL
(and treated as if VIGIL breached Article 8). Upon the request of either Party, the Parties shall discuss in good faith and establish other reasonable arrangements, systems and protocols to ensure that [***] provided to VIGIL will be disclosed or
made available only to the Clean Team and will be used by such Clean Team solely for the Manufacturing Know-How Purpose. 

(f) In the event [***], VIGIL shall first seek support for such request from the Permitted CMO/CRO and, to the extent that the Permitted
CMO/CRO (or another applicable contract manufacturing or contract research organization) is unable to provide the necessary support [***], Amgen will [***]. 

  
 -18- 

 (g) In the event of a VIGIL Change of Control, VIGIL shall ensure that the acquiror,
successor or Sublicensee, as applicable, holds the same rights and obligations as VIGIL in respect of [***] (including, without limitation, with respect to establishing and abiding by the supplemental confidentiality agreement described above). For
clarity, any such acquirer, successor or Sublicensee shall, as a condition to gaining access [***], enter into a supplemental confidentiality agreement with Amgen in the form attached hereto on Exhibit E subject to such revisions as AMGEN may
reasonably implement taking into account specific concerns arising with regard to the acquiror, successor or Sublicensee. 
 (h) Upon a
termination or expiration of the Permitted CMO/CRO Agreement (including, for clarity the [***] Agreement and including as a result of the appointment, with prior written notice to AMGEN, by VIGIL of a replacement Permitted CMO/CRO), the Permitted
CMO/CRO shall, as directed by VIGIL, promptly return any [***] to AMGEN or shall transfer [***] to the replacement Permitted CMO/CRO. If, at any time, VIGIL desires to add a new Third Party contract manufacturer or contract research organization to
Exhibit C, it shall notify AMGEN in writing (a “Permitted CMO/CRO Request”), and AMGEN shall have the right, for [***] ([***]) days after receipt of such Permitted CMO/CRO Request [***]. If AMGEN rejects a Permitted CMO/CRO Request
pursuant to the foregoing, it will notify VIGIL thereof (and its reasons therefor). [***]. 
 (i) Notwithstanding anything in this Agreement
to the contrary, AMGEN shall have no obligation under this Agreement to transfer to VIGIL, its Affiliates or any Third Party any [***], except as expressly provided in this Section 2.5.3. 

(j) Promptly following the Effective Date, the Parties will cooperatively arrange for the transfer from AMGEN to VIGIL of all rights and
obligations to [***] at [***] (“[***]”). Each Party will [***], however, AMGEN does not bear responsibility for the success or failure of [***]. AMGEN shall [***]. AMGEN covenants to VIGIL that AMGEN will (i) comply with the
applicable agreement(s) with [***] to the extent [***], (ii) will promptly provide to VIGIL or VIGIL’s designated representative all [***]; (iii) will not amend or waive its rights under the applicable agreement(s) with [***] in a way that
affects the [***] without Vigil’s consent, (iv) [***] under or with respect to the applicable agreement(s) with [***]. Without limiting the generality of the foregoing, (a) any Patent Rights or
Know-How arising under the applicable agreement(s) with [***], arising from [***] and Controlled by AMGEN shall constitute Licensed Patents or Licensed Know-How under
this Agreement. AMGEN is responsible for (and shall pay) the [***] fees and expenses incurred on or before the Effective Date and VIGIL is responsible for (and shall pay) such fees and expenses arising after the Effective Date. VIGIL shall use
Commercially Reasonable Efforts to enter into a Permitted CMO/CRO Agreement with [***] (the “[***] Agreement”) as soon as reasonably practicable after the Effective Date to allow VIGIL to assume primary operational and contractual
responsibilities with respect to [***]. Until such time as VIGIL has entered into the [***] Agreement, VIGIL will [***] under AMGEN’s agreement with [***] to AMGEN (in accordance with Section 3.4) in a time frame consistent with [***] the
AMGEN-[***] agreement and AMGEN will [***]; provided, the Parties may mutually agree on [***]. After such time as VIGIL has entered into the [***] Agreement and the Parties have transitioned the contractual responsibilities for [***] to VIGIL, VIGIL
will make payments [***] directly to [***]. 

  
 -19- 

 (k) Amgen will [***]. Once VIGIL has entered into the [***] Agreement, AMGEN will [***].

 2.5.4 Limited Warranties. 

(a) VIGIL acknowledges that any materials transferred by AMGEN to VIGIL (or the Permitted CMO/CRO) under this Agreement are experimental in
nature and may have unknown characteristics (including the hazardous and toxicological properties) and therefore agrees to use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of any such
materials. Accordingly, no such materials, shall be used in any human application, including any clinical trial. 
 (b) AMGEN is the sole and
exclusive owner of and has good and valid title to the [***]. Upon delivery to the Permitted CMO/CRO selected by VIGIL (and/or Third Party storage facility as VIGIL may designate), VIGIL will acquire good and valid title to such [***] free and clear
of all liens. AMGEN will provide to VIGIL (and [***], if applicable), a data sheet with respect to [***], which data sheet shall to Amgen’s knowledge, include accurate and complete information with respect to testing and analysis conducted by
or on behalf of AMGEN with respect to such material. AMGEN will also provide to VIGIL a data sheet (e.g., a record of analysis) with respect to certain [***] and provided to VIGIL for which such data sheet is available, which data sheet shall, to
Amgen’s knowledge, include accurate and complete information with respect to testing and analysis, if any, conducted by or on behalf of AMGEN with respect to such material. 

(c) EXCEPT AS SET FORTH IN SECTION 2.5.4(b), ALL MATERIAL IS BEING SUPPLIED TO VIGIL WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. VIGIL HEREBY ACKNOWLEDGES AND AGREES THAT ANY ANALYSIS OF THE REPORT OR RESULTS, OR OTHER DATA, PROVIDED BY AMGEN ARE, EXCEPT AS SET FORTH IN SECTION 2.5.4(b), PROVIDED “AS
IS” WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THEY ARE FREE FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE. 

Section 2.6 Covenant Not to Sue. Upon the closing of the Series A Financing and the grant of the AMGEN Shares pursuant to the Financing
Agreements, [***]. For purposes of this Section 2.6, Amgen Affiliates includes any Acquirees; provided, that [***]. 

  
 -20- 

 Section 2.7 No Other Rights. VIGIL acknowledges that the rights and licenses granted
under this Article 2 (License Grant) and elsewhere in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is
granted whether by implication, estoppel, reliance, or otherwise, by AMGEN to VIGIL. All rights that are not specifically granted herein are reserved to AMGEN. For clarity, except as stated below with respect to Licensed Lead Antibody Compound drug
substance inventory and consumables included within the Licensed Materials, the transfer under this Agreement of Licensed Know-How and Licensed Material (including the AMGEN Cell Line) shall constitute a transfer of possession together with a
limited license to use such Licensed Know-How and Licensed Materials (including the AMGEN Cell Line) as contemplated under this Agreement and shall not constitute a transfer in title in and to such Licensed Know-How and Licensed Materials (including
the AMGEN Cell Line). The transfer of Licensed Lead Antibody Compound drug substance inventory and consumables within the Licensed Materials constitutes a transfer of all right, title and interest in and to such materials, provided that VIGIL may
use such materials solely to Exploit Licensed Products in accordance with this Agreement. 
 Section 2.8 Restrictions. During the term of
the definitive agreement, VIGIL shall not challenge the validity of any of the Licensed Patents. VIGIL agrees (on behalf of itself and its Affiliates), and shall cause each of its Sublicensees and contract manufacturers to agree as a condition to
the grant of a sublicense, (a) not to Exploit any Licensed Know-How or Licensed Patents for any products other than a Product and (b) not to Exploit the [***] or any Sensitive Manufacturing Know-How other than for the manufacture of the
Licensed Lead Antibody Compound or a Licensed Product containing the Licensed Lead Antibody Compound and as permitted by this Article 2. 

ARTICLE 3. EQUITY, MILESTONES, ROYALTIES AND PAYMENTS 

Section 3.1 Equity in VIGIL. As partial consideration for the rights granted to VIGIL hereunder, at each closing of the Series A Financing
(until such time as VIGIL has raised $45,000,000) and in accordance with the Financing Agreements and the Equity Side Letter, VIGIL shall issue to AMGEN an amount of Series A preferred shares such that Amgen’s equity ownership in VIGIL will be
equal to twenty-five percent (25%) of the fully-diluted equity interests in VIGIL post-closing (until such time as VIGIL has raised $45,000,000, with all such shares, whether issued at the first closing or thereafter comprising the
“AMGEN Shares”). 
 Section 3.2 Upfront and Milestone Payments. 

3.2.1 Upfront Payment. As partial consideration for the rights granted to VIGIL hereunder, VIGIL shall pay AMGEN a one-time
non-creditable, non-refundable upfront payment of Five Hundred Thousand Dollars ($500,000) within ten (10) days of the Effective Date, of which [***] ([***]) shall constitute full and complete payment for the Licensed Lead Antibody Compound
drug substance and all other items of tangible personal property (i) included in the Licensed Material and sold to VIGIL or (ii) otherwise transferred to VIGIL hereunder. 

  
 -21- 

 3.2.2 Milestone Payments. As partial consideration for the rights granted to VIGIL
hereunder, VIGIL shall pay AMGEN the following non-creditable, non-refundable payments (described in the table below under the column “Milestone Payment” and each such payment, a “Milestone Payment”) within [***]
([***]) days following the date that each milestone (described in the table below under the column “Milestone”) is achieved by VIGIL, its Affiliates or Sublicensees: 

 

					
	 	  	 Milestone
	  	Milestone
Payment
	 1
	  	[***]	  	[***] ($[***])
	 2
	  	[***]	  	[***] ($[***])
	 3
	  	[***]	  	[***] ($[***])
	Each of Milestone Payments numbers 1-3 are payable no more than twice in total: once for the first MAB Product achieving the applicable Milestone and once for the first Small Molecule Product achieving the applicable
Milestone.
	 4
	  	[***]	  	[***] ($[***])
	 5
	  	[***]	  	[***] ($[***])
	 6
	  	[***]	  	[***] ($[***])
	 7
	  	[***]	  	[***] ($[***])
	 5
	  	[***]	  	[***] ($[***])
	 6
	  	[***]	  	[***] ($[***])

 VIGIL will provide AMGEN with prompt written notice of the accomplishment of each such Milestones and the corresponding
Milestone Payment. 
 Section 3.3 Royalties. 

3.3.1 Royalty Rate; Royalty Term. On a Product-by-Product basis, VIGIL shall pay to AMGEN the following tiered royalties on
annual Net Sales of each Product sold by a Selling Party during the Royalty Term applicable to such Product: 
 (a) [***] percent
([***]%) on the portion of annual Net Sales of such Product less than [***] U.S. Dollars ($[***]); 
 (b) [***] percent ([***]%) on the
portion of annual Net Sales of such Product equal to or greater than [***] U.S. Dollars ($[***]) but less than [***] U.S. Dollars ($[***]); 

(c) [***] percent ([***]%) on the portion of annual Net Sales of such Product that is equal to or greater than [***] U.S. Dollars ($[***]) but
less than [***] U.S. Dollars ($[***]); and 

  
 -22- 

 (d) [***] percent ([***]%) on the portion of annual Net Sales of such Product that is equal
to or greater than [***] U.S. Dollars ($[***]). 
 Royalties will be payable on a quarterly basis; any such payments shall be made within [***] ([***]) days
after the end of the calendar quarter during which the applicable Net Sales occurred. VIGIL’s obligation to pay royalties with respect to each Product in a particular country shall commence upon the First Commercial Sale of such Product in such
country and shall expire on a country-by-country and Product-by-Product basis on the later of (i) the date on which the Exploitation of such Product is no longer Covered by a Valid Claim of a Licensed Patent or Program Patent in such country or
(ii) the tenth (10th) anniversary of the First Commercial Sale of such Product in such country (the “Royalty Term”). 

3.3.2 Royalty Reductions. 

(a) On a country-by-country basis, in the event that the Exploitation of a Licensed Product is not Covered by a Valid Claim of a [***] in such
country, then the royalty rates set forth in Section 3.3.1 (Royalty Rate; Royalty Term) with respect to Net Sales for such Licensed Product in such country shall be reduced by [***] effective as of the date such Licensed Product is no longer
Covered by a Valid Claim of a [***] in such country. 
 (b) On a country-by-country basis, in the event that the Exploitation of a Product is
not Covered by either (1) a Valid Claim of a [***] or (2) a Valid Claim of a [***] in such country, then the royalty rates set forth in Section 3.3.1 (Royalty Rate; Royalty Term) with respect to Net Sales for such Product in such
country shall be reduced by [***] effective as of the date such Product is no longer Covered by a Valid Claim of a [***] in such country. 

(c) On a country-by-country basis, in the event that one or more Generic Products to a Small Molecule Product is launched in any country in the
Territory during the Royalty Term for such Small Molecule Product in such country, and the average quarterly Net Sales of such Small Molecule Product in such country during the subsequent [***] ([***]) Calendar Quarters decrease by more than [***]
percent ([***]%) of the average quarterly Net Sales of such Small Molecule Product in such country during the [***] ([***]) Calendar Quarters immediately preceding the Calendar Quarter in which the first Generic Product is launched in such country,
the royalty rates provided in Section 3.3.1 for such Small Molecule Product shall be reduced in such country by [***] for each Calendar Quarter in the remainder of such Royalty Term. For the purposes of this Section 3.3.2(c), the term
“launched” shall refer to the listing of a wholesale acquisition cost (WAC) price for the Generic Product on the applicable pricing compendium. 

3.3.3 Third Party Royalties. If VIGIL, its Affiliates or any Sublicensee is required by (a) a future order by a court of
competent jurisdiction, (b) settlement agreement, (c) license or contract, or (d) other legally binding commitment to make royalty payments to a Third Party, in each case in exchange for a license or other right under Patent Rights held by
such Third Party and such license or other rights are necessary for the Exploitation of any Licensed Compound or 

  
 -23- 

 
Program Compound that is derived from a Licensed Compound and the Exploitation of such Licensed Compound would also require a license to such Patent Rights in a given country, then VIGIL shall be
entitled to deduct from royalties due to AMGEN under this Agreement with respect to Net Sales on all Licensed Products containing such Licensed Compound or Program Compound in a given Calendar Quarter in each such country an amount equal to [***] of
the royalties actually paid to such Third Party in such Calendar Quarter as consideration for such license under such Patent Rights, up to a maximum amount of [***] of the royalties due to AMGEN in each affected country in such Calendar Quarter.

 3.3.4 Maximum Reduction. Notwithstanding anything to the contrary, the maximum aggregate reduction with respect to
royalties payable on any Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Section 3.3.2 (Royalty Reductions) and Section 3.3.3 (Third Party Royalties) shall be [***]. 

3.3.5 Mutual Convenience of the Parties. The royalty and other payment obligations set forth hereunder have been agreed to by
the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts to AMGEN. 

Section 3.4 Method of Payment. [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 Section 3.5 Royalty
Reports. After the First Commercial Sale of the first Product and until expiration of the last Royalty Term, VIGIL shall prepare and deliver to AMGEN royalty reports of the sale of the Products by the Selling Parties for each calendar
quarter within forty-five (45) days of the end of each such calendar quarter specifying in the aggregate and on the Product-by-Product and country-by-country basis: (a) total gross amounts for each Product sold or otherwise disposed of by
a Selling Party; (b) amounts deducted by category in accordance with the definition of “Net Sales” in Article 1 (Definitions) from gross amounts to calculate Net Sales; (c) Net Sales; and (d) royalties payable. 

Section 3.6 Currency Conversion. With respect to Net Sales invoiced in U.S. Dollars, such Net Sales invoiced shall be expressed in U.S.
Dollars. With respect to Net Sales invoiced in a currency other than U.S. Dollars, such Net Sales invoiced shall be converted into the U.S. Dollar equivalent using a rate of exchange which corresponds to the rate used by the Selling Party in
recording such receipt, for the respective reporting period, related to recording such Net Sales in its books and records that are maintained in accordance with GAAP. If a Selling Party is not required to perform such currency conversion for its
GAAP reporting with respect to the applicable period, then for such period such Selling Party shall convert its amounts received incurred into U.S. Dollars using a rate of exchange which corresponds to the noon buying rate as published in the Wall
Street Journal, Eastern U.S. Edition on the second to last business day of the Calendar Quarter (or such other publication as agreed-upon by the Parties). Any royalty amount shall be calculated based upon the U.S. Dollar equivalent calculated
in accordance with the foregoing. 

  
 -24- 

 Section 3.7 Late Payments. In the event that any payment due hereunder is not made when
due, the payment shall accrue interest beginning on the day following the due date thereof, calculated at the annual rate of the sum of (a) [***] plus (b) the prime rate effective for the date that payment was due, as published by the Wall
Street Journal, Eastern U.S. Edition, the interest being compounded on the last day of each calendar quarter; provided, however, that in no event shall said annual interest rate exceed the maximum rate permitted by Law. Each such
payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of any Party to seek any other remedy, legal or equitable, to which it may be entitled
because of the delinquency of any payment including, but not limited to termination of this Agreement as set forth in Article 10 (Term & Termination). 

Section 3.8 Records and Audits. VIGIL will keep complete and accurate records of the underlying revenue and expense data relating to the
calculations of Net Sales generated in the then current calendar year and payments required under this Agreement, and during the preceding three (3) calendar years. AMGEN will have the right, once annually at its own expense, to have a
nationally recognized, independent, certified public accounting firm, selected by it and subject to VIGIL’s prior written consent (which shall not be unreasonably withheld), review any such records of VIGIL and its Affiliates and Sublicensees
(the “Audited Party”) in the location(s) where such records are maintained by the Audited Party upon reasonable written notice (which shall be no less than thirty (30) days’ prior written notice) and during regular
business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under Section 3.3 Section 3.1 (Royalties) within the thirty-six (36) month period preceding the date
of the request for review. No calendar year or portion thereof will be subject to audit under this Section more than once. VIGIL will receive a copy of each such report concurrently with receipt by AMGEN. Should such inspection lead to the discovery
of a discrepancy to AMGEN’s detriment, VIGIL will, within forty-five (45) days after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy together with interest at the rate set forth in
Section 3.7 (Late Payments). AMGEN will pay the full cost of the review unless the underpayment of amounts due to AMGEN is [***] for the entire period being examined, in which case VIGIL will pay the cost charged by such accounting firm for
such review. Should the audit lead to the discovery of a discrepancy to VIGIL’s detriment, VIGIL may credit the amount of the discrepancy, without interest, against future payments payable to AMGEN under this Agreement, and if there are no such
payments payable, then AMGEN shall pay to VIGIL the amount of the discrepancy, without interest, within [***] days of AMGEN’s receipt of the report. 

Section 3.9 Taxes. 

3.9.1 Use Tax. VIGIL is responsible for the payment of any state or local sales or use, or similar fees or taxes arising as a
result of the transfer of Licensed Materials, including, specifically the Licensed Lead Antibody Compound drug substance inventory and consumables within the Licensed Materials, by AMGEN to VIGIL pursuant to Section 2.5 (Transfer of Licensed
Know-How and Licensed Materials), and VIGIL will remit such fees or taxes to the proper taxing jurisdiction, when deemed taxable by VIGIL. To the extent VIGIL is unable to complete and file any required tax returns or other tax documents relating to
such fees or taxes itself, the Parties will 

  
 -25- 

 
cooperate in completing and filing such returns or documents relating to such fees or taxes. VIGIL will deliver to AMGEN a MA Resale Certificate (ST-4) or MA Exemption Certificate (ST-12), as may
be applicable to the transfer of the Licensed Materials. The Parties shall use their respective commercially reasonable efforts to deliver and receive the Licensed Materials, as appropriate, through electronic delivery (other than Licensed Lead
Antibody Compound drug substance and any other tangible inventory included in the Licensed Material) or in such other manner reasonably calculated in accordance with applicable law, and take all other commercially reasonable actions necessary, to
minimize or avoid the incurrence of any such taxes or fees. 
 3.9.2 Withholding. In the event that any Law requires VIGIL to
withhold taxes with respect to any payment to be made by VIGIL pursuant to this Agreement, VIGIL will notify AMGEN of such withholding requirement prior to making the payment to AMGEN and provide such assistance to AMGEN, including the provision of
such standard documentation as may be required by a tax authority, as may be reasonably necessary in AMGEN’s efforts to claim an exemption from or reduction of such taxes. VIGIL will, in accordance with such Law withhold taxes from the amount
due, remit such taxes to the appropriate tax authority, and furnish AMGEN with proof of payment of such taxes within thirty (30) days following the payment. If taxes are paid to a tax authority, VIGIL shall provide reasonable assistance to
AMGEN to obtain a refund of taxes withheld, or obtain a credit with respect to taxes paid. Taxes withheld pursuant to this Section 3.9.2 will be treated as payments to AMGEN hereunder, and shall reduce payments otherwise required to be made to
AMGEN by the amount withheld. 
 3.9.3 VAT. All payments due to AMGEN from VIGIL pursuant to this Agreement shall be
paid exclusive of any value-added tax (“VAT”) (which, if applicable, shall be payable by VIGIL upon receipt of a valid VAT invoice). If AMGEN determines that it is required to report any such tax, VIGIL shall promptly provide AMGEN
with applicable receipts and other documentation necessary or appropriate for such report. For clarity, this Section 3.9.3 (VAT) is not intended to limit VIGIL’s right to deduct value-added taxes in determining Net Sales. 

3.9.4 Tax Treatment of Equity and Payments. 

(a) AMGEN and VIGIL intend to treat the issuance to AMGEN of the AMGEN Shares and the payment of any Milestone Payments and any royalties
pursuant to this Article 3 as consideration for the transfer of Licensed Patents and Licensed Know-How to VIGIL for U.S. federal income Tax purposes (and applicable state, local or non-U.S. Tax purposes). 

(b) AMGEN and VIGIL intend to treat the transfer of the Licensed Patents and Licensed Know-How to VIGIL in exchange for the AMGEN Shares , any
Milestone Payments and any royalties pursuant to this Article 3 as part of an integrated transaction constituting a transfer described in Section 351 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and any analogous
provision of applicable state, local or non-U.S. law, and agree that the fair market value of the AMGEN Shares as of the issuance date thereof shall be equal to the product of the price per share paid by investors for such shares multiplied by the
number of shares issued to AMGEN. 

  
 -26- 

 (c) AMGEN and VIGIL intend to treat the issuance of the AMGEN Shares issued after the first
closing and the payment of any Milestone Payments or royalties under this Agreement as additional consideration in respect of the transfer of the Licensed Patents and Licensed Know-How to VIGIL for U.S. federal income tax purposes and for applicable
state, local and non-U.S. purposes as part of an integrated transaction constituting a transfer described in Section 351 of the Code and any analogous provision of applicable state, local or non-U.S. law, and agree that the AMGEN shares issued
at or after the initial closing of the Series A Financing shall have a fair market value equal to the product of the price per share paid by investors for such shares multiplied by the number of shares issued to AMGEN. 

(d) AMGEN and VIGIL shall file all Tax returns, reports, schedules, information statements and other documents consistently with the
understandings set forth in this Section 3.9.4, and shall take no contrary position on any such Tax return, or in any audit, claim, investigation or proceeding in respect of Taxes unless otherwise by applicable Federal, state, local or non-U.S.
law. 
 (e) AMGEN represents that the Licensed Patents, the Licensed Know How and any other property contributed or licensed to VIGIL
pursuant to this Agreement (i) constitute “property” within the meaning of Section 351 of the Code and (ii) do not have an adjusted tax basis for applicable tax purposes in AMGEN’s hands. 

(f) AMGEN (i) will not elect out of the installment method of reporting under Section 453 of the Code with respect to the
transactions set forth in this Agreement and (ii) represents and warrants to VIGIL that Section 362(e)(2)(C) of the Code does not and will not apply to the transactions set forth in this Agreement. 

ARTICLE 4. PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT 

Section 4.1 Intellectual Property Ownership. 

4.1.1 Except to the extent expressly specified to the contrary in this Agreement: (i) each Party shall retain and own all right,
title, and interest in and to all Patent Rights, trade secrets, proprietary rights and other intellectual property rights (collectively “Inventions”) conceived or created solely by such Party; (ii) the Parties shall jointly own
all right, title, and interest in and to Inventions conceived or created jointly by the Parties pursuant to this Agreement (“Joint Inventions”) and, subject to the provisions of this Agreement, neither Party shall have any duty to
account or obtain the consent of the other Party (such consent deemed given hereunder) in order to exploit, license or assign its respective rights in Joint Inventions; and (iii) inventorship and authorship of any Invention or work of
authorship conceived or created by either Party or jointly by the Parties pursuant to this Agreement, shall follow the rules of the U.S. Patent and Trademark Office and the Laws of the U.S. (without reference to any conflict of law principles). For
clarification, any interest of AMGEN in or with respect to Joint Inventions shall constitute Licensed Patents or Licensed Know-How, as the case may be, licensed to VIGIL pursuant to the terms of this Agreement. 

  
 -27- 

 4.1.2 Notwithstanding the foregoing, all right, title, and interest in and to
Inventions exclusively related to Program Compounds (and any associated Patent Rights) shall be owned exclusively by VIGIL regardless of inventorship. Amgen hereby assigns to VIGIL all of its entire right and title in any Program Compounds and
inventions related thereto. 
 Section 4.2 Prosecution and Maintenance. 

4.2.1 VIGIL shall have the first right to file, prosecute and maintain all Patent Rights specified under
Licensed Patents and Program Patents at VIGIL’s sole expense using outside counsel selected by VIGIL and reasonably acceptable to AMGEN. VIGIL will use Commercially Reasonable Efforts to prepare, file, prosecute, defend and maintain all Patent
Rights specified under Licensed Patents and Program Patents. AMGEN shall reasonably cooperate with VIGIL’s requests for data, affidavits, and other information and assistance to support prosecution and maintenance of the Patent Rights in the
Licensed Patents; provided, however, that VIGIL shall reimburse AMGEN for its reasonable, documented out-of-pocket expenses with respect to such cooperation. VIGIL shall promptly upon receipt forward to AMGEN copies of
any significant office actions, communications, and correspondence relating to the Licensed Patents and Program Patents. AMGEN shall have the right to comment on and to discuss prosecution and maintenance activities with VIGIL, and VIGIL shall
consider the same in good faith. For purpose of clarity, VIGIL may at its discretion file new patent applications for Program Patents and may include in such applications data or discoveries included within the Licensed Know-How; provided, however,
VIGIL, its Affiliates and Sublicensees may not file patent applications claiming any AMGEN Cell Line or any Licensed Manufacturing Know-How. 

4.2.2 Notwithstanding the foregoing, if VIGIL declines to file, prosecute or maintain any Patent Rights, elects to allow any Patent
Rights to lapse in any country, or elects to abandon any Patent Rights (in each case to the extent contained in the Licensed Patents or Program Patents) before all appeals within the respective patent office have been exhausted (each, an
“Abandoned Patent Right”), then: 
 (a) VIGIL shall provide AMGEN with reasonable notice of such decision so as to
permit AMGEN to decide whether to file, prosecute or maintain such Abandoned Patent Rights and to take any necessary action (which notice shall, in any event, be given no later than [***] ([***]) days prior to the next deadline for any action that
may be taken with respect to such Abandoned Patent Right with the U.S. Patent & Trademark Office or any foreign patent office). 

(b) AMGEN, at AMGEN’s expense, may assume control of the filing, prosecution and/or maintenance of such Abandoned Patent Rights. 

(c) AMGEN shall have the right to transfer the responsibility for such filing, prosecution and maintenance of such Abandoned Patent Rights to
patent counsel (outside or internal) selected by AMGEN. 
 (d) VIGIL shall assist and cooperate with AMGEN’s reasonable requests to
support prosecution and maintenance of such Abandoned Patent Rights; provided, however, that AMGEN shall reimburse VIGIL for its reasonable expenses with respect to such cooperation (including VIGIL’s employee’s time at the FTE Rate). 

  
 -28- 

 (e) In the event a patent issues with respect to any such Abandoned Patent Rights, AMGEN
shall provide reasonable notice to VIGIL thereof and such Abandoned Patent Right shall be excluded from the license granted by AMGEN to VIGIL under Section 2.1 (Grant), unless VIGIL (i) reimburses AMGEN for its reasonable, documented,
internal and external costs and expenses related to the prosecution and maintenance of such Abandoned Patent Right within [***] ([***]) days of notice of issuance of any such patent and (ii) assumes, in writing, the responsibility for the
continued prosecution and maintenance of such Patent Rights in accordance with the provisions of Section 4.1 (Prosecution and Maintenance). For the avoidance of doubt, the Abandoned Patent Rights shall not be excluded from the license granted
by AMGEN to VIGIL under Section 2.1 (Grant) unless and until after expiry of the [***] ([***]) day period referred to under (i) above and if VIGIL elects not to exercise its rights under (i) and (ii) above. 

Section 4.3 Enforcement. 

4.3.1 VIGIL Enforcement. Each Party will notify the other promptly in writing when any Infringement of a Licensed Patent or a
Program Patent by a Third Party is uncovered or reasonably suspected. VIGIL shall have the first right to enforce any patent within the Licensed Patents or Program Patents against any Infringement or alleged Infringement thereof, and shall at all
times keep AMGEN informed as to the status thereof. VIGIL may, at its own expense, institute suit against any such infringer or alleged infringer and control and defend and settle such suit in a manner consistent with the terms and provisions hereof
and recover any damages, awards or settlements resulting therefrom, subject to Section 4.5 (Recovery). AMGEN shall reasonably cooperate in any such litigation (including joining or being named a necessary party thereto) at VIGIL’s expense.
VIGIL shall not enter into any settlement of any claim described in this Section 4.3.1 (VIGIL Enforcement) that admits to the invalidity or unenforceability of the Licensed Patents or Program Patents, incurs any financial liability on the part
of AMGEN or requires an admission of liability, wrongdoing or fault on the part of AMGEN, without AMGEN’s prior written consent, in each case, such consent not to be unreasonably withheld. 

4.3.2 AMGEN Enforcement. If VIGIL elects not to enforce any patent within the Licensed Patents or Program Patents, then it shall
so notify AMGEN in writing within [***] ([***]) months of receiving notice that an Infringement exists (or such shorter period as may be necessary to prevent exhaustion of a statute of limitations (or laches) applicable to such Infringement). VIGIL
shall consider in good faith a request by AMGEN to at its own expense, take steps to enforce any such patent and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof. If AMGEN pursues such action, it may
recover any damages, awards or settlements resulting therefrom, subject to Section 4.5 (Recovery). VIGIL shall reasonably cooperate in any such litigation (including joining or being named a necessary party thereto) at AMGEN’s expense.
AMGEN shall not enter into any settlement of any claim described in this Section 4.3.2 (AMGEN Enforcement) that admits to the invalidity or unenforceability of the Licensed Patents or Program Patents, incurs any financial liability on the part
of VIGIL or requires an admission of liability, wrongdoing or fault on the part of VIGIL without VIGIL’s prior written consent. 

  
 -29- 

 4.3.3 Progress Reports. The Party initiating or defending any such enforcement
action (the “Enforcing Party”) shall keep the other Party reasonably informed of the progress of any such enforcement action, and such other Party shall have the individual right to participate with counsel of its own choice at its
own expense. 
 Section 4.4 Defense of Third Party Claims. If either (a) any Licensed Product Exploited by or under authority
of VIGIL becomes the subject of a Third Party’s claim or assertion of Infringement of a patent relating to the manufacture, use, sale, offer for sale or importation of such Licensed Product in the Licensed Field in the Territory, or (b) a
declaratory judgment action is brought naming either Party as a defendant and alleging invalidity or unenforceability of any of the Licensed Patents or Program Patents, the Party first having notice of the claim or assertion shall promptly notify
the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action. Subject to Article 8 (Indemnification), unless the Parties otherwise agree in writing, each Party shall have the right to
defend itself against a suit that names it as a defendant (the “Defending Party”). Neither Party shall enter into any settlement of any claim described in this Section 4.4 that admits to the invalidity or unenforceability of
the Licensed Patents or, Program Patents, incurs any financial liability on the part of the other Party, requires an admission of liability, wrongdoing or fault on the part of the other Party or, without such other Party’s prior written
consent, in each case, such consent not to be unreasonably withheld. In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party’s request and expense. 

Section 4.5 Recovery. Except as otherwise provided, the costs and expenses of the Party bringing suit under Section 4.3 (Enforcement)
shall be borne by such Party, and any damages, settlements or other monetary awards recovered shall be shared as follows: (a) the amount of such recovery actually received by the Party controlling such action shall first be applied to the
out-of-pocket costs of each Party in connection with such action; and then (b) the remainder of the recovery shall be shared as follows: 

(i) If VIGIL is the Enforcing Party, [***]; and 

(ii) If AMGEN is the Enforcing Party, [***]. 

Section 4.6 Patent Term Extensions and Filings for Regulatory Exclusivity Periods. VIGIL will advise AMGEN when it is considering any
patent term extension or supplementary protection certificates or their equivalent for the Licensed Patents. AMGEN will cooperate with VIGIL in the preparation and filing of any patent term extension application with respect to the Licensed Patents.
With respect to any patent listings required for any Regulatory Exclusivity for a Licensed Product, [***]. 
 Section 4.7 Patent Marking.
VIGIL will mark, and will cause all other Selling Parties to mark, the Licensed Product with all Licensed Patents in accordance with applicable Law, which marking obligation will continue for as long as (and only for as long as) required under
applicable Law. 

  
 -30- 

 ARTICLE 5. OBLIGATIONS OF THE PARTIES 

Section 5.1 Responsibility. Following the Effective Date and at all times during the Term (except as expressly stated otherwise herein),
VIGIL shall be solely responsible for, and shall bear all costs associated with, the research, development and commercialization of the Products in the Territory, including regulatory, manufacturing, distribution, marketing and sales activities.
Subject to the express written terms of this Agreement, all decisions concerning the development, marketing and sales of Products in the Territory including the clinical and regulatory strategy, design, sale, price and promotion of Products covered
under this Agreement shall be within the sole discretion of VIGIL. 
 Section 5.2 Diligence. VIGIL shall (directly and/or through one or
more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts to develop, manufacture, gain Marketing Authorization and commercialize at least one (1) MAB Product and at least one (1) Small Molecule Product in each of the [***].
Within twelve (12) months of the Effective Date, VIGIL will prepare and provide to AMGEN a development plan for the MAB Product and [***] (which development plans shall describe generally the activities for conducting development with respect
to such Products under this Agreement, including by specifying activities to be conducted and anticipated development activities for the Products). For the purpose of clarity, VIGIL may from time to time amend each development plan in its sole
discretion. VIGIL shall notify AMGEN immediately upon obtaining Marketing Approval for the Product in each country. 
 Section 5.3
Reports. Within [***] of the beginning of each Calendar Year, VIGIL shall submit to AMGEN a report providing the status of VIGIL’s and its Affiliates’ and Sublicensees’ activities related to the research and development of
and Marketing Approval for the MAB Products and the Small Molecule Products during the [***], and plans for future activities related to the research and development of and Marketing Approval for the MAB Products and the Small Molecule Products
during [***], in each case in relation to the last updated development plan, as may be applicable, including any updates to the related clinical plans. 

Section 5.4 Distracting Programs. 

5.4.1 Distracting Programs. Except as set forth in Section 5.4.3 (Post-Effective Date Affiliates) and 5.4.4 (Termination or
Divestiture) and subject to Section 5.4.2 (VIGIL Election), during the Term until the [***] anniversary of the First Commercial Sale of the first Licensed Product in the [***], VIGIL shall not (and shall ensure its Affiliates and Sublicensees
do not) directly or indirectly conduct, enable, or participate in any Distracting Program. For clarity, any failure of any VIGIL Affiliate or Sublicensee to comply with this Section 5.4.1 shall be deemed a breach by VIGIL. 

5.4.2 VIGIL Election. 

(a) Distracting Program. In the event that VIGIL or its Affiliates gains rights to a Distracting Program, then VIGIL shall provide
prompt written notice (in all events within fifteen days of gaining such rights) to AMGEN and include in such notice whether VIGIL elects to treat all such related Distracting Product(s) as “Product(s)” under this Agreement. 

  
 -31- 

 (b) De Novo Compounds. In the event that VIGIL or its Affiliates gains rights to a De
Novo Compound or De Novo Product, then VIGIL shall provide prompt written notice (promptly following the filing of any patent application with respect to a De Novo Compound or De Novo Product and in all cases before any Licensed Patent or Licensed
Know How is used or practiced in connection with such De Novo Compound or De Novo Product) to AMGEN and include in such notice whether VIGIL elects to treat any such De Novo Compound and related De Novo Product as a “Product” under this
Agreement. 
 (c) Newly Added Products. If VIGIL makes such election in such notice, then any such Distracting Product (including, for
clarity, a De Novo Compound) will thereafter be considered a “Product” for purposes of this Agreement (a “Newly Added Product”) and would cease to be considered a “Distracting Product” giving rise to a
“Distracting Program” that is prohibited under Section 5.4.1. VIGIL’s exploitation of the Newly Added Product would be subject to all diligence and reporting obligations under this Agreement as well as Milestone Payment and
royalty obligations contemplated under this Agreement in each case from and after the time such Product becomes a Newly Added Product (for clarification, there shall be no obligation to make any back-payment of Milestone Payments that would have
been triggered by such Newly Added Product had such Newly Added Product been considered a “Product” at the time such Milestone occurred). Any Patent Rights controlled by VIGIL or its Affiliates (including, for clarity, any in-licensed
Patent Rights) Covering such Newly Added Product would be considered “Program Patents” for purposes of determining the Royalty Term, royalties, royalty reductions (for clarification, the [***] reduction under Section 3.3.2(a) would be
inapplicable) and milestone payment obligations applicable to such Newly Added Product. 
 5.4.3 Post-Effective Date
Affiliates. In the event that VIGIL or its Affiliates enters into a Distracting Transaction with a Third Party (and for clarity, VIGIL has not elected to treat such Distracting Product as a Newly Added Product pursuant to Section 5.4.2),
then VIGIL shall provide prompt written notice to AMGEN. Until the provisions of Section 5.4.4 (Termination or Divestiture) are effectuated, VIGIL shall ensure that information and materials relating to the Product or activities hereunder are
not shared with or used for the benefit of, and are sequestered from, Distracting Transaction Affiliate(s). 
 5.4.4 Termination or
Divestiture. The notice provided pursuant to Section 5.4.3 (Post-Effective Date Affiliates) shall include a notification as to whether VIGIL intends to: (a) Divest the Distracting Program, in which case VIGIL shall hold separate such
Distracting Program (including ensuring that no manufacturing, process development, research, or clinical development personnel working on the Product or activities hereunder works on a Distracting Program (and vice versa), and ensuring that
information from the Product (including all Licensed Know-How) or activities hereunder is sequestered from manufacturing, process development, research, or clinical development personnel working on the Distracting Program (and vice versa)) and use
its commercially reasonable, good-faith efforts to Divest such Distracting Program; or (b) terminate such Distracting Program, in which case VIGIL shall terminate all manufacturing, clinical development and/or commercialization activities of
such program within [***] days after the 

  
 -32- 

 
closing of the Distracting Transaction (provided that any ongoing clinical studies may continue if necessary or advisable for patient safety and provided further than out-licensing and similar
business development efforts may continue), during which period VIGIL shall hold separate such Distracting Program (including ensuring that no manufacturing, process development, research, or clinical development personnel working on the Product(s)
or activities hereunder works on a Distracting Program (and vice versa), and ensuring that information from the Product or activities hereunder is sequestered from manufacturing, process development, research, or clinical development personnel
working on the Distracting Program (and vice versa)). In the event VIGIL elects to Divest the Distracting Program under subsection (a) and fails to complete such Divestiture within [***] of the closing of the Distracting Transaction, then VIGIL
shall be deemed to have chosen to terminate such Distracting Program and shall promptly, and no later than within [***] days, comply with the requirements of subsection (b), above. 

Section 5.5 Amgen Restrictions. During the Term until the [***] of the Effective Date, AMGEN will not and will ensure its Affiliates do not
directly or indirectly conduct, enable, or participate in the research (other than the use as tool molecules), manufacture, clinical development or commercialization of any [***] that binds to TREM2 [***] and [***]. Except in connection with the
Ongoing Studies, AMGEN will not and will ensure its Affiliates do not directly or indirectly [***] that (x) binds to TREM2 [***] and (y) includes complementarity-determining region (CDRs) [***] (without regard to intended
therapeutic use). [***] 
 Section 5.6 Reasonable Restrictions. Each of the Parties acknowledges that the provisions of Sections
5.4 (Distracting Programs) and 5.5 (Amgen Restrictions) are reasonable and necessary to protect the legitimate interests of the other Party and to encourage the free sharing of information between the Parties with respect to the Products and each of
the Parties agrees not to contest such limitations in any proceeding. 
 ARTICLE 6. REPRESENTATIONS 

Section 6.1 Mutual Representations and Warranties. Each of AMGEN and VIGIL represent and warrant that: 

(a) it is duly organized and validly existing under the Law of the jurisdiction of its formation, and has full power and authority to enter
into this Agreement and to carry out the provisions hereof; 
 (b) it is duly authorized to execute and deliver this Agreement and to perform
its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite action; 

(c) it shall comply with all applicable Law (including applicable Law relating to data protection and privacy), Proper Conduct Practices, and
Anti-Corruption Laws in connection with the performance of its rights, duties and obligations under this Agreement; and 
 (d) this Agreement
is legally binding upon it and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by
which it may be bound, nor violate any material applicable Law. 

  
 -33- 

 Section 6.2 Additional AMGEN Warranties. AMGEN warrants to VIGIL that, as of the
Effective Date (except with respect to clause (f) below): 
 (a) AMGEN has full legal or beneficial title and ownership to the Licensed
Patents listed on Exhibit B as is necessary to grant the licenses to VIGIL to such Licensed Patents that AMGEN grants pursuant to this Agreement; 

(b) AMGEN has the rights necessary to grant the licenses to VIGIL to Licensed Know-How that AMGEN grants pursuant to this Agreement; 

(c) The Patent Rights included in the Licensed Patents are not subject to any liens or encumbrances and AMGEN has not granted to any Third
Party any rights or licenses under such Patent Rights and has not granted to any Third Party any rights or licenses under such Licensed Know-How that would conflict with the licenses granted to VIGIL hereunder including, for clarity under any
research or manufacturing agreements entered into by AMGEN with respect to the Licensed Compounds. No patent application or registration within the Licensed Patents is the subject of any pending interference, opposition, cancellation or patent
protest pursuant to 37 C.F.R. §1.291 or any foreign counterpart; 
 (d) No Third Party has made any claim or allegation to AMGEN or its
Affiliates in writing that a Third Party has any right or interest in or to the Licensed Patents listed on Exhibit B; and 
 (e) To
the knowledge of AMGEN’s patent litigation attorneys and patent attorneys involved in the prosecution or management of the Licensed Patents, no claim or litigation has been brought or threatened in writing by any Third Party alleging that
(i) the Licensed Patents are invalid or unenforceable or (ii) the manufacture, sale, offer for sale, or importation of Licensed Product in the Licensed Field in the Territory infringes or misappropriates or would infringe or misappropriate
any Patent Rights or other right of any Third Party; 
 (f) The compounds listed on Exhibit D comprise all compounds that: (a) are
Controlled by AMGEN or its Affiliates; (b)(1) for a monoclonal antibody, binds to TREM2 [***] and has agonist activity on TREM2 [***] and (2) for a small molecule, binds to TREM2 and has agonist activity on TREM2 [***]; and (c) were
discovered, researched or developed in the conduct of the Licensed MAB Program or the Licensed Small Molecule Program by AMGEN or its Affiliates prior to the Effective Date. 

(g) Exhibit A attached hereto lists a complete and accurate list of all final reports or electronic lab notebook entries for all completed
preclinical studies related to the Licensed Compounds conducted by or on behalf of AMGEN and its Affiliates prior to the Effective Date. Such studies were conducted in accordance with applicable legal and professional standards. 

  
 -34- 

 (h) As of the Effective Date, neither AMGEN, its Affiliates nor its respective employees,
agents or contractors have employed or otherwise used in any capacity in connection with the development of the Licensed Compound the services of any Person debarred or excluded under United States Law, including under 21 U.S.C. § 335a and 42
U.S.C. § 1320a-7(a), or any foreign equivalent thereof, including any Person that has been: (i) debarred by the FDA (or subject to a similar sanction of a Regulatory Authority), or that is subject of an FDA debarment investigation or
proceeding (or similar proceeding of a Regulatory Authority), or is otherwise ineligible to participate in federal healthcare programs or federal procurement or non-procurement programs; or (ii) has been convicted of a criminal offense that
falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible. 

Section 6.3 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 6 (REPRESENTATIONS)_OR, WITH RESPECT TO AMGEN, SECTIONS
2.5.3(a)(iv), 2.5.4 AND 3.9.4(e) and (f), NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT,
OR VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS, OR THAT ANY PATENTS WILL ISSUE BASED ON A
PENDING APPLICATION. WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART. 

Section 6.4 Additional VIGIL Warranties. VIGIL warrants to AMGEN that, as of the Effective Date: 

(a) Neither VIGIL nor its directors, officers or employees have been debarred, excluded or the subject of debarment or exclusion proceedings by
any Governmental Authority; 
 (b) Neither VIGIL nor its officers or directors are Sanctioned Persons, nor are they owned fifty percent
(50%) or more individually, or in the aggregate by, or Controlled by, any Sanctioned Person; 
 (c) VIGIL has established and maintains
(or shall establish within 180 days of the Effective Date and thereafter maintain) reasonable internal policies and controls, including codes of conduct and ethics and reasonable reporting requirements, intended to ensure compliance with
Anti-Corruption Laws, International Trade Laws and other applicable Law, to the extent applicable to VIGIL under the laws of the jurisdiction of its incorporation, including healthcare compliance, privacy laws and data protection laws; and 

(d) VIGIL is not a Covered Individual and Entity. 

  
 -35- 

 Section 6.5 VIGIL Covenants. VIGIL covenants to AMGEN that: 

(a) it will conduct, and will cause its contractors to conduct, all preclinical and clinical studies for the Product and manufacturing of the
Product, in accordance with (i) all U.S. Laws and the Laws of the country in which such clinical studies are conducted, and (ii) the known or published standards of the FDA and the Regulatory Authority in such country, including but not
limited to good laboratory practice, good clinical practice, and current good manufacturing practices. Neither VIGIL, nor any officer, employee or agent of VIGIL, will knowingly make an untrue statement of a material fact to any Regulatory Authority
with respect to the Product (whether in any submission to such Regulatory Authority or otherwise), and neither will knowingly fail to disclose a material fact required to be disclosed to any Regulatory Authority with respect to the Product; 

(b) it (and its Affiliates) will use Commercially Reasonable Efforts to not employ or otherwise use in any capacity the services of any Person
debarred or excluded under United States Law, including under 21 U.S.C. § 335a and 42 U.S.C. § 1320a-7(a), or any foreign equivalent thereof, including any Person that has been: (i) debarred by the FDA (or subject to a similar
sanction of a Regulatory Authority), or that is subject of an FDA debarment investigation or proceeding (or similar proceeding of a Regulatory Authority), or is otherwise ineligible to participate in federal healthcare programs or federal
procurement or non-procurement programs; or (ii) has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible; 

(c) if, during any period in which AMGEN owns [***] or more of the outstanding voting shares of VIGIL, VIGIL becomes aware that any Person
employed or retained by it to perform any of its obligations under, or services related to, this Agreement: (i) comes under investigation by the FDA, or a similar Regulatory Authority, (ii) is debarred, excluded, suspended, disqualified or
subject to a similar sanction of a Regulatory Authority, or (iii) engages in any conduct or activity that could lead to any of the aforementioned actions or similar sanctions of a Regulatory Authority, VIGIL shall immediately notify AMGEN; 

(d) it shall comply with all applicable Law, International Trade Law, Proper Conduct Practices, and Anti-Corruption Laws in connection with the
performance of its rights, duties and obligations under this Agreement; 
 (e) upon reasonable request, it shall provide AMGEN with any
information under its control that is required by Amgen to comply with International Trade Laws; 
 (f) it shall, during any period in which
Amgen owns [***] ([***]%) or more of the outstanding voting shares of VIGIL, promptly provide AMGEN with written notice upon receiving a formal notification that it is the target of a formal or informal request for information, subpoena,
investigation, litigation, penalty, or claim from any Governmental Authority, for violation or potential violation of any applicable Anti-Corruption Law, International Trade Laws or Proper Conduct Practices; 

  
 -36- 

 (g) during any period in which AMGEN owns [***] ([***]%) or more of the outstanding voting
shares of VIGIL, prior to beginning any commercialization of any Product under this Agreement, each of its employees, agents, independent contractors or Affiliates involved in the commercialization of any Product shall be required to undergo
compliance training with respect to Proper Conduct Practices and Anti-Corruption Laws; 
 (h) it shall use only legitimate and ethical
business practices (including Proper Conduct Practices) in connection with activities conducted in connection with this Agreement whether directly, through the use of Representatives or otherwise, and shall not take any action that would subject any
other Party to penalties under any applicable Law; 
 (i) it shall cause Affiliates under its control and its and their officers, directors,
employees and agents engaged in activities involving Product to comply with this Agreement, including the covenants in this Section 6.5; 

(j) (i) it shall comply with all applicable U.S. Laws prohibiting the re-export, directly or indirectly, of certain controlled U.S.-origin
items without a license to parties located in certain countries or appearing on certain U.S. Government lists of restricted parties; (ii) it shall comply with all applicable U.S. Laws prohibiting participation in non-U.S. boycotts that the
United States does not support; (iii) it shall comply with all applicable U.S. Laws prohibiting the sale of products to parties from any country subject to U.S. economic sanctions or who are identified on related U.S. Government lists of
restricted parties; (iv) it shall use Commercially Reasonable Efforts to comply with all applicable International Trade Laws, and (v) it shall use Commercially Reasonable Efforts to comply with all applicable data privacy laws of the
applicable jurisdiction, including the General Data Protection Regulation (Regulation (EU) 2016/679), and all data breach notification and information securities laws and regulations specific thereto; and 

(k) as of the Effective Date to and through the expiration or termination of this Agreement, (i) it, and, to the best of its knowledge,
its Representatives, shall not, directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any Person for the purposes of obtaining or retaining business through any improper advantage
in connection with this Agreement, or that would otherwise violate any applicable Laws, rules and regulations concerning or relating to public or commercial bribery or corruption, (ii) that its books, accounts, records and invoices related to
this Agreement or related to any work conducted for or on behalf of the other Party are and will be complete and accurate, and (iii) that AMGEN may terminate this Agreement if (a) VIGIL or VIGIL’s Representatives fails to comply with
the Anti-Corruption Laws or with this provision, or (b) AMGEN has a good faith belief that VIGIL or VIGIL’s Representatives has violated, intends to violate, or has caused a violation of the Anti-Corruption Laws. AMGEN may request from
time to time that VIGIL complete a compliance certification regarding the foregoing; and 

  
 -37- 

 (l) if VIGIL engages one or more Covered Individuals and Entities contributes to or performs
any of VIGIL obligations hereunder (including the performance of clinical research with respect to a Product or in the commercialization of a Product), payments made by or on behalf of VIGIL to each such Covered Individual and Entity or other
compensation or consideration received by each such Covered Individual and Entity on account of its contributions to or performance of any of VIGIL obligations hereunder shall comply with all applicable Law, including, to the extent provided for in
applicable Law, (i) represent fair market value, (ii) not be determined in a manner that that takes into account the volume or value of any future business that might be generated between the Parties, and (iii) not be construed to
require a Covered Individual and Entity to promote, purchase, prescribe, or otherwise recommend an Amgen Therapeutic Product being marketed or under development. If VIGIL is or becomes a Covered Individual and Entity or if VIGIL becomes, owned,
operated or controlled by one or more Covered Individuals and Entities, VIGIL shall notify AMGEN of such and, after receipt of such notification or upon VIGIL becoming a Covered Individual and Entity, VIGIL agrees that AMGEN shall have the right,
upon notice to VIGIL, to initiate good faith negotiations with VIGIL to modify the terms of this Agreement as may be reasonably necessary or appropriate to address AMGEN’s bona fide concerns with respect to compliance by AMGEN’s or, as
applicable, one or more of its Affiliate’s requirements for interactions with a Covered Individual and Entity. VIGIL will give good faith consideration to any reasonable request, provided that nothing shall be construed to require VIGIL to
increase any payment obligations, to reduce the scope of the intellectual property rights licensed hereunder or to incur additional costs or expenses to satisfy AMGEN’s requests. VIGIL will not unreasonably refuse to meet any additional
reporting or documentation obligations, provided that it may deduct the reasonable costs of meeting any such obligations from amounts otherwise payable hereunder. Additionally and without limiting any other rights or remedies of AMGEN, if on or
after the Effective Date, VIGIL, is or becomes, a Covered Individual and Entity or is, or becomes, owned, operated or controlled by a Covered Individual and Entity, AMGEN shall have the right to assign this Agreement immediately, and AMGEN shall not
be liable to VIGIL for any costs, expenses, or losses arising out of such assignment. For purposes of this section, “owned, operated or controlled” shall mean that one or more Covered Individual and Entities is in a position to direct or
control the performance of VIGIL’s obligations hereunder, or that one or more Covered Individuals and Entities is in a position to direct or control VIGIL’s management or operations, including, without limitation, when a Covered Individual
and Entity owns a majority of the voting power or other equity interests in VIGIL. 

  
 -38- 

 Section 6.6 AMGEN Covenants. AMGEN covenants to VIGIL that until the completion of the
Ongoing Studies and all activities related thereto: It will (i) comply with the Ongoing Studies Agreement to the extent implicating to the Licensed Compounds, (ii) it will promptly provide to VIGIL or VIGIL’s designated representative
all study reports, invention disclosures, data and proposed presentations or manuscripts provided by [***] pursuant to the Ongoing Studies Agreement with respect to the Licensed Compounds or otherwise arising from the Ongoing Studies;
(iii) will not amend or waive its rights under the Ongoing Studies Agreement in a way that affects the Ongoing Studies or with respect to the Licensed Compounds without Vigil’s consent, (iv) take measures reasonably requested by Vigil
to provide Vigil with the benefits of AMGEN’s rights associated with the Licensed Compounds under or with respect to the Ongoing Studies Agreement. Without limiting the generality of the foregoing, (a) any Patent Rights or Know-How arising
under the Ongoing Studies and Controlled by AMGEN shall constitute Licensed Patents or Licensed Know-How under this Agreement and (b) if VIGIL desires to obtain a license to any intellectual property rights of [***] associated with the Licensed
Compounds, AMGEN shall use reasonable efforts to assist VIGIL to obtain such license. 
 ARTICLE 7. INDEMNIFICATION 

Section 7.1 Indemnity. 

7.1.1 By AMGEN. AMGEN agrees to defend VIGIL and its (and its Affiliates’) directors, officers, employees and agents (the
“VIGIL Indemnified Parties”) at AMGEN’s cost and expense, and will indemnify and hold VIGIL and the other VIGIL Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses (including legal
fees and expenses) (collectively, “Losses”) to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a) the negligence or willful misconduct of AMGEN or
its Affiliates in connection with its activities under this Agreement, (b) the material breach of this Agreement or the representations and warranties made hereunder by AMGEN, except, in the case of each of (a) or (b) of this
Section 7.1.1 (By AMGEN), to the extent such Losses result from clause (a), (b) or (c) of Section 7.1.2 (By VIGIL). In the event of any such claim against the VIGIL Indemnified Parties by a Third Party, the foregoing indemnity
obligations shall be conditioned upon (x) VIGIL promptly notifying AMGEN in writing of the claim (provided, however, that any failure or delay to notify shall not excuse any obligations of AMGEN except to the extent
AMGEN is actually materially prejudiced thereby) and (y) VIGIL granting AMGEN sole management and control, at AMGEN’s sole expense, of the defense of the claim and its settlement (provided, however, that AMGEN
shall not settle any such claim without the prior written consent of VIGIL if such settlement does not include a complete release from liability or if such settlement would involve VIGIL undertaking an obligation (including the payment of money by a
VIGIL Indemnified Party), would bind or impair a VIGIL Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of VIGIL (including rights licensed hereunder from AMGEN) or this Agreement is
invalid, narrowed in scope or unenforceable), and (z) the VIGIL Indemnified Parties reasonably cooperating with AMGEN (at AMGEN’s expense). The VIGIL Indemnified Parties may, at their option and expense, be represented in any such action
or proceeding by counsel of their own choosing. 

  
 -39- 

 7.1.2 By VIGIL. VIGIL agrees to defend AMGEN and its (and its
Affiliates’) directors, officers, employees and agents (the “AMGEN Indemnified Parties”) at VIGIL’s cost and expense, and will indemnify and hold AMGEN and the other AMGEN Indemnified Parties harmless from and against any
Losses to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a) the negligence or willful misconduct of VIGIL, its Affiliates, or their respective Sublicensees in
connection with its activities under this Agreement, (b) the material breach of this Agreement or the representations, warranties and covenants made hereunder by VIGIL, or (c) the Exploitation of any Product by or on behalf of VIGIL, its
Affiliates, or their respective Sublicensees (including from product liability and intellectual property infringement claims); except, in each case, to the extent such Losses result from clause (a) or (b) of Section 7.1.1 (By AMGEN).
In the event of any such claim against the AMGEN Indemnified Parties by a Third Party, the foregoing indemnity obligations shall be conditioned upon (x) AMGEN promptly notifying VIGIL in writing of the claim (provided, however,
that any failure or delay to notify shall not excuse any obligation of VIGIL except to the extent VIGIL is actually materially prejudiced thereby) and (y) AMGEN granting VIGIL sole management and control, at VIGIL’s sole expense, the
defense of the claim and its settlement (provided, however, that VIGIL shall not settle any such claim without the prior written consent of AMGEN if such settlement does not include a complete release from liability or if such
settlement would involve undertaking an obligation (including the payment of money by an AMGEN Indemnified Party), would bind or impair an AMGEN Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or
proprietary right of AMGEN (including rights licensed hereunder from AMGEN) or this Agreement is invalid, narrowed in scope or unenforceable), and (z) the AMGEN Indemnified Parties reasonably cooperating with VIGIL (at VIGIL’s expense).
The AMGEN Indemnified Parties may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing. 

Section 7.2 LIMITATION OF DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE, INDIRECT,
SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION 7.2
(LIMITATION OF DAMAGES) SHALL NOT APPLY WITH RESPECT TO (A) ANY BREACH OF ARTICLE 8 (CONFIDENTIALITY) OR (B) THE INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY. NOTHING IN THIS SECTION 7.2 (LIMITATION OF DAMAGES) IS INTENDED TO
LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY UNDER THIS ARTICLE 7 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION WITH A THIRD- PARTY CLAIM. 

Section 7.3 Insurance. At least [***] days prior to the Initiation of the first clinical trial of a Product, VIGIL shall at its own expense
procure and maintain during the Term (and for [***] years thereafter) clinical trial liability insurance coverage adequate to cover its obligations hereunder and which is/are consistent with normal business practices of prudent pharmaceutical
companies. Additionally, at least [***] days prior to First Commercial Sale of any Product in the Territory, VIGIL shall at its own expense procure and maintain during the Term (and for [***] years thereafter) product liability insurance coverage
adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent pharmaceutical companies. Each insurance policy required by and procured by VIGIL under this Section 7.3 (Insurance) shall name AMGEN
as an additional insured. Such insurance shall not be construed to create a limit of VIGIL’s liability with respect to its indemnification obligations under this Article 7 

  
 -40- 

 
(Indemnification). VIGIL shall provide AMGEN with a certificate of insurance or other evidence of such insurance, upon request. VIGIL shall provide AMGEN with written notice at least [***] days
prior to the cancellation, non renewal or a material change in such insurance which materially adversely affects the rights of AMGEN hereunder, and [***] days prior written notice of cancellation for non-payment of premiums. VIGIL’s insurance
hereunder shall be primary with respect to the obligations for which VIGIL is liable hereunder. 
 ARTICLE 8. CONFIDENTIALITY 

Section 8.1 Confidential Information. 

8.1.1 Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential information of Disclosing Party in connection with this Agreement. The term
“Confidential Information” will mean (a) all Licensed Know-How, (b) all Licensed Materials, and (c) all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether
or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party or at the request of Receiving Party, including any of the foregoing of Third Parties. Without limiting the foregoing, Licensed
Know-How and Licensed Materials will be considered Confidential Information of AMGEN, and all research and development updates as well as financial and business disclosures from VIGIL to AMGEN will be considered Confidential Information of VIGIL.
During the Term, AMGEN shall keep confidential all Licensed Know-How and Licensed Materials to the extent disclosure of such Confidential Information would negatively impact in any material way the Exploitation of any Product in the Territory by
VIGIL or its Affiliates or Sublicensees. 
 8.1.2 Restrictions. During the Term and for [***] years thereafter,
Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree
of care). Receiving Party will not use Disclosing Party’s Confidential Information except in connection with the performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose
Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving Party’s Affiliates and their employees, subcontractors, consultants
or agents who have a need to know such Confidential Information in order to perform its obligations and exercise its rights under this Agreement and who are required to comply with the restrictions on use and disclosure in this Section 8.1.2
(Restrictions). Receiving Party will use diligent efforts to cause those entities and persons to comply with the restrictions on use and disclosure in this Section 8.1.2 (Restrictions). Receiving Party assumes responsibility for those entities
and persons maintaining Disclosing Party’s Confidential Information in confidence and using same only for the purposes described herein. 

  
 -41- 

 8.1.3 Exceptions. Receiving Party’s obligation of nondisclosure and the
limitations upon the right to use the Disclosing Party’s Confidential Information will not apply to the extent that Receiving Party can demonstrate that the Disclosing Party’s Confidential Information: (a) was known to Receiving Party
or any of its Affiliates prior to the time of disclosure; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (c) is obtained by Receiving Party or any of its Affiliates from a Third
Party under no obligation of confidentiality to Disclosing Party; or (d) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its Affiliates without the use of Disclosing Party’s
Confidential Information, as evidenced by contemporaneous written records. 
 8.1.4 Permitted Disclosures. Receiving Party may
disclose Disclosing Party’s Confidential Information to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(a) in order to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with a legal
or administrative proceeding; 
 (b) in connection with prosecuting or defending litigation, Marketing Approvals and other regulatory filings
and communications, and filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and 

(c) in connection with exercising its rights hereunder, to its Affiliates; potential and future collaborators (including Sublicensees where
VIGIL is the Receiving Party); potential and permitted acquirers or assignees; and potential investment bankers, investors and lenders; provided, however, that (1) with respect to Sections 8.1.4(a) or 8.1.4(b), where reasonably possible,
Receiving Party will notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem
appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Section 8.1.4(c), each of those named people and entities are required to comply with the restrictions on use and disclosure in
Section 8.1.2 (Restrictions) (other than investment bankers, investors and lenders, which must be bound prior to disclosure by commercially reasonable obligations of confidentiality). 

Section 8.2 Terms of this Agreement; Publicity. 

8.2.1 Restrictions. The Parties agree that the terms of this Agreement will be treated as Confidential Information of both
Parties, and thus may be disclosed only as permitted by Section 8.1.4 (Permitted Disclosures). Except as required by Law, each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or
the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party not to be unreasonably withheld (or as such consent may need to be obtained in accordance with Section 8.2.2 (Review) or 8.3.1 (Right
to Publish)). 

  
 -42- 

 8.2.2 Review. In the event either Party (the “Issuing Party”)
desires to issue a press release or other public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party will provide the other Party (the “Reviewing
Party”) with a copy of the proposed press release or public statement (the “Release”). The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a
reasonable period of time within which the Receiving Party may provide any comments on such Release (but in no event less than [***] business days). If the Receiving Party provides any comments, the Parties will consult on such Release and work in
good faith to prepare a mutually acceptable Release. Either Party may subsequently publicly disclose any information previously contained in any Release, provided that the other Party provided its written consent hereto as stated in 8.2.1
(Restrictions). For the avoidance of doubt (and notwithstanding anything contained in this Agreement to the contrary), VIGIL, in its sole discretion, may make disclosures relating to the grant of any Sublicense, the development or commercialization
of the Product, including the results of research and any clinical trial conducted by VIGIL, its Affiliates or Sublicensees or any health or safety matter related to the Product. 

Section 8.3 Publications. 

8.3.1 Right to Publish. Subject to the provisions of Sections 8.1 (Confidential Information), 8.2 (Terms of this Agreement;
Publicity) and 8.3.2 (Review), VIGIL shall have the right to publish with respect to the Products, and to make scientific presentations on the Products. Except with respect to the Ongoing Studies, AMGEN shall not publish with respect to the Products
nor make any scientific presentations on the Products. Neither Party shall publish the sequence of the Licensed Lead Antibody Compound or information concerning the manufacture of the Licensed Lead Antibody Compound without the prior written consent
of the other Party. The Parties acknowledge and agree that all VIGIL publications pursuant to this section shall be developed by VIGIL in accordance with VIGIL’s publications policies and practices. In addition, authorship by VIGIL of any
publication arising from this Agreement submitted to a medical or other peer- reviewed scientific journal will be undertaken in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines for authorship. Consistent with
those guidelines, authorship will be based upon substantial contribution to the design, analysis, interpretation of data, drafting and/or critically revising any publication(s) derived from the Agreement, and authors must engage in the drafting of
the publication or revise it critically for important intellectual content. VIGIL agrees to maintain evidence of its compliance with the ICMJE guidelines for authorship, and that it will provide such evidence to AMGEN upon request. Publications
shall acknowledge use of any AMGEN data, support, or other contributions as appropriate and consistent with medical journal guidelines. 

8.3.2 Review. 

(a) Except as required by Law or court order, for any proposed publication submitted by Vigil for presentation at a scientific meeting or to a
medical or other peer-reviewed scientific journal regarding any Licensed Product in the Territory if such publication does or may include any Licensed Know-How, patentable subject matter or AMGEN Confidential Information, VIGIL: (1) shall
transmit a copy of the proposed publication for review and comment to AMGEN at least [***] days for abstracts and presentations prior to submission to a Third Party and at least [***] [***] days prior to the submission for manuscripts of such
publication to a Third Party; (2) shall postpone such publication for up to an additional thirty (30) days upon request of AMGEN to allow the consideration of appropriate patent applications or other protection to be filed; (3) upon
request of AMGEN shall remove all Confidential Information of AMGEN (excluding, for clarity, anything permitted to be disclosed by VIGIL pursuant to the last sentence of Section 8.2.2 (Review)); and (4) shall consider all reasonable
comments made by AMGEN. 

  
 -43- 

 (b) For any proposed publication by AMGEN or [***] in connection with the Ongoing Studies,
AMGEN: (1) shall transmit a copy of the proposed publication for review and comment to VIGIL at least [***] days for manuscripts prior to the submission of such publication to a Third Party; (2) shall postpone such publication for up to an
additional [***] days upon request of VIGIL to allow the consideration of appropriate patent applications or other protection to be filed; and (3) shall consider all reasonable comments made by VIGIL. 

Section 8.4 Relationship to the Confidentiality Agreement. This Agreement supersedes that certain Confidential Disclosure Agreement between
AMGEN and Atlas Venture Life Science Advisors LLC dated November 11, 2019; provided, however, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential
Information” hereunder and will be subject to the terms and conditions of this Agreement. 
 Section 8.5 Attorney-Client
Privilege. Neither Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges recognized under the applicable Law of any
jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the
disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties may become joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine
that they share a common legal interest in disclosure between them that is subject to such privileges and protections, and in such event, may enter into a joint defense agreement setting forth, among other things, the foregoing principles but are
not obligated to do so. 
 ARTICLE 9. TERM & TERMINATION 

Section 9.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date, and unless terminated
earlier as provided in this Article 9 (Term & Termination), shall continue in full force and effect until expiration of obligations to pay royalties under this Agreement for any Products in the Territory. Upon expiration of this Agreement,
the licenses granted to VIGIL by AMGEN under this Agreement to Exploit the Product shall be fully paid-up, irrevocable and non-exclusive. 

Section 9.2 Termination by AMGEN. 

9.2.1 Breach. AMGEN will have the right to terminate this Agreement upon delivery of written notice
to VIGIL in the event of material breach of this Agreement by VIGIL provided, however, 
 (a) that
such termination will not be effective if such breach has been cured within [***] days after written notice thereof is given by AMGEN to VIGIL specifying in reasonable detail the nature of the alleged breach; 

  
 -44- 

 (b) that to the extent such material breach involves the material undisputed failure to make
a payment when due, such breach must be cured within [***] days after written notice thereof is given by AMGEN to VIGIL; 
 (c) that if the
material breach is not reasonably capable of being cured within the [***] day cure period, and if VIGIL (i) proposes within such [***] day period a written plan, reasonably acceptable to AMGEN, to cure such breach, and (ii) makes good
faith efforts to cure such default and to implement such written cure plan, then, until the first anniversary of receipt of notice of termination, AMGEN may not terminate this Agreement for so long as VIGIL is diligently pursuing such cure in
accordance with such plan; 
 (d) that AMGEN will not have the right to terminate this Agreement under this Section 9.2.1 (Termination
for Breach) for any act or omission by any Sublicensee if VIGIL terminates such Sublicense within [***] days of AMGEN’s notice to VIGIL under this Section 9.2.1 (Termination for Breach); and 

(e) If VIGIL in good faith disputes such material breach and provides written notice of that dispute to AMGEN within [***] days of receipt of
AMGEN’s notice to VIGIL under this Section 9.2.1 (Termination for Breach), this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 10.4 and it has been determined under
Section 10.4 that VIGIL is in material breach of this Agreement. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall
continue to perform all of their respective obligations hereunder. 
 9.2.2 Termination for IP Challenge. AMGEN will have the
right to terminate this Agreement in full upon written notice to VIGIL in the event that VIGIL or any of its Affiliates or Sublicensees directly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any
Licensed Patents; provided, however, that AMGEN will not have the right to terminate this Agreement under this Section 9.2.2 (Termination for IP Challenge) for any such challenge by any
Sublicensee if (a) VIGIL terminates such Sublicense within [***] days of AMGEN’s notice to VIGIL under this Section 9.2.2 (Termination for IP Challenge) or (b) such challenge is dismissed within [***] days of AMGEN’s notice
to VIGIL under this Section 9.2.2 (Termination for IP Challenge) and not thereafter continued. 
 9.2.3 Termination for a
VIGIL Distracting Product. AMGEN will have the right to terminate this Agreement in full upon written notice to VIGIL in the event that VIGIL violates Section 5.4.1 (Distracting Programs) and does not elect to treat such Distracting
Product(s) as “Products” under this Agreement pursuant to Section 5.4.2 (VIGIL Election). 
 9.2.4 Termination
for Failure to Achieve Series A Financing. AMGEN will have the right to terminate this Agreement in full upon written notice to VIGIL in the event that either (i) the Series A Preferred Financing does not occur within [***] days of the
Effective Date or (ii) Amgen does not receive the Amgen Shares in association with the Series A Preferred Financing. 

  
 -45- 

 Section 9.3 Termination by VIGIL. 

9.3.1 Breach. VIGIL will have the right to terminate this Agreement in full upon delivery of written
notice to AMGEN in the event of any material breach by AMGEN of this Agreement; provided, however, 

(a) that such termination will not be effective if such breach has been cured within [***] days after written notice thereof is given by VIGIL
to AMGEN specifying the nature of the alleged breach; 
 (b) that if the material breach is not reasonably capable of being cured within the
[***] day cure period, and if AMGEN (i) proposes within such [***] day period a written plan, reasonably acceptable to VIGIL, to cure such breach, and (ii) makes good faith efforts to cure such default and to implement such written cure
plan, then, until the first anniversary of receipt of notice of termination, VIGIL may not terminate this Agreement for so long as AMGEN is diligently pursuing such cure in accordance with such plan; and 

(c) If AMGEN in good faith disputes such material breach and provides written notice of that dispute to VIGIL within [***] days of receipt of
VIGIL’s notice to AMGEN under this Section 9.3.1 (Breach), this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section 10.4 and it has been determined under Section 10.4
that AMGEN is in material breach of this Agreement. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all
of their respective obligations hereunder; and 
 (d) if VIGIL can reasonably establish pursuant to the dispute resolution provisions of
Section 10.4 that the material breach is limited to, and only has an impact on the MAB Program but not the Small Molecule Program or vice versa, then AMGEN shall only be entitled to terminate this Agreement with respect to the MAB Program or
the Small Molecule Program, as the case may be, and the termination of the Agreement with respect to the program (i.e. either the MAB Program or the Small Molecule Program) which is terminated due to breach shall not impact VIGIL’s rights with
respect to the other Program or the Products developed under the other Program. In such event, the provisions of Section 9.3.2 shall apply with respect to the Terminated Program and the Terminated Products within such Terminated Program. 

9.3.2 Discretionary Termination. VIGIL will have the right to terminate this Agreement in full or in part, with respect to
VIGIL, its Affiliates or Sublicensee’s Exploitation of MAB Products (the “MAB Program”) or Exploitation of Small Molecule Products (the “Small Molecule Program”): 

(a) In the time period prior to the initiation of clinical development for any MAB Product (with respect to the MAB Program) or Small Molecule
Product (with respect to the Small Molecule Program), upon thirty (30) day’s prior written notice to AMGEN 

  
 -46- 

 (b) In the time period after the initiation of clinical development for any MAB Product
(with respect to the MAB Program) or Small Molecule Product (with respect to the Small Molecule Program), upon one hundred twenty (120) day’s prior written notice to AMGEN 

if, in each case, VIGIL concludes due to scientific, technical, regulatory or commercial reasons, including (i) safety or efficacy concerns, including
adverse events of such Product, (ii) concerns relating to the present or future marketability or profitability of such Product, (iii) reasons related to patent coverage or (iv) existing and anticipated competition, renders the
Exploitation of the MAB Product or Small Molecule Product no longer commercially practicable for VIGIL. Following any such notice of termination, VIGIL shall have no further obligation pursuant to Section 5.2 (Diligence) to further Exploit any
MAB Product (with respect to the termination of the MAB Program) or any Small Molecule Product (with respect to the termination of the Small Molecule Program) (each such affected Licensed Product, a “Terminated Product” and the
terminated MAB Program and/or Small Molecule Program, a “Terminated Program”), however, VIGIL shall use its reasonable efforts to facilitate a smooth, orderly and prompt transition of all Terminated Products Controlled by VIGIL
prior to the effective date of termination of this Agreement from VIGIL to AMGEN. 
 Section 9.4 Termination Upon Bankruptcy. Either
Party may terminate this Agreement if, at any time, the other Party shall (a) file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization
or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, (b) propose a written agreement of composition or extension of its debts, (c) be served with an involuntary petition against it, filed in
any insolvency proceeding, and such petition has not been dismissed within [***] days after the filing thereof, (d) propose or be a party to any dissolution or liquidation, (e) make an assignment for the benefit of its creditors or
(f) admit in writing its inability generally to meet its obligations as they fall due in the general course. 
 Section 9.5 Effects of
Termination. Upon termination by either Party under Section 9.2 (Termination by AMGEN), Section 9.3 (Termination by VIGIL) or Section 9.4 (Termination Upon Bankruptcy): 

(a) VIGIL will responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices and all legal and
regulatory requirements, any on-going clinical studies involving a Terminated Product for which it has responsibility hereunder in which patient dosing has commenced or, if reasonably practicable and not adverse to patient safety and requested by
AMGEN, VIGIL shall complete such trials and AMGEN shall reimburse VIGIL its reasonable, out-of-pocket costs and internal labor costs at the FTE Rate associated therewith. For the purpose of clarity, except as provided for above, VIGIL may wind-down
any ongoing clinical trials prior to the date of termination in accordance with accepted pharmaceutical industry norms and ethical practices and VIGIL will be responsible for any costs associated with such wind-down. 

  
 -47- 

 (b) A termination of this Agreement will automatically terminate any sublicense of Licensed
Know-How and Licensed Patents relating to the Terminated Program(s) (including all Products in such Terminated Program(s)) granted by VIGIL pursuant to Section 2.2 (Sublicenses) unless AMGEN has approved such sublicense in writing, in which
case all rights under such sublicense shall be deemed to survive termination as long as Sublicensee complies with its obligations thereunder, and provided that in no event will AMGEN be obligated to fulfill any of VIGIL’s obligations under such
sublicense. 
 (c) All rights and licenses granted by AMGEN to VIGIL in Article 2 (License Grant) and all restrictions on AMGEN under
Section 2.3 (Retained Rights and Limitations) will terminate, and VIGIL and its Affiliates, and (subject to Section 9.5(b)) Sublicensees will cease all use of Licensed Know-How relating to the Terminated Program(s) and Licensed Patents
relating to the Terminated Program(s) and all Exploitation of any Terminated Product, except to the extent required hereunder. For clarity, after termination, while VIGIL will retain rights in any Newly Added Product(s) (the “Retained
Products”), the licenses granted by AMGEN to VIGIL in Article 2 (License Grant) will terminate with respect to such Retained Products relating to the Terminated Program(s) and VIGIL and its Affiliates, and (subject to Section 9.5(b))
Sublicensees will cease all use of Licensed Know-How relating to such Retained Products. 
 (d) Upon AMGEN’s request, all Marketing
Approvals and other regulatory filings and communications owned (in whole or in part) or otherwise controlled by VIGIL and its Affiliates, and (subject to Section 9.5(b)) Sublicensees, and all other documents relating to or necessary to further
Exploit any Terminated Product, as such items exist as of the effective date of such termination (including all documents related to completed and ongoing clinical studies) will be assigned to AMGEN to the extent practicable (or, if not so assigned,
VIGIL shall make the benefit of the foregoing reasonably available to AMGEN), and VIGIL will provide to AMGEN one (1) copy of the foregoing and all documents contained in or referenced in any such items, together with the raw and summarized
data for any clinical studies (and where reasonably available, electronic copies thereof). All expenses in relation to such assignment will be borne by AMGEN. In the event of any failure to obtain assignment, VIGIL hereby consents and grants to
AMGEN the right to access and reference (without any further action required on the part of VIGIL, whose authorization to file this consent with any Regulatory Authority is hereby granted) any such item. 

(e) Upon AMGEN’s election, VIGIL shall and hereby does grant to AMGEN and its Affiliates effective upon such AMGEN election at the time of
termination (i) an automatic, worldwide, perpetual and irrevocable exclusive license, with the right to grant sublicenses through multiple tiers, solely for use in Exploiting such Terminated Product, under Know-How and Patent Rights that are
Controlled by VIGIL or any of its Affiliates and Sublicensees prior to termination and that Cover such Terminated Product and which are necessary for Exploiting such Terminated Product and any improvement of any of the foregoing, and (ii) an
automatic, 

  
 -48- 

 
worldwide, perpetual and irrevocable non-exclusive license, with the right to grant sublicenses through multiple tiers, solely for use in Exploiting such Terminated Product, under Know-How and
Patent Rights that are Controlled by VIGIL or any of its Affiliates and (subject to Section 9.5(b)) Sublicensees that are not solely related to such Terminated Product but that are necessary for Exploiting such Terminated Product and any
improvement to any of the foregoing. For the purpose of clarity, upon AMGEN’s election at the time of termination, (1) such license shall be effective only as of and after the effective date of such termination and (2) Amgen will be
obligated to pay royalties during the Royalty Term(s) as provided for in Section 3.3 (Royalties); provided, all deductions and reductions contemplated in Section 3.3 will apply to such payments and the definition of Net Sales and Sections
3.4 (Method of Payment) -3.9 (Taxes) (inclusive) will apply mutatis- mutandis to Amgen in connection with the payment of such royalties and provided further that the royalty rates shall be [***] the rates set forth in Section 3.3 with respect
to any Terminated Product. Notwithstanding the foregoing, in the event that any of the foregoing Know-How or Patent Rights are not Controlled by VIGIL (or any of its Affiliates and Sublicensees) due to the fact that such party would be obligated to
make any payments to a Third Party in connection with the grant of the foregoing licenses, then AMGEN shall have the right to assume such payment obligations and should it elect to do so, such Know-How and Patent Rights shall be included in such
license grant. 
 (f) Upon AMGEN’s request, VIGIL will assign (or, if applicable, will cause its Affiliates or (subject to
Section 9.5(b)) Sublicensees to assign) to AMGEN all of VIGIL’s (and such Affiliates’ and Sublicensees’) right, title and interest in and to any (1) registered or unregistered trademarks or internet domain names that are
specific to the Terminated Product(s), provided that such assignment is in accordance with VIGIL’s policy on trademarks (it being understood that the foregoing will not include any trademarks or internet domain names that contain the corporate
or business name(s) of VIGIL) and (2) Program Patents that claim any Licensed Know-How. 
 (g) VIGIL agrees (and shall cause its
Affiliates and Sublicensees as a condition of the grant of the applicable Sublicense to so agree) to fully cooperate with AMGEN and its designee(s) to facilitate a smooth, orderly and prompt transition of the Exploitation of the Terminated Products
in the Territory to AMGEN and/or its designee(s). Upon request by AMGEN, VIGIL shall transfer to AMGEN some or all quantities of the Terminated Product(s) in its possession. If VIGIL is, at the time of such termination of this Agreement, party to
any Third Party contracts with respect to such Terminated Product(s), then it shall provide AMGEN notice of and (to the extent permitted to do so), copies thereof. VIGIL shall assign to AMGEN any such contracts requested by AMGEN, to the extent
relating to such Terminated Product(s) and to the extent it has the right under such contract(s) to do so (and shall use commercially reasonable efforts to obtain any required consents, which efforts shall not require making any payments or
incurring any liabilities unless AMGEN agrees to reimburse VIGIL therefor (and VIGIL shall inform AMGEN of any such required payment or liability)). In addition, VIGIL shall, at AMGEN’s 

  
 -49- 

 
cost and expense, (i) provide any cooperation reasonably requested by AMGEN to ensure uninterrupted supply of such Terminated Product(s) (including VIGIL’s employees’ time at the
FTE Rate), and (ii) if VIGIL manufactured such Terminated Product(s) at the time of termination, continue to provide for manufacturing of such Terminated Product for AMGEN, at [***] of the fully-burdened manufacturing cost therefor, from the
date of notice of such termination until the sooner to occur of such time as AMGEN is able, using commercially reasonable efforts to do so, to secure an acceptable alternative commercial manufacturing source from which sufficient quantities of such
Terminated Product(s) may be procured and legally sold in the Territory or [***] months from the effective date of termination of this Agreement. 

(h) VIGIL shall duly execute and deliver, or cause to be duly executed and delivered, such instruments and shall do and cause to be done such
activities and things, including the filings of such assignments, agreements, documents and instruments, as may be necessary under, or as AMGEN may reasonably request in connection with, AMGEN’s rights under this Section 9.5 (Effects of
Termination). 
 (i) Notwithstanding a partial termination of this Agreement pursuant to Section 9.2.1 or 9.3.2 or a complete
termination of this Agreement pursuant to Section 9.2, Section 9.3.1 or Section 9.4, VIGIL’s obligations to pay royalties and milestone payments under Section 3.3.2 and Section 3.3 shall continue with respect to any
Retained Product , in each case on a Retained-Product-by-Retained-Product and country-by-country basis until the expiration of the Royalty Term with respect to such Retained Product. 

(j) VIGIL shall remain financially responsible for (and shall pay to AMGEN) (1) the Reservation Fee and Reservation Agreement Process
Consumables Fees and (2) all amounts due under the Order and the Reservation Agreement, as contemplated in Section 2.5.3(a). 
 (k)
VIGIL shall return to AMGEN (or cause to be returned to Amgen) all Licensed Materials 
 (l) In the event of a termination under
Section 9.3.2 (Discretionary Termination) or Section 9.3.1, in either case with respect to a Terminated Program only (and not with respect to this Agreement in its entirety), VIGIL’s obligations under Section 5.2 with respect to
Products in the Terminated Program shall cease and Amgen’s restrictions under Section 5.5 (Amgen Restrictions) shall cease with respect to (1) small molecules (if the Terminated Program is the Small Molecule Program) or
(2) antibodies (if the Terminated Program is the MAB Program). 
 Section 9.6 Survival. In addition to the termination consequences
set forth in Section 9.5 (Effects of Termination), the following provisions will survive termination or expiration of this Agreement: Articles 1 (Definitions), 7 (Indemnification), 8 (Confidentiality), and 10 (Miscellaneous) and Sections 2.5.3
(AMGEN Cell Line and Licensed Manufacturing Know-How) (with respect to VIGIL’s payment obligations in respect of the Order or as otherwise accrued 

  
 -50- 

 
before such expiration or termination), 2.7 (No Other Rights), 3.1 (Equity in Vigil), 3.2 (Upfront and Milestone Payments) (with respect to payment obligations accrued before such expiration or
termination and with respect to Retained Products), 3.3 (Royalties) (with respect to sales of Licensed Product made before such expiration or termination and with respect to all future sales of Retained Products), 3.4 (Method of Payment) through 3.9
(Taxes) (inclusive) (with respect to all payments due prior to the termination of the agreement and for all future payments due post-terminations), 4.3 (Enforcement) through 4.5 (Recovery) (inclusive) (with respect to any action initiated prior to
such expiration or termination), 6.3 (Disclaimer), and this Section 9.6 (Survival). Termination or expiration of this Agreement are neither Party’s exclusive remedy and will not relieve the Parties of any liability or obligation which
accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice
either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate upon expiration of this Agreement. 

ARTICLE 10. MISCELLANEOUS 

Section 10.1 Entire Agreement; Amendment. This Agreement and all Exhibits attached to this Agreement constitute the entire agreement
between the Parties as to the subject matter hereof. All prior and contemporaneous negotiations, representations, warranties, agreements, statements, promises and understandings with respect to the subject matter of this Agreement are hereby
superseded and merged into, extinguished by and completely expressed by this Agreement. None of the Parties shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises or understandings not
specifically set forth in this Agreement. No amendment, supplement or other modification to any provision of this Agreement shall be binding unless in writing and signed by all Parties. 

Section 10.2 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement
are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code to the extent
permitted thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete
duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to
perform all of its obligations under this Agreement. 
 Section 10.3 Independent Contractors. The relationship between VIGIL and AMGEN
created by this Agreement is solely that of independent contractors. This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties. Neither Party is a
legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Each Party shall use its own
discretion and shall have complete and authoritative control over its employees and the details of performing its obligations under this Agreement. 

  
 -51- 

 Section 10.4 Dispute Resolution; Governing Law; Jurisdiction. The Parties recognize that
a dispute may arise relating to this Agreement (a “Dispute”). Any Dispute, including Disputes that may involve the Affiliates of any Party, shall be resolved in accordance with this Section 10.4. If there are any Disputes in
connection with this Agreement, including Disputes related to proposed termination of this Agreement under Article 9, all rights and obligations of the Parties shall continue until such time as the Dispute has been resolved in accordance with the
provisions of this Section 10.4. Any Dispute, including any claim, or controversy as to the breach, enforcement, interpretation or validity of this Agreement shall be referred to a member of each Party’s executive management team (the
“Executive Officers”) for attempted resolution. If the Executive Officers are unable to resolve such Dispute within [***] days of such Dispute being referred to them, the Parties hereby agree that either Party may initiate litigation in a
court of competent jurisdiction located in New York, New York to address such Dispute. This Agreement and its effect are subject to and shall be construed and enforced in accordance with the law of the State of New York, without regard to its
conflicts of laws, except as to any issue which depends upon the validity, scope or enforceability of any Licensed Patent, which issue shall be determined in accordance with the laws of the country in which such patent was issued. Each of the
Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of New York for any matter arising out of or relating to this Agreement and the transactions contemplated hereby, and agrees
not to commence any litigation relating thereto except in such courts. Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement or the transactions
contemplated hereby in the courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an
inconvenient forum. The Parties agree that a final judgment in any such matter shall be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law. Any proceeding brought by either Party
under this Agreement shall be exclusively conducted in the English language. 
 Section 10.5 Notice. All notices or communication
required or permitted to be given by either Party hereunder shall be deemed sufficiently given if mailed by registered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the other Party at its
respective address set forth below or to such other address as one Party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the third (3rd) business day following the date of mailing.
Notices sent by overnight courier shall be deemed received the following business day. 
  

			
	 If to VIGIL:
	  	VIGIL NEUROSCIENCE, INC.
		  	400 Technology Square, 10th Floor
		  	Cambridge, MA 02139
		  	Attn: CEO
		
		  	With a copy to:
		  	Cooley LLP
		  	500 Boylston Street, 14th Floor
		  	Boston, MA 02116-3736
		  	Attn: Marc Recht

  
 -52- 

			
	 If to AMGEN:
	  	Amgen Inc.
		  	One Amgen Center Drive
		  	Thousand Oaks, CA 91320
		  	Attn: [***]

 Section 10.6 Compliance With Law; Severability. Nothing in this Agreement shall be construed to require the
commission of any act contrary to Law. If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected provisions of this Agreement shall be curtailed and limited only to the extent necessary to bring it
within the applicable legal requirements and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. 

Section 10.7 Non-Use of Names. AMGEN shall not use the name, trademark, logo, or physical likeness of VIGIL or any of its officers,
directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without such VIGIL’s prior written consent. AMGEN shall require its Affiliates to comply with the foregoing. VIGIL shall not use the
name, trademark, logo, or physical likeness of AMGEN or any of its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without AMGEN’s prior written consent. VIGIL shall
require its Affiliates and Sublicensees to comply with the foregoing in connection with each such Sublicensee’s sublicense. Notwithstanding the foregoing, VIGIL and its Affiliates and Sublicensees may identify the existence of their rights as
licensees of the Licensed Patents as necessary or appropriate to exercise rights under this Agreement. 
 Section 10.8 Successors and
Assigns. Neither this Agreement nor any of the rights or obligations created herein may be assigned by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld or delayed except
that either Party shall be free to assign this Agreement (a) to an Affiliate of such Party (for so long as such Affiliate remains an Affiliate) provided that such Party shall remain liable and responsible to the other Party for the performance
and observance of all such duties and obligations by such Affiliate, or (b) in connection with any merger, consolidation or sale of such Party or sale of all or substantially all of the assets of the Party that relate to this Agreement (a
“Sale Transaction”), without the prior consent of the non-assigning Party. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the Parties hereto. Any assignment of this Agreement in contravention
of this Section 10.8 (Successors and Assigns) shall be null and void. 
 Section 10.9 Sale Transaction or AMGEN Acquisition. In the
event of (x) a Sale Transaction, or (y) the acquisition by AMGEN or VIGIL of all or substantially all of the business of a Third Party (together with any entities that were Affiliates of such Third Party immediately prior to such
acquisition, an “Acquiree”), whether by merger, sale of stock, sale of assets or otherwise (an “Acquisition”), intellectual property rights of the acquiring party in a Sale Transaction, if other than one of the Parties to this
Agreement (together with any entities that were affiliates of such Third Party immediately prior to such Sale Transaction, a “Third Party Acquirer”), or the Acquiree, as applicable, shall not be: (a) included (as the licensor or
licensee) in the technology licensed hereunder, (b) the subject (either granting or receiving) of any covenant not to sue hereunder except as provided for in Section 2.6 or (c) otherwise subject to this Agreement, except as specified
in Section 5.4 with respect to Distracting Products. 

  
 -53- 

 Section 10.10 Waivers. A Party’s consent to or waiver, express or implied, of any
other Party’s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party. A Party’s failure to complain of any act,
or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof, no matter how
long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition. A Party’s consent in any one instance shall not limit or waive the necessity to
obtain such Party’s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such consent or waiver. 

Section 10.11 No Third Party Beneficiaries. Except as expressly provided with respect to AMGEN Indemnified Parties and VIGIL Indemnified
Parties in Article 7 (Indemnification), nothing in this Agreement shall be construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or
any provision hereof. 
 Section 10.12 Headings; Exhibits. Article and Section headings used herein are for convenient reference only,
and are not a part of this Agreement. All Exhibits are incorporated herein by this reference. 
 Section 10.13 Interpretation. Except
where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The
term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. The term “will” as used herein means shall. All references to a “business day” or
“business days” in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States. The language in all parts of this Agreement shall be deemed to be
the language mutually chosen by the Parties. The Parties and their counsel have cooperated in the drafting and preparation of this Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter
thereof. 
 Section 10.14 Equitable Relief. Each Party acknowledges that a breach by it of the provisions of this Agreement may not
reasonably or adequately be compensated in damages in an action at law and that such a breach may cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party is entitled to seek, in addition to any
other remedies it may have under this Agreement or otherwise, preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of this Agreement by the other Party and is otherwise entitled to specific performance of
the terms hereof; provided, however, that no specification in this Agreement of a specific legal or equitable remedy will be construed as a waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a
breach. 

  
 -54- 

 Section 10.15 Force Majeure. Neither Party shall be held liable or responsible to the
other Party, nor be deemed to have defaulted under or breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes
beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes, a pandemic (including
COVID19 related interruptions), lockouts or other labor disturbances, acts of God, or any acts, omissions, or delays in acting by any governmental authority or the other Party; provided, however, that the affected Party promptly notifies the other
Party in writing (and continues to provide monthly status updates to the other Party for the duration of the effect); and provided further, however, that the affected Party shall use its commercially reasonable efforts to avoid or remove such causes
of nonperformance and to mitigate the effect of such occurrence, and shall continue performance with reasonable dispatch whenever such causes are removed. The Parties acknowledge and agree that as of the Execution Date, the activities of both
Parties may be interrupted due to the COVID-19 pandemic and, as a result, each Party’s performance of some or all of the activities relating to the transfer of Licensed Material and Licensed Know-How may be delayed. Further, as COVID-19
pandemic circumstances evolve, there may be additional delays or other circumstances for either Party that were not initially foreseeable. In light of the foregoing, the Parties agree to discuss in good faith an extension to timelines contemplated
in this Agreement, as may be applicable. 
 Section 10.16 Further Assurances. Each Party shall execute, acknowledge, and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

Section 10.17 Counterparts. This Agreement may be executed in counterparts by a single Party, each of which when taken together shall
constitute one and the same agreement, and may be executed through the use of facsimiles or .pdf or other electronically transmitted documents. 

[signature page follows] 

  
 -55- 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

  

									
	VIGIL NEUROSCIENCE, INC	 	AMGEN INC.
					
	By:	 	 /s/ Ommer Chohan
	 		 	By: 	 	 /s/ Peter H. Griffith

	Name:	 	Ommer Chohan	 		 	Name:	 	Peter H. Griffith
	Title:	 	Chief Financial Officer	 		 	Title:	 	EVP & CFO
					
		 		 		 	By:	 	 /s/ David M. Reese

		 		 		 	Name:	 	David M. Reese
		 		 		 	Title:	 	EVP, Research & Development

  

			
		  	

 EXHIBIT A 

LICENSED KNOW-HOW 
 Access to documents
listed below in the fields of regulatory, research, pharmacology, toxicology, bioanalytical, pharmacokinetics, and their supporting information, including but not limited to, the final reports, study files, study samples/specimens, and individual
data files, will be made available to VIGIL within the timeframes shown below after the Effective Date. 
 [***] 

[***] 
  

	 	•	 	 [***] 

  

					
	 [***]
	  	 [***]

	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	1

					
	 [***]
	  	 [***]

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	2

					
	 [***]
	  	 [***]

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	3

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	4

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	5

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 

[***] 
  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	6

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	7

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
		  		  	
	[***]	  	[***]	  	[***]
		  		  	

  

			
		  	8

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]

  

			
		  	9

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	10

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

					
	 [***]
	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 

[***] 
  

					
	 [***]
	  	 
		  		  	[***]
	[***]	  	[***]	  	[***]
			
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	11

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
		  	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
		  	12

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	 	  	 	  	 
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	13

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	14

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	15

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	16

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	17

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	18

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	19

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	20

																	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
									
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

  

			
		  	21

 EXHIBIT B 

LICENSED PATENTS 
  

							
	 Country
	  	 Application No.
	  	 Filing Date
	  	 Title

				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]

  

			
		  	

							
	 Country
	  	 Application No.
	  	 Filing Date
	  	 Title

				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]

  

			
		  	

 EXHIBIT C 

PERMITTED CMOS/CROs 
 [***] 

 EXHIBIT D 

LICENSED COMPOUNDS 
 [***] 

 EXHIBIT E 

SUPPLEMENTAL CONFIDENTIALITY AGREEMENT 

[***] 

 [***] 

[***] 
  

					
	[***]	  	[***]	  	[***]

 EXHIBIT F 

RESERVATION AGREEMENT 

[***] 

 [***] 
 [***]

 [***] 

 EXHIBIT G 

ONGOING STUDIES 
  

													
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 Exhibit H 

[***] Order Summary 
  

					
	[***]                                
                                
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]EX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS
EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 
 (1) FUJIFILM
DIOSYNTH BIOTECHNOLOGIES UK LIMITED 
 (2) FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC 

(3) FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC 

(4) FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS 

AND 
 (5) VIGIL
NEUROSCIENCE, INC. 
 MASTER SERVICES AGREEMENT 

 CONTENTS 

 
  

							
	 1.
	 	Definitions and Interpretation	  	 	1	 
	 2.
	 	Appointment of Fujifilm	  	 	9	 
	 3.
	 	Term	  	 	10	 
	 4.
	 	Performance of Programs	  	 	10	 
	 5.
	 	Quality and regulatory matters	  	 	11	 
	 6.
	 	Conforming batches, non-conforming batches, demonstration batches and engineering batches	  	 	13	 
	 7.
	 	Delivery, title and risk	  	 	14	 
	 8.
	 	Price and Payment	  	 	16	 
	 9.
	 	Liability	  	 	18	 
	 10.
	 	Intellectual Property	  	 	23	 
	 11.
	 	Intellectual Property Indemnity	  	 	24	 
	 12.
	 	Confidentiality	  	 	25	 
	 13.
	 	Change	  	 	27	 
	 14.
	 	Delay, Cancellation, Termination and consequences	  	 	28	 
	 15.
	 	Force Majeure	  	 	32	 
	 16.
	 	Dispute Resolution	  	 	33	 
	 17.
	 	Audit	  	 	34	 
	 18.
	 	Notices	  	 	35	 
	 19.
	 	Export/Import Controls and Sanctions Compliance	  	 	36	 
	 20.
	 	Modern Slavery and Corruption	  	 	38	 
	 21.
	 	Assignment and sub-contracting	  	 	39	 
	 22.
	 	General	  	 	40	 
	 23.
	 	Governing Law	  	 	42	 
	 Schedule 1
	 	Charges	  	 	46	 
	 Schedule 2
	 	Addresses for Notice	  	 	51	 
		 	Signature Page	  	 	44	 

 THIS AGREEMENT is made on the date it is signed by the last signing party. 

BETWEEN 
  

	(1)	 FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED incorporated and registered in England and Wales with
company number 05803359 whose registered office is at Belasis Avenue, Billingham, TS23 1LH, England (“FDBK”); 

  

	(2)	 FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC incorporated and registered in Texas whose principal place
of business is at 100 Discovery Drive, Suite 200 College Station, Texas 77845 United States of America (“FDBT”); 

  

	(3)	 FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC incorporated and registered in Delaware whose principal
place of business is at 101 J Morris Commons Lane, Morrisville, North Carolina 27560, United States of America (“FDBU”); 

  

	(4)	 FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS incorporated and registered in Denmark with company
number 26060702 whose registered office is at Biotek Alle 1, 3400 Hillerød, Denmark (“FDBD”); and 

  

	(5)	 VIGIL NEUROSCIENCE, INC. incorporated and registered in the State of Delaware having an address at 400
Technology Square, 10th Floor, Cambridge, MA 02139 (the “Customer”). 

 BACKGROUND 

 

	(A)	 Fujifilm (as defined below) is a biopharmaceutical contract development and manufacturing organization. The
Customer wishes to appoint Fujifilm to carry out development and manufacturing services in relation to certain of the Customer’s products. 

  

	(B)	 Fujifilm and the Customer have agreed to work together on the terms and conditions contained in this Agreement.

 AGREED TERMS 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 In this Agreement the following words have the following meanings unless inconsistent with the context:

  

			
	“Affiliate”	  	means in relation to an entity, each or any other entity who for the time being, that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such entity. For purposes
hereof (and clause 14.2), “control” shall mean: (a) holding the majority of the voting rights or share capital of such entity; (b) any power (whether direct or indirect and whether by the ownership of share capital, the
possession of voting power, contract, or otherwise) to appoint

  
 1 

			
		  	and/or remove all or such of the members of the board or other governing body of a body corporate as are able to cast the majority of the votes capable of being cast by members of that board or body on all, or substantially all,
matters, or (c) otherwise to control or have the power to control the policies, management and affairs of that body corporate;
		
	“Ancillary Services”	  	has the meaning given to it in Schedule 1 (Charges);
		
	“Applicable Laws”	  	applicable law, regulations and binding guidance which applies in the jurisdiction in which the Program is being performed;
		
	“Background IP”	  	 all Intellectual Property Rights controlled, owned or jointly owned by any party (or a third party on its behalf) prior to the Effective Date
or developed independently from the Program. Fujifilm’s proprietary manufacturing, expression or purification technologies, including:
  

(a)   an expression system within the scope of international patent application [***] (the
“pAVEwayTM Expression System”);
  

(b)   expression technology within the scope of international patent application [***] (the
“ApolloTM Expression Technology”); and
  

(c)   Fujifilm’s proprietary alcohol oxidase yeast Pichia pastoris expression system (the
“Yeast Expression System”),
  
 (“Fujifilm Expression
Technology”) is Fujifilm’s Background IP;

		
	“Batch”	  	a specific quantity of material produced in a process or series of processes. In the case of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed
quantity or by the amount produced in a fixed time interval.;
		
	“Batch Cancellation Fee”	  	the Batch Cancellation Fee described in Schedule 1;
		
	“Batch Fee”	  	if the Batch Fee is clearly described in the applicable SoW the Batch Fee for that SoW shall be the Batch Fee described in the SoW, however, if the Batch Fee is not clearly described in the applicable SoW it will be deemed to be, in
respect of any Batch under that SoW, all agreed upon Charges for Fujifilm Services in respect of the Manufacturing Stages carried out in connection with that Batch;

  
 2 

			
		
	“Business Day”	  	 (a)   in relation to notices given under this Agreement rather than a specific
Scope of Work a day other than a Saturday, Sunday or public holiday in England, the US, Denmark and/or the country in which the Customer’s head office is located; and
  

(b)   in relation to notices given under a specific Scope of Work a day other than a Saturday,
Sunday or public holiday in England if FDBK is a contracting party, the US if FDBT or FDBU is a contracting party, Denmark if FDBD is a contracting party and/or the country in which the Customer’s head office is located;

		
	“cGMP”	  	Current Good Manufacturing Practice as defined in (i) the Federal Register volume 66 No 186 and those sections applicable within the FDA Regulations 21 CFR Part 11, 210, 211, 600, 601 and 610 and (ii) the rules governing
medicinal products in the European Union Eudralex Volume 4 – Guidelines for good manufacturing practices for medicinal products for human and veterinary use. Part I – Basic Requirements for Medicinal Products. Part II – Basic
Requirements for Active Substances used as Starting Materials and ICHQ7;
		
	“cGMP Batch”	  	a Batch identified in a Scope of Work which is intended to be manufactured during a Manufacturing Stage and subject to Disposition in each case in accordance with cGMP;
		
	“Change”	  	has the meaning given to it in clause 13;
		
	“Charges”	  	has the meaning set out in clause 8.2;
		
	“Commercially Reasonable Efforts”	  	with respect to the activities pursuant to a Program, the reasonable efforts and resources used by a reputable biopharmaceutical contract manufacturing organization for Drug Substances of similar nature, complexity and developmental
stage in the same or similar circumstances;
		
	“Competitor”	  	a contract development and/or manufacturing organization in the biopharmaceutical industry;
		
	“Confidential Information”	  	the fact and terms of this Agreement and any Scope of Work, and all information (in whatever form) in respect of the business of each of the parties and each of its Affiliates including any ideas; business methods; finance; prices,
business, financial, marketing or development plans; products or services, know-how or other matters connected with products or services manufactured and/or marketed; customer lists or details; computer
systems and software; which is (in each case) provided or obtained by one party to or for the other;

  
 3 

			
		
	“Conforming Batch”	  	a cGMP Batch which has been produced in accordance with cGMP, and which meets the Product Specification;
		
	“Consumable”	  	a consumable item used or intended for use in a Program, including PEG, reagents (including analytical reagents), raw materials, packaging components, chromatography resins, filters, filtration membranes, media, buffer bags, refold
bags, tubing, hoses, disposable analytical test kits, in-process measurement probes, columns (including analytical columns) and disposable containers;
		
	“Customer Foreground IP”	  	all Foreground IP that constitutes an improvement or modification which is specific to the Customer’s Background IP, the Product or manufacture thereof;
		
	“Delay”	  	has the meaning given to it in clause 14.1.1;
		
	“Demonstration Batch”	  	a Batch which is manufactured in a non cGMP R&D facility for demonstration purposes and which is not intended for human use and is identified as such in the applicable SoW;
		
	“Deviation”	  	a cGMP deviation as detailed in the Quality Agreement;
		
	“Disposition”	  	the Stage during which (i) the Product is tested for compliance versus the Product Specification; (ii) all production instruction and analytical records relating to cGMP manufacture of each cGMP Batch prepared by Fujifilm
are reviewed; and (iii) a Fujifilm recommendation for Product release or reject is made; in each case as applicable;
		
	“Drug Product”	  	the final dosage form of product which contains Product in association with other active or inactive ingredients;
		
	“Drug Substance”	  	Any substance or mixture of substances intended to be used in the manufacture of a Drug Product and that, when used in the production of a drug, becomes an active ingredient of the Drug Product. Such substances are intended to
furnish pharmacological activity or other direct effect on the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.
		
	“Effective Date”	  	February 11, 2021;

  
 4 

			
		
	“Engineering Batch”	  	a Batch that is manufactured in a cGMP Facility at scale using the Process but which is not intended for human use and is identified as such in the applicable SoW;
		
	“Facility”	  	any of Fujifilm’s manufacturing facilities in which a Program will be performed;
		
	“Force Majeure Event”	  	any event or circumstances outside the reasonable control of a party affecting its ability to perform any of its obligations under this Agreement including act of God, fire, flood, severe weather, epidemic or pandemic, war,
revolution, acts of terrorism, riot or civil commotion, acts of government, trade embargo, labor disputes (excluding labor disputes involving the party in question), interruption of utility service, restraints or delays affecting shipping or
carriers, inability or delay in obtaining supplies of adequate or suitable materials, inability or delay in obtaining third party services, breakdown or failure in equipment or machinery, cyber-attack, currency restrictions but shall not include the
failure of Drug Product in clinical trials or failure of Drug Product to gain regulatory approval;
		
	“Foreground IP”	  	all Intellectual Property Rights that arise or are obtained or developed by or on behalf of any party in the course of the performance of a Program;
		
	“Fujifilm”	  	FDBK, FDBT, FDBU and/or FDBD as the context requires in accordance with clause 1.3;
		
	“Fujifilm Foreground IP”	  	all Foreground IP other than Customer Foreground IP;
		
	“Fujifilm Services”	  	the research and development services to be provided by Fujifilm for the Customer during a Program as the same are described in the relevant Scope of Work excluding the Ancillary Services;
		
	“Gross Negligence”	  	a conscious and voluntary disregard of the need to use reasonable care, which is likely to cause foreseeable grave injury or harm to persons, property, or both;
		
	“Historic Documents”	  	any historic contractual documentation which cover the same subject matter as a Program as incorporated by reference into the relevant SoW;

  
 5 

			
		
	“Indemnify”	  	on demand to indemnify and keep indemnified, and hold harmless, the party to be indemnified on an after tax basis;
		
	“Intellectual Property Right”	  	any current and future intellectual property rights and interests including patents, utility models, designs, design rights, copyright (including rights in software), decryption rights, database rights, trade marks, rights pursuant
to passing off, service marks, business and trade names, domain names, know-how, results, data, databases, formulations, compounds, rights in biological or chemical materials, rights under data exclusivity
laws, rights under unfair competition laws, topography rights, inventions, rights in confidential information (including technical and commercial trade secrets); supplementary protection certificates and image rights, and rights of a similar or
corresponding character in any part of the world, in each case whether registered or not and including any application for registration and renewals or extensions of such rights in any country in the world and whether subsisting now or in the
future;
		
	“Liabilities”	  	any (i) liabilities of any nature, whether accrued, absolute, contingent or otherwise and whether in contract, tort (including negligence) or otherwise; (ii) losses, costs (including internal costs/overheads), damages,
fines or expenses including reasonable legal fees; and (iii) claim, demand, proceeding, action or cause of action including those by third parties; in each case howsoever arising. “Liability” shall be construed
accordingly;
		
	“Manufacturing Stage”	  	a Stage of a Program during which production, testing and Disposition (if applicable) of Engineering Batches or cGMP Batches are intended to take place, including pre and post manufacturing activities; Facility change–over,
setup, and cleaning before, between and after Batch manufacturing;
		
	“Modifications”	  	a modification to a Facility; or equipment (including Process specific qualification and installation of existing equipment), required in order to perform a Process and detailed in the applicable Scope of Work;
		
	“Non-Conforming Batch”	  	a cGMP Batch which has not been produced in accordance with cGMP and/or does not meet the Product Specification;
		
	“Non-Manufacturing Stage”	  	a Stage of a Program, which is not a Manufacturing Stage, during which the non-manufacturing activities described in the relevant SoW are undertaken including the production and testing of
Demonstration Batches;

  
 6 

			
		
	“Process”	  	a particular process used, or to be used, for manufacture of a Product;
		
	“Process Specification”	  	the Process operating parameters and specifications as documented in the regulatory submission and/or a QA Document which has been agreed by the parties for cGMP Batch production;
		
	“Process-Specific Consumable”	  	a Consumable which is required to operate the Process and which is specific to the Process or a Consumable which is required in such large volumes as would not be possible for Fujifilm to consume during other manufactures and/or
within the shelf life of such Consumable;
		
	“Process-Specific Equipment”	  	an item of equipment which is required by Fujifilm to operate the Process and which is specific to the Process in addition to that equipment which Fujifilm uses in its Facilities as at the SoW Effective Date (which existing
equipment is not already dedicated to other customer(s) of Fujifilm);
		
	“Product”	  	the particular product or substance (compound or molecule) created during and as a result of performing the Process. The name of the relevant Product is identified in the applicable Scope of Work;
		
	“Product Specification”	  	the Product specification, mutually agreed by the parties, which is documented in a QA Document;
		
	“Program”	  	a program of work as set out in the applicable Scope of Work (or more than one Scope of Work, as the case may be) to be carried out by Fujifilm in accordance with the terms of this Agreement;
		
	“Program Cancellation Fee”	  	the Program Cancellation Fee described in Schedule 1;
		
	“Program Manager”	  	the Program manager appointed by each of Fujifilm and the Customer under the applicable SoW;
		
	“Program Plan”	  	the Program plan controlled by Fujifilm’s Program Management and communicated to the customer from time to time;
		
	“Quality Agreement”	  	the document agreed by the parties which sets out the mutually agreed quality standards applicable for any cGMP activity under the Program;
		
	“QA Documents”	  	the Quality Agreement and the documents produced and approved in accordance with the Quality Agreement;

  
 7 

			
		
	“Regulatory Authority”	  	the U.S. Food and Drug Administration, the European Medicines Agency, the Medicines & Healthcare products Regulatory Agency, the Danish Medicines Agency and any successor to any such entities;
		
	“Scope of Work” or “SoW”	  	the document setting out the detail of the work to be undertaken by Fujifilm for the Customer;
		
	“SoW Effective Date”	  	for each Scope of Work, the date that the Scope of Work is fully signed by all relevant parties;
		
	“Special Waste”	  	waste or effluent which requires special handling including waste or effluent which is required to be collected in a special container (for example by tanker) for external disposal or which requires incineration;
		
	“Stage”	  	a stage of the Program as described in the SoW;
		
	“Subcontracted Work”	  	work subcontracted by Fujifilm under clause 21.3 but excluding any work subcontracted between FDBK, FDBT, FDBU and/or FDBD;
		
	“Tax”	  	value added tax, sales tax or any other similar type of turnover tax; and
		
	“Willful Misconduct”	  	a knowing violation of a reasonable and uniformly enforced rule or policy. It means intentionally doing that which should not be done or intentionally failing to do that which should be done, knowing that injury will probably result
or recklessly disregarding the possibility that injury may result.

  

	1.2	 In this Agreement (except where the context otherwise requires) any words following the terms
“including”, “include”, “for example” or any similar expression are by way of illustration and emphasis only and shall not limit the generality or extent of any other words or expressions.

  

	1.3	 Each Scope of Work will be entered into by FDBK, FDBT, FDBU or FDBD or a combination of FDBK, FDBT, FDBU and/or
FDBD and, subject to clause 18.3, each reference to Fujifilm or a “party” in this Agreement shall apply only to such of FDBK, FDBT, FDBU and/or FDBD as is carrying out the Program under the relevant Scope of Work. Whichever of FDBK, FDBT,
FDBU and/or FDBD has entered into the Scope of Work in respect of that Program shall be fully and solely responsible for the obligations and liabilities of that party under the Scope of Work. 

  
 8 

	1.4	 Insofar as this Agreement obliges any party to this Agreement to negotiate, take action or to do something,
that party shall conduct such negotiations, take such action or do such thing in good faith and, in the case of Fujifilm, using Commercially Reasonable Efforts to achieve the result contemplated in this Agreement. There shall be a general obligation
on the parties to act in good faith in relation to the matters contemplated in this Agreement. 

  

	1.5	 In the case of conflict or ambiguity between terms of the main body of this Agreement, any Schedule to this
Agreement or any other terms in any Scope of Work, the order of priority shall be as follows: (i) the main body of the Agreement; (ii) the Schedules to the Agreement; and (iii) the main body of the Scope of Work unless a Scope of Work
specifically varies a provision of the Agreement or a Schedule to the Agreement by reference to the provision it is amending in which case the Scope of Work shall take precedence in that instance. 

 

	1.6	 In the case of conflict or ambiguity between the terms of this Agreement or any specific Scope of Work and the
terms of the QA Documents, the terms of the QA Documents shall prevail solely in relation to cGMP quality matters subject to clause 9.10. 

  

	1.7	 Where a defined term is used in clause 9 (Liability) it shall retain its meaning even when the entire word that
is a defined term is in capitals. 

  

	2.	 APPOINTMENT OF FUJIFILM 

 

	2.1	 This Agreement establishes the general terms and conditions applicable to Fujifilm’s performance of each
Program for the Customer and is structured so that a separate, numbered, Scope of Work (or in some cases multiple Scope of Works) shall be entered into by the parties for the provision of each Program. 

  
 9 

	2.2	 The provisions of this Agreement shall apply to each Scope of Work and no Scope of Work shall be effective or
binding on any party until it has been signed by an authorized representative of each contracting party. 

  

	2.3	 Nothing in this Agreement or any Scope of Work shall oblige any party to enter into any Scope of Work and each
Scope of Work constitutes a separate contract. 

  

	3.	 TERM  

  

	3.1	 This Agreement shall come into force on the Effective Date and shall continue until terminated by a party in
accordance with the terms of this Agreement. 

  

	3.2	 A party may terminate this Agreement upon giving 3 (three) months’ written notice to the others, provided
that there are no uncompleted Programs existing at the date such notice is given. 

  

	3.3	 Each Scope of Work will take effect from the SoW Effective Date and shall continue until the earlier of:

  

	 	3.3.1	 the date specified in the Scope of Work, or if no such date is specified, the date the Program, or part of the
Program referred to in the Scope of Work is completed; or 

  

	 	3.3.2	 termination of this Agreement or the relevant Scope of Work in accordance with the terms of this Agreement.

  

	4.	 PERFORMANCE OF PROGRAMS 

 

	4.1	 Fujifilm shall carry out each Program, or parts of a Program, using Commercially Reasonable Efforts in
accordance with: 

  

	 	4.1.1	 the terms of this Agreement and any Scope of Work; 

 

	 	4.1.2	 Applicable Laws; 

  

	 	4.1.3	 the Quality Agreement and cGMP (in both cases when applicable); and 

  
 10 

	 	4.1.4	 the Process Specification for the applicable cGMP Batch (if any). 

 

	4.2	 The parties agree that it shall not be considered a breach of this Agreement by Fujifilm if an objective of a
Program is not achieved provided that Fujifilm has complied with its obligations set out in clause 4.1 and the cause of such non-achievement is [***]. Notwithstanding any contrary provisions in this Agreement,
the parties acknowledge and agree that the services to be performed during the Programs are by their nature developmental and Fujifilm cannot (and consequently does not) guarantee to the Customer the achievement of a successful outcome for a
Program, production of Conforming Batches or production of a specified volume of Product. 

  

	4.3	 Each Scope of Work contains assumptions on which Fujifilm’s ability to perform the Program depends. If an
assumption set out in the Scope of Work proves to be materially incorrect or actual circumstances materially differ from an assumption (including if such assumption cannot be met at such time as Fujifilm reasonably requires to enable it to perform
its obligations) then the parties shall agree a Change to account for the change in assumption. 

  

	4.4	 The Customer shall: 

  

	 	4.4.1	 meet all its obligations and responsibilities under this Agreement, any Scopes of Work (including, in
particular, any Customer dependencies set out in a Scope of Work) and the Quality Agreement; 

  

	 	4.4.2	 comply with Applicable Laws; and 

 

	 	4.4.3	 promptly provide all assistance, information, and advice and do all acts which Fujifilm may reasonably request
to enable Fujifilm to comply with its obligations and responsibilities under this Agreement, any Scope of Work and the Quality Agreement. 

  

	5.	 QUALITY AND REGULATORY MATTERS 

 

	5.1	 Quality Agreement 

 

	 	5.1.1	 As soon as reasonably practicable following the Effective Date the parties shall execute the Quality Agreement
(unless the Quality Agreement has already been executed prior to the Effective Date). 

  
 11 

	 	5.1.2	 The Customer acknowledges that Fujifilm shall not commence any cGMP activity until the Quality Agreement is
executed by both parties. 

  

	5.2	 Regulatory Assistance  

 

	 	5.2.1	 The Customer shall provide Fujifilm with a copy of the Customer’s Chemistry, Manufacturing and Controls
section of any submission to a Regulatory Authority supporting the Customer’s regulatory filing activities for the applicable Drug Product or Process which relates to or contains information about the Process; the Facility (including Fujifilm
equipment); the Fujifilm Services and/or the Ancillary Services (“CMC Section”) in accordance with the Quality Agreement. The Customer shall not submit a CMC Section without Fujifilm’s written approval in relation to any information
regarding, or impacting, Fujifilm including any information regarding the Process, equipment, controls and analytics or any information provided to the Customer by Fujifilm related to or in accordance with the Quality Agreement.

  

	 	5.2.2	 During each Program the Customer may request assistance from Fujifilm in respect of the CMC Section, subject to
payment by the Customer of a reasonable commercial rate for such assistance and Fujifilm’s reasonable expenses. However, no advice or assistance given by Fujifilm shall be deemed to be or construed as a guarantee that a Drug Product will
receive regulatory approval. 

  

	 	5.2.3	 Fujifilm will provide one electronic (PDF) copy of any documents which may be reasonably required by the
Customer in support of its regulatory filing activities. If the Customer requires copies of the laboratory notebooks, provision of these will be subject to discussion and agreement by the parties and agreement of an additional fee associated with
copying. 

  

	 	5.2.4	 The Customer shall have the right and responsibility for determining regulatory strategy, decisions and actions
relating to each Program and any Product and/or Drug Product subject to clause 5.2.5 and provided that Fujifilm shall have the right and responsibility for determining regulatory strategy, decisions and actions to the extent relating to:

  

	 	(a)	 the Facility (including in particular utilities and equipment); 

 

	 	(b)	 Fujifilm’s quality systems, policies and internal procedures; 

 

	 	(c)	 any requirement imposed on Fujifilm by a Regulatory Authority; or 

 

	 	(d)	 any other commitments made by Fujifilm prior to the relevant SoW Effective Date of the applicable Program,

 (each a “Fujifilm Regulatory Responsibility”). 

  
 12 

	 	5.2.5	 The Customer acknowledges that Fujifilm Quality Assurance team reserves the right to Disposition Product to the
Customer in accordance with the Quality Agreement. 

  

	 	5.2.6	 The Customer shall not make any change to its regulatory filings, including its Investigational New Drug
application, which may have an impact on any Fujifilm Regulatory Responsibility without prior written agreement with Fujifilm. 

  

	5.3	 No Debarment.  

 

	 	5.3.1	 Each Party represents and warrants to the other that neither it nor any of its officers, directors, or its
employees performing services under this Agreement has been debarred, or convicted of a crime which could lead to debarment, under the Generic Drug Enforcement Act of 1992, 21 United States Code §§335(a) and (b). 

6. CONFORMING BATCHES AND NON-CONFORMING BATCHES 

 

	6.1	 Each cGMP Batch will be determined to be a Conforming Batch or a
Non-Conforming Batch. 

  

	6.2	 Deviations will be handled in accordance with the Quality Agreement and, for the avoidance of doubt, the
Customer acknowledges that the occurrence of a Deviation does not automatically mean that a Batch is a Non-Conforming Batch. 

 

	6.3	 In respect of Conforming Batches, Fujifilm will complete Disposition, issue a certificate of analysis and a
cGMP compliant statement. The provisions of clauses 6.1 and 6.6 shall apply to Non-Conforming Batches only. 

  

	6.4	 If a Batch is a Non-Conforming Batch and the cause of that Batch being
a Non-Conforming Batch is not a failure by Fujifilm to comply with clause 4.1 [***] then the Customer shall pay the Charges relating to the Non-Conforming Batch
in full and the relevant Manufacturing Stage, Disposition and all related and ancillary activities shall be deemed to have been completed under the Scope of Work. Any further work in relation to the
Non-Conforming Batch (such as analysis of the Batch) or manufacture of a replacement cGMP Batch shall be carried out at a time and price to be agreed in writing by the parties in a Change.

  
 13 

	6.5	 If a Batch is a Non-Conforming Batch and the cause of the Batch being a
Non-Conforming Batch is a failure by Fujifilm to comply with clause 4.1 or caused by the Gross Negligence or Willful Misconduct of Fujifilm, its employees or contractors, then Fujifilm shall use Commercially
Reasonable Efforts to manufacture a replacement cGMP Batch (“Replacement Batch”) as soon as is reasonably practicable. In these circumstances the Customer shall pay for: 

 

	 	6.5.1	 all Charges in respect of the original Non-Conforming Batch in
accordance with the SoW (save that any installments of the Charges which are not due until after the date that the Non-Conforming Batch is determined to be a
Non-Conforming Batch shall become due on completion of the Replacement Batch); and 

  

	 	6.5.2	 the Charges for the Ancillary Services provided in relation to the Replacement Batch but the Fujifilm Services
provided in relation to the Replacement Batch shall be free of charge. 

  

	6.6	 If the Customer requests delivery of a Non-Conforming Batch, the
parties shall agree in writing (in a Change) on fair consideration payable for that Non-Conforming Batch. Fujifilm agrees to deliver a Non-Conforming Batch to the
Customer on the express condition that it (i) will not be used for human or clinical trials; (ii) will be labeled as “Not for Human Use”; and (iii) is subject to the Customer’s indemnity given under clause 9.6.

  

	7.	 DELIVERY, TITLE AND RISK 

 

	7.1	 Delivery by Fujifilm to the Customer, or the Customer’s designee, of any material in connection with the
Program including any quantity of Product manufactured during the Program, any Process-Specific Equipment and/or Process-Specific Consumables and return of any samples and cell lines supplied by the Customer (“Materials”) will be
made Ex Works the Facility (Incoterms 2010) and clauses 7.2 to 7.6 shall apply to such Materials. Fujifilm shall package the relevant Material ready for shipment in accordance with the Customer’s reasonable instructions. 

  
 14 

	7.2	 Delivery of Materials will be deemed to be complete on the date which Fujifilm makes the Materials available
for collection by the Customer (which is the point of delivery as set forth in Ex Works (Incoterms 2010)) following notification, of at least [***], by Fujifilm to the Customer that it will make those Materials available for collection (the
“Delivery Date”). For the avoidance of doubt, Product subject to Disposition will not be made available for collection by the Customer until Disposition is complete and Product for which a licence is required under clause
10.3 will not be made available for collection by the Customer until a licence has been signed by the parties. 

  

	7.3	 If the Customer fails to collect Materials within [***] of the Delivery Date, Fujifilm will issue a further
notice to the Customer specifying that the Materials will be destroyed if they are not collected within [***] from the date of the notice. If the Customer does not collect the Materials within that [***] period, Fujifilm may destroy the Materials at
the Customer’s risk and expense. 

  

	7.4	 Risk in Material shall pass to the Customer on the Delivery Date; save for risk in Product for which a licence
is required under clause 10.3 in relation to which risk shall pass on the date on which Fujifilm notifies the Customer it would have made the Materials available for collection if a licence had been signed by the parties. 

 

	7.5	 Title to the Product shall pass to the Customer on the Delivery Date. 

 

	7.6	 Title to, and risk in, the Process-Specific Equipment and/or Process-Specific Consumables purchased by the
Customer in accordance with Schedule 1 shall pass to the Customer when Fujifilm has received payment in full (in cash or cleared funds) for such items in accordance with paragraph 1.1 of Schedule 1 [***]. 

 

	7.7	 From time to time Fujifilm may agree to store Materials (including intermediate Product for future processing)
for Customer. If Fujifilm agree to store Materials the parties will enter into a storage agreement on Fujifilm’s standard terms. 

  
 15 

	7.8	 Delivery of any materials which the Customer is required to supply to Fujifilm pursuant to the SoW shall be
delivered to Fujifilm DDP, the Facility (Incoterms 2010). Risk in those materials remains with the Customer [***]. 

  

	8.	 PRICE AND PAYMENT 

 

	8.1	 Under this Agreement, and the relevant Scope of Work, the Customer appoints Fujifilm to carry out services
concerning the research and development, testing, manufacture and Disposition of the Product by Fujifilm under a Program. The Charges relate specifically to those services; and are not in consideration of the supply of any material (including
Product) which Fujifilm may produce as a consequence of the performance of those services. 

  

	8.2	 The Customer shall pay to Fujifilm for each Program: 

 

	 	8.2.1	 the fees for the Fujifilm Services as set out in the relevant Scope of Work; and 

 

	 	8.2.2	 the fees for Ancillary Services in accordance with Schedule 1, together the “Charges”.

  

	8.3	 Fujifilm may invoice the Customer for the Charges in respect of each Program in accordance with the terms set
out in the Scope of Work and Schedule 1. 

  

	8.4	 The Customer shall pay each invoice issued to it by Fujifilm within [***] of the date of invoice, in full and
in cleared funds in the currency specified in the SoW by electronic transfer to the financial institution specified in the relevant invoice. 

  

	8.5	 The Charges are exclusive of any Tax which may apply and which shall be payable by the Customer to Fujifilm at
the rate prescribed by law. 

  

	8.6	 If there is a change in the rate of Tax payable or in the Tax treatment of some or all of the services provided
by Fujifilm or the Product, a change of law or practice or interpretation of the existing legislation or revised determination by HMRC (Her Majesty’s Revenue and Customs) or the IRS (Internal Revenue Service), then the 

  
 16 

	 	
Customer agrees that Fujifilm shall be entitled, where Tax is imposed on a supply by Fujifilm under or in connection with this Agreement, to invoice the Customer (in a valid Tax invoice) for a
sum equal to the amount of the Tax which becomes due on that supply and any fees and/or interest which HMRC and/or the IRS levies on Fujifilm in relation to the outstanding sums and/or non-payment, unless such
fees or interests arise directly from Fujifilm’s negligence or Willfull Misconduct. The Customer shall pay those invoices in accordance with clause 8.4. 

  

	8.7	 The Customer shall: 

  

	 	8.7.1	 be responsible for the collection, remittance and payment of any or all taxes, charges, levies, assessments and
other fees of any kind imposed by governmental or other authority in respect of the purchase, importation, exportation, sale or other distribution of any materials delivered to it by Fujifilm in connection with the Program; and

  

	 	8.7.2	 make all payments under this Agreement without withholding or deduction of, or in respect of, any tax unless
required by law. If withholding tax is deducted then the Customer will provide all documentation required to enable Fujifilm to recover the tax withheld. 

  

	8.8	 Without prejudice to any other right or remedy that it may have, if the Customer fails to pay any sum to
Fujifilm on the due date for payment: 

  

	 	8.8.1	 (except where the Customer has complied with its obligations in clause 8.9 below) the Customer shall pay
interest on the overdue amount at the rate of [***] ([***] per cent) per month. Such interest shall be payable in respect of the period from the due date until actual payment of the overdue amount (whether before or after judgment) in accordance
with clause 8.4; and 

  

	 	8.8.2	 (except where the Customer has complied with its obligations in clause 8.9 below) Fujifilm may notify the
Customer that if it does not pay Fujifilm will suspend work on the Program in respect of which payment is overdue, and if payment is not made within [***] of such notice, Fujifilm may suspend such work until payment has been made in full.

  

	8.9	 If the Customer disputes the payment of any Charges or a part of them, the Customer shall:

  
 17 

	 	8.9.1	 notify Fujifilm of the disputed amount within [***] of its receipt of the invoice in which such disputed amount
is included giving reasonable details of the dispute; and 

  

	 	8.9.2	 pay the amount of Charges not in dispute in accordance with clause 8.4, and the dispute shall be dealt with
under the dispute resolution process set out in clause 16. 

  

	8.10	 If the Customer fails to pay any sum which is not the subject of a bona fide dispute under clause 8.9 when the
same is due in accordance with clause 8.4 then Fujifilm may elect, at its discretion, to treat such non-payment as a material breach of either the relevant SoWs under clause 14.5.1 or a material breach of this
Agreement under clause 14.2.1. 

  

	8.11	 A party shall not be entitled to withhold, set off or reduce payment of any amounts payable under this
Agreement by any amounts which it claims are owed to it by another party under this Agreement or any other agreement. 

  

	9.	 LIABILITY 

  

	9.1	 Nothing in this Agreement limits or excludes the liability of any party to the other for any liability that is
not permitted to be limited or excluded by law and clauses 9.2 to 9.7 are expressly agreed to be subject to this clause 9.1. 

  

	9.2	 EXCEPT IN RESPECT OF BREACH BY FUJIFILM OF CLAUSE 12 (CONFIDENTIALITY) OR LIABILITY ARISING UNDER CLAUSE 11.1
(IPR INDEMNITY) AND SUBJECT TO CLAUSE 9.6.1, FUJIFILM’S TOTAL LIABILITY, WHETHER OR NOT ARISING PURSUANT TO AN INDEMNITY, IN CONTRACT, TORT (INCLUDING NEGLIGENCE OR BREACH OF STATUTORY DUTY), MISREPRESENTATION, RESTITUTION OR OTHERWISE ARISING
UNDER THIS AGREEMENT OR A SCOPE OF WORK OR IN CONNECTION WITH THE PERFORMANCE OR CONTEMPLATED PERFORMANCE OF THIS AGREEMENT OR A SCOPE OF WORK SHALL IN ALL CIRCUMSTANCES BE LIMITED AS FOLLOWS: 

  
 18 

	 	9.2.1	 WHEN THERE HAS BEEN NO GROSS NEGLIGENCE OR WILLFUL MISCONDUCT BY FUJFILM: IN RESPECT OF ALL LIABILITY ARISING
UNDER A SCOPE OF WORK, FUJIFILM’S LIABILITY TO CUSTOMER SHALL BE LIMITED PER CALENDAR YEAR TO AN AMOUNT EQUAL TO THE CHARGES FOR FUJIFILM SERVICES PAID BY CUSTOMER IN RESPECT OF THAT SCOPE OF WORK DURING THAT CALENDAR YEAR; OR

  

	 	9.2.2	 WHEN THERE HAS BEEN GROSS NEGLIGENCE OR WILLFUL MISCONDUCT BY FUJFILM: IN RESPECT OF ALL LIABILITY ARISING
UNDER A SCOPE OF WORK, FUJIFILM’S LIABILITY TO CUSTOMER SHALL BE LIMITED PER CALENDAR YEAR TO AN AMOUNT EQUAL TO [***] OF THE CHARGES FOR FUJIFILM SERVICES PAID BY CUSTOMER IN RESPECT OF THAT SCOPE OF WORK DURING THAT CALENDAR YEAR; AND

  

	 	9.2.3	 IN RESPECT OF ANY OTHER LIABILITY RELATING TO THIS AGREEMENT, FUJIFILM’S TOTAL LIABILITY TO CUSTOMER SHALL
BE LIMITED PER CALENDAR YEAR TO [***] ([***]PER CENT) OF THE TOTAL CHARGES FOR FUJIFILM SERVICES PAID UNDER ALL SOWS IN FORCE DURING THAT CALENDAR YEAR. 

  

	9.3	 UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), FOR
BREACH OF STATUTORY DUTY OR OTHERWISE, ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR: LOSS OF PROFIT; LOSS OF BUSINESS; DEPLETION OF GOODWILL; LOSS OF ANTICIPATED SAVINGS; LOSS OR CORRUPTION OF DATA OR INFORMATION; OR ANY SPECIAL, INDIRECT,
CONSEQUENTIAL LOSS, COSTS, DAMAGES, CHARGES OR EXPENSES, INCLUDING, IN THE CASE OF FUJIFILM’S LIABLIITY, THE COSTS OF ANY RECALL OF THE PRODUCT OR DRUG PRODUCT. THE FOREGOING LIMITATION OF LIABILITY SHALL NOT BE CONSTRUED AS LIMITING A
PARTY’S INDEMFNICATION OBLIGATIONS UNDER THS AGREEMENT FOR CLAIMS MADE BY THIRD PARTIES. 

  
 19 

	9.4	 Liability for Product and Drug Product: the Customer shall Indemnify Fujifilm from and against all
Liabilities incurred by Fujifilm or its Affiliates arising out of or resulting from the use or resale of the Product or the Drug Product or any other deliverable arising out of the Program except when those Liabilities have arisen pursuant to Gross
Negligence or Willful Misconduct of Fujifilm in which case Fujifilm shall bear such Liabilities up to the amounts for which Fujifilm is liable to the Customer under clause 9.2.2. 

 

	9.5	 Liability for the Process: the Customer shall Indemnify Fujifilm from and against all Liabilities
arising from third party claims incurred by Fujifilm or its Affiliates arising out of or resulting from the use or operation of the Process (or any part of the Process) except [***] to the extent that Fujifilm is liable under clause 11.1.

  

	9.6	 Liability for Non-Conforming Batches: 

  

	 	9.6.1	 THE PROVISIONS OF CLAUSE 6 SHALL APPLY TO NON-CONFORMING BATCHES AND
FUJIFILM SHALL HAVE NO LIABILITY IN RESPECT OF NON-CONFORMING BATCHES EXCEPT TO COMPLY WITH CLAUSE 6. 

  

	 	9.6.2	 FUJIFILM GIVES NO, AND DISCLAIMS ANY, WARRANTIES, UNDERTAKINGS OR SIMILAR TERMS WHATSOEVER (WHETHER AS TO
COMPLIANCE WITH CGMP OR OTHERWISE) IN RESPECT OF NON-CONFORMING BATCHES OR THE USE BY THE CUSTOMER OF NON-CONFORMING BATCHES. 

 

	 	9.6.3	 If the Non-Conforming Batch is delivered to the Customer pursuant to
clause 6, the Customer shall fully Indemnify Fujifilm from and against all Liabilities incurred by Fujifilm or its Affiliates arising out of or resulting from the use of that Non-Conforming Batch.

  

	 	9.6.4	 The Customer uses any material produced in a Non-Conforming Batch at
its own risk and shall undertake such tests as are necessary in order to satisfy itself that such materials are fit for the purposes for which the Customer proposes to use such materials. 

 

	9.7	 Liability for Demonstration and Engineering Batches 

 

	 	9.7.1	 FUJIFILM GIVES NO, AND DISCLAIMS ANY, WARRANTIES, UNDERTAKINGS OR SIMILAR TERMS WHATSOEVER (WHETHER AS TO
COMPLIANCE WITH CGMP OR OTHERWISE) IN RESPECT OF THE DEMONSTRATION BATCHES OR ENGINEERING BATCHES OR THE USE BY THE CUSTOMER OF AN ENGINEERING BATCH OR DEMONSTRATION BATCH. 

  
 20 

	 	9.7.2	 FUJIFILM SHALL HAVE NO LIABILITY TO THE CUSTOMER IN CONNECTION WITH DEMONSTRATION BATCHES OR ENGINEERING
BATCHES OR THE USE BY THE CUSTOMER OF THE DEMONSTRATION BATCHES OR ENGINEERING BATCHES. 

  

	 	9.7.3	 The Customer shall fully Indemnify Fujifilm from and against all Liabilities incurred by Fujifilm or its
Affiliates arising out of or resulting from the use of the Demonstration Batches or Engineering Batches. 

  

	 	9.7.4	 The Customer uses any material produced in a Demonstration Batch or Engineering Batch at its own risk and shall
undertake such tests as are necessary in order to satisfy itself that such materials are fit for the purposes for which the Customer proposes to use such materials. Customer expressly agrees that Product produced pursuant to a Demonstration Batch or
an Engineering Batch is not suitable, and will not be used, for human consumption or use or in clinic trials. 

  

	9.8	 FUJIFILM GIVES NO, AND DISCLAIMS ANY, WARRANTIES, UNDERTAKINGS OR SIMILAR TERMS WHATSOEVER IN RESPECT OF ANY
ADVICE OR ASSISTANCE GIVEN BY FUJIFILM IN CONNECTION WITH THE USE OF THE PRODUCT IN OR AS A DRUG PRODUCT (INCLUDING ADVICE OR ASSISTANCE RELATED TO ANY REGULATORY APPROVAL). 

 

	9.9	 ALL WARRANTIES, CONDITIONS AND OTHER TERMS, EXPRESS (OTHER THAN THOSE SET OUT IN THIS AGREEMENT) OR IMPLIED,
STATUTORY, CUSTOMARY OR OTHERWISE WHICH BUT FOR THIS CLAUSE 9 WOULD OR MIGHT SUBSIST IN FAVOR OF THE CUSTOMER, ARE (TO THE FULLEST EXTENT PERMITTED BY LAW) EXCLUDED FROM THIS AGREEMENT INCLUDING, IN PARTICULAR, ANY IMPLIED WARRANTIES RELATING TO
MERCHANTABILITY, FITNESS FOR A PARTICULAR USE AND NON-INFRINGEMENT. 

  

	9.10	 No claim for Liabilities incurred pursuant to the Quality Agreement may be made under the Quality Agreement by
any party. Accordingly, performance of the Quality Agreement shall be deemed to be performance under the SoW to which the Quality Agreement relates and as such any breach of the Quality Agreement shall be deemed to be a breach of the relevant SoW
and all Liabilities shall be construed and limited in accordance with this clause 9. 

  
 21 

	9.11	 If the parties enter into a Scope of Work for stability or analytical services subject to this Agreement, the
parties agree that such services shall are incidental and it is therefore reasonable that such Scope of Work may contain lower limits on Fujifilm’s Liability than are contained in this Agreement, in which case such limitation as set out in such
Scope of Work shall apply to such Scope of Work. 

  

	9.12	 Each party agrees to take all reasonable steps to mitigate any Liabilities that it may seek to claim from the
other under or in connection with this Agreement including pursuant to any Indemnity. 

  

	9.13	 If a party is entitled to benefit from an Indemnity (the “Indemnified Party”) from another
party (the “Indemnifying Party”) in accordance with this Agreement (an “Indemnity Claim”), the Indemnified Party shall notify the Indemnifying Party in writing of the Indemnity Claim (providing all necessary
details) and the Indemnifying Party shall at its own expense conduct all negotiations and any litigation arising in connection with the Indemnity Claim provided always that: 

 

	 	9.13.1	 the Indemnifying Party shall consult the Indemnified Party on all substantive issues which arise during the
conduct of such litigation and negotiations and shall take due and proper account of the interests of the Indemnified Party; 

  

	 	9.13.2	 the Indemnifying Party shall not settle or compromise the Indemnity Claim without the Indemnified Party’s
prior written consent (not to be unreasonably withheld or delayed) and shall ensure that any settlement or compromise does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of the Indemnified
Party; 

  

	 	9.13.3	 the Indemnified Party shall not make any admissions or admit liability in relation to the Indemnity Claim or
otherwise settle any Indemnity Claim without the written agreement of the Indemnifying Party; and 

  

	 	9.13.4	 the Indemnified Party shall fully cooperate and assist the Indemnifying Party, at the Indemnifying Party’s
cost and expense, in relation to the Indemnity Claim (without limiting the extent of the Indemnity). 

  
 22 

	9.14	 Each party shall maintain adequate insurance (which may be through self-insurance) to enable it to satisfy its
Liabilities under this Agreement as they arise. 

  

	10.	 INTELLECTUAL PROPERTY  

 

	10.1	 Subject to clause 10.2 and clause 10.7, no party shall acquire any right, title or interest in another
party’s Background IP. 

  

	10.2	 The Customer grants to Fujifilm a royalty-free, worldwide licence to use Customer’s Background IP for the
exclusive purpose of performance of the Program. Customer warrants that, to its knowledge, the use by Fujifilm (or its Authorized Third Parties) of Customer’s Background IP in accordance with this clause 10.2 shall not infringe any third
party’s Intellectual Property Rights. 

  

	10.3	 Fujifilm shall not be obliged to deliver any materials (including any cell bank or cell paste) comprising
Fujifilm Expression Technology unless and until a licence is granted in writing on terms to be agreed under the relevant Background IP. Fujifilm shall be entitled to charge the Customer for storage of any such materials which would have been
delivered under clause 7.2 if a licence had been granted under this clause 10.3 until the time that such licence is granted. Customer acknowledges that storage may be at a third party storage facility unless Fujifilm and Customer have agreed in
writing otherwise. Fujifilm shall not employ Fujifilm Expression Technology in a Process without Customer’s prior written consent. 

  

	10.4	 All title to and all rights and interest in any Customer Foreground IP shall vest in Customer. Fujifilm hereby
assigns to the Customer all title to and all rights and interest it owns in any Customer Foreground IP. 

  

	10.5	 All title to and all rights and interest in any Fujifilm Foreground IP shall vest in Fujifilm. The Customer
hereby assigns to Fujifilm all title to and all rights and interest it owns in any Fujifilm Foreground IP. 

  
 23 

	10.6	 If requested to do so by another party, each party shall at the expense of the requesting party execute all
documents and do all such further acts as the requesting party may reasonably require to perfect the assignment under clause 10.4 or 10.5. 

  

	10.7	 Fujifilm grants to Customer a royalty free, non exclusive, worldwide licence to use the Fujifilm Foreground IP
and Fujifilm Background IP other than Fujifilm Expression Technology employed in a Process for the exclusive purpose of manufacturing the Product. 

11. INTELLECTUAL PROPERTY INDEMNITY  
  

	11.1	 Fujifilm shall fully Indemnify the Customer from and against all Liabilities incurred by the Customer or its
Affiliates arising out of any third party claim that Fujifilm’s use of Fujifilm’s Background IP or Fujifilm Foreground IP in performing the Program infringes such third party’s Intellectual Property Rights. 

 

	11.2	 The Customer shall fully Indemnify Fujifilm from and against all Liabilities incurred by Fujifilm or its
Affiliates arising out of any third party claim that: 

  

	 	11.2.1	 Fujifilm’s use of (i) materials provided by the Customer to Fujifilm or (ii) Customer’s
Intellectual Property Right, in accordance with this Agreement; or 

  

	 	11.2.2	 (excluding Liabilities in relation to which Fujifilm Indemnifies the Customer pursuant to clause 11.1) the
development or manufacture of the Product and/or any other deliverables which are an output of the Program or the use of the Process in accordance with this Agreement, infringes such third party’s Intellectual Property Rights.

  

	11.3	 If a third party claim is made in accordance with clause 11.1 or 11.2 then the Indemnified Party may require
the Indemnifying Party to prove that it has adequate financial means to pay out under the indemnity provisions provided for in those clauses (for example by way of set aside capital or insurance). If the Indemnifying Party cannot so prove it has the
financial standing to meet its obligations with respect to the Indemnities under the applicable clause then the Indemnified Party has the option to terminate this Agreement on written notice. If Fujifilm exercises its option to terminate under this
clause 11.3 then (without prejudice to the survival of the relevant Indemnity obligations) such termination shall be treated as a termination under clause 14.3.2. 

  
 24 

 12. CONFIDENTIALITY 
  

	12.1	 Each party (the “Receiving Party”) agrees with the other (the “Disclosing
Party”): 

  

	 	12.1.1	 to keep the Disclosing Party’s Confidential Information confidential; 

 

	 	12.1.2	 not to access or use the Disclosing Party’s Confidential Information save for the purposes of:

  

	 	(a)	 complying with its obligations under this Agreement and each SoW; 

 

	 	(b)	 complying with, or exercising its rights under, any confidentiality disclosure agreement then in force between
the parties; or 

  

	 	(c)	 undertaking activity by and between the parties to enable the parties to explore a new business opportunity
involving the Customer and one or more of the other parties (“New Opportunity”); 

  

	 	12.1.3	 not to disclose the Disclosing Party’s Confidential Information to a third party other than to the
Receiving Party’s: 

  

	 	(a)	 Affiliates; 

  

	 	(b)	 officers and employees and those of its Affiliates that need to know the Confidential Information for the
purpose of performing its obligations under this Agreement or in relation to a New Opportunity; 

  

	 	(c)	 contractors and sub-contractors, professional advisers, consultants and
agents and those of its Affiliates who are engaged to advise that party in connection with the Program or this Agreement or in relation to a New Opportunity; and 

 

	 	(d)	 any other person to whom the Disclosing Party agrees in writing that Confidential Information may be disclosed
in connection with the Program, 

 the “Authorized Third Parties”. By way of clarification, Authorized
Third Parties include the persons described above regardless of whether the Disclosing Party disclosed Confidential information to such persons or if Receiving Party discloses Confidential Information to such persons. 

  
 25 

	12.2	 The Receiving Party shall procure that each of the Authorized Third Parties agree or are otherwise bound to
written or professional confidentiality, nondisclosure and nonuse obligations substantially similar to those set forth in this clause 12 and shall remain primarily liable to the Disclosing Party for any act or omission of any of the Authorized Third
Parties (including failure of such Authorized Third Parties to comply with such confidentiality, nondisclosure and nonuse obligations. 

  

	12.3	 The Receiving Party shall within [***] of receipt of the Disclosing Party’s written request (including
after termination of this Agreement and any SoW): 

  

	 	12.3.1	 deliver up to the Disclosing Party all items and copies of all or any Confidential Information of the
Disclosing Party; 

  

	 	12.3.2	 expunge and/or make irretrievable all Confidential Information of the Disclosing Party from any computer or
other similar device in which it is stored and, if further requested, certify in writing signed by an authorized representative that it has done the same (provided that this clause 12.3.2 shall not apply to automatically archived electronic files or
electronic back-ups made in the ordinary course of business, on secured central servers, which cannot reasonably be deleted and such electronic files shall be retained subject to the obligations of confidence
set out in this clause 12); and 

  

	 	12.3.3	 destroy all hard copies of notes, analyses or memoranda containing the Disclosing Party’s Confidential
Information (and, if further requested, certify in writing signed by an authorized representative that it has done the same) 

provided that the Receiving Party shall be entitled to retain copies of the Confidential Information to enable it to monitor its obligations
under this Agreement or which is required to be maintained by Applicable Laws or a Regulatory Authority subject always to the obligations of confidence under this Agreement. 
  

	12.4	 Confidential Information shall not include information which: 

 

	 	12.4.1	 is, or becomes, generally available to the public other than as a direct or indirect result of the information
being disclosed by the Receiving Party or its Authorized Third Parties in breach of this Agreement (except that any compilation of otherwise public information in a form not publicly known shall still be treated as Confidential Information);

  

	 	12.4.2	 was available to the Receiving Party on a non-confidential basis prior
to disclosure by the Disclosing Party; 

  

	 	12.4.3	 was, is, or becomes available to the Receiving Party on a
non-confidential basis from a person who, to the Receiving Party’s knowledge, is not under any confidentiality obligation in respect of that information; 

  
 26 

	 	12.4.4	 was lawfully in the possession of the Receiving Party without an obligation of confidentiality before the
information was disclosed by the Disclosing Party 

  

	 	12.4.5	 is developed by or for the Receiving Party independently of the information disclosed by the Disclosing Party;

  

	 	12.4.6	 is necessarily disclosed by the Receiving Party pursuant to a statutory or regulatory obligation, but then only
to the extent of such required disclosure and save that the Receiving Party shall, to the extent it is lawful to do so, give prompt notice to the Disclosing Party of any such potential disclosure and allow the Disclosing Party a reasonable
opportunity to limit such disclosure; or 

  

	 	12.4.7	 the Disclosing Party and the Receiving Party agree in writing is not confidential. 

 

	12.5	 Customer may use and disclose Confidential Information of Fujifilm solely to the extent necessary in
communications with existing or prospective Customer’s investors, sub-licensees or commercial partners provided that: (a) such recipients are under obligations of confidentiality at least as
restrictive as the terms of this clause 12; (b) none of the financial terms of the Agreement are disclosed to any such investor, sublicensee or commercial partner without the prior written consent of Fujifilm; (c) no disclosures are made to
contract development and/or manufacturing organizations in the biopharmaceutical industry without Fujifilm’s prior written consent; and (d) such recipients are treated as Authorized Third Parties for the purposes of clause 12.2.
Additionally, Customer shall notify Fujifilm of any disclosure to any investors, sub-licensees or commercial partners, including the name of the recipient and date and nature of disclosure.

  

	12.6	 [***] 

13. CHANGE 
  

	13.1	 If a party wishes to change (“Change”) any aspect of this Agreement or any Scope of Work
(including if additional or different work is requested or required such as the production of a different number of Batches or if such work is required to be carried out at a different time or if actual circumstances differ from the assumptions set
out in the Scope of Work (including if such assumptions cannot be met at all or in a timely fashion)) then Fujifilm shall draft a Change document using its standard format for that Change and the Change shall not be effective until the applicable
Change document is signed by each party. 

  
 27 

	13.2	 If the parties are unable to agree the terms of a Change and the dispute resolution process set out in clause
16 has been unsuccessfully exhausted Fujifilm may terminate the relevant SoW(s) and any cancellation or termination fees [***]. 

  

	14.	 DELAY, CANCELLATION, TERMINATION AND CONSEQUENCES 

 

	14.1	 Delay:  

  

	 	14.1.1	 If the Customer either causes or requests a delay to any Stage; Stages; or the Program as a whole and that
delay prevents, or will prevent, Fujifilm from performing a Manufacturing Stage or the Program as a whole in accordance with the Program Plan (a “Delay”) and the parties cannot agree a Change to accommodate that Delay:

  

	 	(a)	 then either the Batch Cancellation Fee(s) or the Program Cancellation Fee (as applicable) shall be payable; and

  

	 	(b)	 the Batch Cancellation Fee or Program Cancellation Fee (as applicable) shall be calculated by reference to the
date on which such written request was given by the Customer in relation to the Delay if such written request is given, or the date on which the Delay is caused, as determined by Fujifilm acting reasonably. 

 

	 	14.1.2	 If the parties agree a Change to accommodate the Delay and that results in the Delayed Stage(s) or Program (as
applicable) being performed partially within the original period reserved for the Delayed Stage(s) or Program as a whole, then the Batch Cancellation Fee(s) or the Program Cancellation Fee (as applicable) shall be reduced proportionally to reflect
the period of time that the Program was Delayed (as determined by Fujifilm acting reasonably). 

  

	14.2	 Termination of this Agreement as a whole 

 

	 	14.2.1	 Fujifilm collectively or the Customer shall be entitled to terminate this Agreement (and all Scope of Works
made under it) immediately upon giving notice to the other if: 

  

	 	(a)	 the other party commits a material breach of this Agreement and such breach: 

  
 28 

	 	(i)	 is not capable of remedy (a breach shall be considered capable of remedy if the party in breach can comply with
the provision in question in all respects other than as to time of performance); or 

  

	 	(ii)	 is capable of remedy, [***] period after receipt of notice giving full particulars of the breach and requiring
it to be remedied, provided, however, that (a) material breaches of clause 8.4 must be cured within [***] and (b) such cure period shall be suspended during any time that a party seeks resolution of a dispute as to whether an alleged
material breach occurred pursuant to clause 16; 

  

	 	(b)	 the other party takes any step or action in connection with its entering administration, provisional
liquidation or any composition or arrangement with its creditors (other than in relation to a solvent restructuring), being wound up (whether voluntarily or by order of the court, unless for the purpose of a solvent restructuring), having a receiver
appointed to any of its assets or ceasing to carry on business or, if the step or action is taken in another jurisdiction, in connection with any analogous procedure in the relevant jurisdiction; 

 

	 	(c)	 the other party or the person controlling the other party has a change in control and the new controlling
entity is reasonably considered by the party giving notice either to be its direct competitor or not to have reasonable financial creditworthiness. 

  

	14.3	 Termination of a Stage/Program by the Customer for Convenience 

 

	 	14.3.1	 The Customer may cancel a Non-Manufacturing Stage or Non-Manufacturing Program for convenience by giving written notice to Fujifilm in which case: 

  

	 	(a)	 the SoW shall terminate in respect of that Stage if a Stage is being terminated but in all other respects the
SoW shall continue in full force; 

  

	 	(b)	 the SoW(s) in respect of that Program shall terminate if a Program as a whole is being terminated; and

  

	 	(c)	 the Customer shall pay Fujifilm the Charges that are due for the Fujifilm Services that have been performed and
[***] of the Charges for the Fujifilm Services that have not yet been performed in that Non-Manufacturing Stage or Program (as applicable) [***] plus any Charges owed in respect of Ancillary Services.

  

	 	14.3.2	 The Customer may cancel any Manufacturing Stage for convenience by giving written notice to Fujifilm in which
case: 

  

	 	(a)	 the SoW shall terminate in respect of that Stage; 

  
 29 

	 	(b)	 in all other respects the SoW shall continue in full force; 

 

	 	(c)	 the Customer shall pay the Charges that are due for the Fujifilm Services that have been performed, the
relevant Batch Cancellation Fee plus any Charges owed in respect of Ancillary Services. 

  

	 	14.3.3	 The Customer may cancel a Program which includes Manufacturing for convenience by giving written notice to
Fujifilm in which case: 

  

	 	(a)	 the SoW(s) in respect of that Program shall terminate; 

 

	 	(b)	 the Customer shall pay the Charges that are due for the Fujifilm Services that have been performed, the Program
Cancellation Fee plus any Charges owed in respect of Ancillary Services. 

  

	 	14.3.4	 If a critical Stage, or more than one Stage, under a Program which includes Manufacturing is cancelled and that
has the effect of cancelling that Program as a whole (as determined by Fujifilm acting reasonably) then clause 14.3.3 shall apply instead of clauses 14.3.1 and/or 14.3.2. 

 

	14.4	 Termination of a Program Due to Technical Issues.  

 

	 	14.4.1	 Fujifilm may terminate a Program at any time up to completion of the
Non-Manufacturing Stages by giving written notice to the Customer if Fujifilm reasonably believes that it will be unable to carry out and complete such Program in accordance with the Scope of Work(s) due to
discovery of a factor (other than an breach by Fujifilm of clause 4.1) which: 

  

	 	(a)	 adversely affects the development of the Process; or 

 

	 	(b)	 adversely affects, or is likely to adversely affect, production of Product in the Facility when conducted in
accordance with Fujifilm’s standard operating procedures or methods 

  

	 	(c)	 is likely to have an adverse effect on a customer’s Product licence (being the licence authorising
marketing of a medicinal product granted by a Regulatory Authority (also known as a “Marketing Authorisation” in Europe)) or Manufacturing Licence (being the licence to manufacture biotechnology-derived Drug Substances issued to Fujifilm
by the applicable Regulatory Authority) as a result of the Product being introduced into the Facility and that customer was a customer of Fujifilm prior to the Program commencement,, 

provided that, in each case, the factor was not known and could not reasonably have been known at the commencement of the applicable Program
and provided further that Fujifilm has used commercially reasonable efforts in its attempts to address the factor prior to such termination. 

  
 30 

	 	14.4.2	 If Fujifilm terminates a Program under clause 14.4.1 then the Customer shall pay the Charges that are due for
the Fujifilm Services that have been performed and [***] of the Program Cancellation Fee plus any Charges owed in respect of Ancillary Services. 

  

	14.5	 Termination of a Scope of Work for Breach 

 

	 	14.5.1	 If any party commits a material breach of a Scope of Work, the
non-breaching party may give written notice to the other party, specifying the nature of the material breach and, [***] after receipt of such notice (provided, however, that (a) payment obligations must
be cured within [***] and (b) the cure period shall be suspended during any time that a party seeks resolution of a dispute as to whether an alleged material breach occurred pursuant to clause 16), then the
non-breaching party shall have the right, in its sole discretion, to immediately terminate that Scope of Work. 

  

	 	14.5.2	 If Fujifilm terminates a Scope of Work under this clause 14.5 or all Scopes of Work under clause 14.2 then,
without prejudice to Fujifilm’s other rights and remedies, the Program Cancellation Fee shall be payable by the Customer to Fujifilm plus any Charges owed in respect of Ancillary Services. 

 

	14.6	 If a party exercises any of its rights of termination in respect of only one or more SoWs then:

  

	 	14.6.1	 this Agreement shall terminate in respect of those SoWs and the provisions of this Agreement relating to
termination of this Agreement shall apply in relation to those SoWs; and 

  

	 	14.6.2	 in all other respects this Agreement shall continue in full force and those SoWs in respect of which the party
has terminated this Agreement will be deemed to be removed from the definition of the SoWs. 

  

	14.7	 Additional Consequences of Termination 

 

	 	14.7.1	 The termination of this Agreement or any Scope of Work shall be without prejudice to the rights and remedies of
any party which may have accrued up to the date of termination. 

  

	 	14.7.2	 On termination of this Agreement or any SoW (as applicable) for any reason whatsoever: 

 

	 	(a)	 save as set out in clause 10 the relationship of the parties shall cease and any rights or licenses granted
under or pursuant to this Agreement shall cease to have effect save as (and to the extent) expressly provided for in this clause 14; 

  
 31 

	 	(b)	 the provisions of the following clauses together with any provision which expressly or by implication is
intended to come into or remain in force on or after termination shall continue in full force and effect clauses 1, 6 [***] 8, 9, 10, 11, 12, 14, 16, 18, and 23; and 

 

	 	(c)	 the Customer shall immediately pay to Fujifilm all of Fujifilm’s outstanding unpaid invoices and interest
and, in respect of Fujifilm Services and Ancillary Services supplied but for which no invoice has been submitted, Fujifilm may submit an invoice, which shall be payable immediately on receipt. 

 

	15.	 FORCE MAJEURE 

 

	15.1	 Based on conditions as of the Effective Date, Fujifilm has the capacity to undertake the anticipated Fujifilm
Services under this Agreement. However, Fujifilm is unable to predict how the global COVID-19 pandemic (the “Pandemic”) may affect Fujifilm’s ability to perform its
obligations set forth in this Agreement or a Scope of Work. Effects of the Pandemic, including staff shortages (either as a result of government recommended/mandated physical isolation or distancing or illness of our workers) and the inability
to obtain required supplies or services, may require Fujifilm to alter the way its facilities operate after the Effective Date. As of the Effective Date, Fujifilm has a process to fairly address the needs of its various
customers. However, Customer acknowledges and accepts that factors arising from the Pandemic may impact Fujifilm’s ability to perform its obligations under this Agreement or a Scope of Work for an indeterminate
period of time, and as a result, the expected timing of performance of Fujifilm Services (or Ancillary Services) on behalf of Customer under a Scope of Work may need to be deferred upon notice to Customer by Fujifilm. 

 

	15.2	 Subject to clause 15.33, no party shall be liable to the other(s) for any delay or non-performance of its obligations under any Scope of Work (except for the payment of money) arising from a Force Majeure Event. 

  
 32 

	15.3	 If a party is delayed or prevented from performing its obligations due to a Force Majeure Event such party
shall: 

  

	 	15.3.1	 give notice of such delay or prevention due to the Force Majeure Event to the
non-affected parties as soon as reasonably practical stating the commencement date and extent of such delay or prevention, the cause thereof and its estimated duration; 

 

	 	15.3.2	 use reasonable endeavors to mitigate the effects of such Force Majeure Event, provided that such party shall
not be required to procure materials or services at unreasonable prices or under unreasonable terms; and 

  

	 	15.3.3	 resume performance of its obligations as soon as reasonably practicable. 

 

	15.4	 If a party’s delay or prevention due to the Force Majeure Event in question continues for more than [***]
any party to the affected Scope of Work may give notice in writing to the other(s) to terminate that Scope of Work. The notice to terminate must specify the termination date, which must not be less than [***] after the date on which the notice is
given, and once such notice has been validly given, that Scope of Work will terminate on that termination date. 

  

	16.	 DISPUTE RESOLUTION  

 

	16.1	 Quality Disputes: If there is a dispute in relation to or in connection with the QA Documents,
such dispute shall be dealt with in accordance with the procedures set out in the Quality Agreement. 

  

	16.2	 Business Escalation: 

 

	 	16.2.1	 In respect of any dispute concerning this Agreement (other than a dispute in connection with the QA Documents)
the parties shall seek to resolve the matter as follows: 

  

	 	(a)	 by referral in writing summarizing the nature of the dispute by a party in the first instance to the decision
of each party’s Program Manager; 

  

	 	(b)	 if the dispute is not resolved within [***] of its referral to the Program Managers it shall be referred to the
decision of Fujifilm’s Chief Business Officer and the Customer’s Chief Executive Officer; and 

  
 33 

	 	(c)	 if the dispute is not resolved within [***] of its referral to Fujifilm’s Chief Business Officer and the
Customer’s Chief Executive Officer it shall be referred to the decision of each party’s President or Chief Executive Officer (as applicable/appropriate). 

 

	16.3	 Arbitration: 

 

	 	16.3.1	 Any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination,
enforcement, interpretation or validity thereof (including all issues or disputes regarding the existence, validity, scope or applicability of this agreement to arbitrate, the arbitrability of any claims, and the proper parties to the arbitration)
shall be determined by arbitration in New York, New York and the arbitration shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures 

before three arbitrators. Judgment on the Award may be entered in any court having jurisdiction. 

 

	16.4	 General: Notwithstanding the provisions of this clause 16 any party may commence or take
proceedings or seek remedies before the courts or any other competent authority for interim, interlocutory or injunctive remedies in relation to this Agreement. 

17. AUDIT 
  

	17.1	 Quality Audit: 

 

	 	17.1.1	 The Customer may carry out quality audits at the times, and in accordance with the terms, set out in the
Quality Agreement provided that access by the Customer and/or its representatives to records, information and systems shall be on a supervised basis, subject to the Customer complying with security and confidentiality requirements of Fujifilm to
protect information which relates to anything other than the Programs and shall be limited to a maximum of [***] people for [***]. 

  

	 	17.1.2	 Audit access shall not be extended to confidential records which [***]. 

 

	 	17.1.3	 If Fujifilm is in material breach of clause 4.1.3 of this Agreement or if the Customer reasonably believes that
Fujifilm is in material breach of clause 4.1.3 of this Agreement, the Customer may upon giving reasonable written notice to Fujifilm carry out an audit on the same basis as in clauses 17.1.1 and 17.1.2. 

 

	 	17.1.4	 Additional audits (other than those carried out pursuant to clause 17.1.3) may be carried out on the same basis
as in clauses 17.1.1 and 17.1.2 subject to (i) payment of Fujifilm’s costs and expenses and the agreement of a commercial rate; and (ii) the Customer ensuring such audit will not delay or disrupt Fujifilm’s operations at the
Facility. 

  
 34 

	18.	 NOTICES 

  

	18.1	 Subject to clause 18.2 the parties may communicate with each other in any way that is normal in the course of
their business. 

  

	18.2	 Any notice required to be given under clauses 3, 8, 9, 11, 12, 14, 15, 16, 17, 18.2, 19, 20 or 21 shall only be
effective if it is in writing, sent to a party at its address or email address and for the attention of the individual, as set out in Schedule 2 (or such other address, email address or individual as that party may notify the other in accordance
with this clause 18) and is given in accordance with clauses 18.31.1 to 18.5 below. 

  

	18.3	 Where a notice must be given to Fujifilm under clauses 3.2, 14 or 21.2 such notice must be given to FDBK, FDBT,
FDBU and FDBD. 

  

	18.4	 Notice may be given by hand or sent by email, recorded delivery, registered post or airmail and will be deemed
to have been duly served: 

  

	 	18.4.1	 if delivered by hand, at the time and date of delivery; 

 

	 	18.4.2	 if sent by email, at the time and date of sending; 

 

	 	18.4.3	 if sent by recorded delivery or registered post, [***] from the date of posting (such date as evidenced by
postal receipt); and 

  

	 	18.4.4	 if sent by registered airmail, [***] from the date of posting, 

provided that, where in the case of delivery by hand or transmission by email, such delivery or transmission occurs either after 4.00pm on a
Business Day, or on a day other than a Business Day, service will be deemed to occur at 9.00am on the next Business Day. 
  

	18.5	 In proving service of a notice it will be sufficient to prove that delivery was made or that the envelope
containing the notice or document was properly addressed and posted (either by prepaid first class recorded delivery post or by prepaid airmail, as the case may be) or that no failed delivery message was received, as the case may be.

  
 35 

 19. EXPORT/IMPORT CONTROLS AND SANCTIONS COMPLIANCE  

 

	19.1	 The Customer shall at all times during the term of this Agreement comply with applicable Sanctions or
Export/Import Laws and ensure that it has in place appropriate controls and safeguards to prevent any action being taken by it that would amount to or result in a violation of or non-compliance with any
Sanctions or Export/Import Laws. 

  

	19.2	 The Customer shall provide all information that Fujifilm may reasonably require from time to time in order for
Fujifilm to assess and/or manage its compliance with Sanctions and Export/Import Laws (including provision of end-user statements or applicable Authorizations and notifying Fujifilm of any restrictions or
export compliance obligations prior to providing Fujifilm access to controlled information/technology). 

  

	19.3	 The Customer will not directly or indirectly use, sell, dispose of, (re)export, transship or otherwise transfer
any Product, software, technology or Confidential Information: (i) unlawfully to any country in respect of which a Sanctions Authority maintains Sanctions or a Sanctioned Person; (ii) in a manner that would expose Fujifilm to the risk of
negative consequences under Sanctions; or (ii) in violation of Export/Import Laws. 

  

	19.4	 If any Authorization is required so that the performance of a Program does not contravene any Sanctions or
Export/Import Laws, the Customer will at its own cost and expense obtain that Authorization and Fujifilm shall provide any commercially reasonable assistance (including reasonable information) that the Customer may require for the purposes of
obtaining that Authorization. The Customer’s rights and Fujifilm’s obligations under this Agreement or any SoW in relation to that Program shall immediately be suspended if any required Authorization is not obtained. In the event that the
Customer’s rights and Fujifilm’s obligations are suspended for more than [***] calendar days, a Program may be terminated immediately by Fujifilm giving written notice to the Customer. If Fujifilm terminates a Program under this clause
19.4 then the Customer shall pay the Charges that are due for the Fujifilm Services that have been performed during that Program and [***] of the Program Cancellation Fee plus any Charges owed in respect of Ancillary Services. 

  
 36 

	19.5	 The Customer shall Indemnify Fujifilm against any and all Liabilities which Fujifilm incurs as a result of the
Customer’s non-compliance with the terms of this clause 19. 

  

	19.6	 In this clause 19 the following terms have the following meanings: 

 

			
	“Authorization”	  	all consents, licences, authorisations, approvals, permissions, registrations, certificates and clearances and any precondition in any relevant jurisdiction;
		
	“Export/Import Laws”	  	(a) any laws of the United States of America, the United Kingdom, the European Union or of any of its Member States or Japan that relate to the control of (re)export, transfer or import of Products, software or technology and
technical data; or (b) any other (re)export, transfer or import controls or restrictions imposed or adopted by any government, state or regulatory authority in a country in which obligations under this Agreement are to be performed;
		
	“Sanctions”	  	any economic, financial, trade or other sanction, embargo, import or export ban, prohibition on transfer of funds or assets or on performing services or equivalent measure imposed by any Sanctions Authority or by the laws of any
state or any union of states from time to time;

  
 37 

			
		
	“Sanctions Authority”	  	means (a) the Security Council of the United Nations, (b) the Organization for Security and Co-operation in Europe (c) the United Kingdom, (d) the European Union, (e) any
Member State of the European Union, (f) the United States of America, (g) Japan (h) the governments and official institutions or agencies of any of paragraphs (a) to (h) above and (i) any other regulatory body imposing or
enforcing sanctions legislation in any country or territory from which or into which the Customer is exporting or importing; and
		
	“Sanctioned Person”	  	any person who appears on or is owned, operated or controlled by any person who appears on any list issued or maintained by any Sanctions Authority or is referred to in any list or public announcement issued by any Sanctions
Authority, in each case as amended, supplemented or substituted from time to time.

 20. MODERN SLAVERY AND CORRUPTION 
  

	20.1	 Each party shall endeavour to hold itself and its suppliers to the highest performance, ethical and compliance
standards, including basic human rights, not engaging in any activity, practice or conduct which would constitute an offence under anti-slavery legislation in the United Kingdom, the U.S.A or Denmark, encouraging fair and equal treatment for all
persons, the provision of safe and healthy working conditions, respect for the environment, the adoption of appropriate management systems and the conduct of business in an ethical manner. In performing its duties under this Agreement, each party
acknowledges the value and importance of performance and ethical behaviour in its performance under this Agreement. 

  
 38 

	20.2	 Each party warrants that on the Effective Date and each SoW Effective Date, it, its directors, officers or
employees have not offered, promised, given, authorized, solicited or accepted any undue pecuniary or other advantage of any kind (or implied that they will or might do any such thing at any time in the future) in any way connected with this
Agreement or a SoW and that it has taken reasonable measures to prevent subcontractors, agents or other third parties, subject to its control or determining influence, from doing so. 

 

	20.3	 The parties agree that, at all times in connection with and throughout the term of this Agreement, they will
comply with and that they will take reasonable measures to ensure that their subcontractors, agents or other third parties will comply with all applicable anti-corruption legislation including the Bribery Act 2010, the Foreign Corrupt Practices Act
1977 and the Danish Criminal Code. 

  

	20.4	 Each party shall not do, or omit to do, any act that would cause one of the other parties to be in breach of
any anti-corruption legislation including the Bribery Act 2010, the Foreign Corrupt Practices Act 1977 and the Danish Criminal Code. 

  

	21.	 ASSIGNMENT AND SUB-CONTRACTING 

 

	21.1	 A party may assign or transfer all of its rights and responsibilities under this Agreement to:

  

	 	21.1.1	 an Affiliate provided that such Affiliate has reasonable financial creditworthiness; or 

 

	 	21.1.2	 a purchaser of all or substantially all of the equity of the assigning party provided that such third party has
reasonable financial creditworthiness and is not a Competitor; or 

  

	 	21.1.3	 a purchaser of all or substantially all of assets to which this Agreement relates provided that such third
party has reasonable financial creditworthiness and is not a Competitor; or 

  

	 	21.1.4	 an exclusive licensee of the Product provided that such third party has reasonable financial creditworthiness
and is not a Competitor, 

 but not otherwise without written consent of the other parties (such consent not to be
unreasonably withheld or delayed) and provided that (a) the assignee agrees in writing to assume all obligations undertaken by its assignor in this Agreement and (b) in relation to assignment in part no such assignment shall relieve the
assigning party of responsibility for the performance of any of its obligations under this Agreement. 

  
 39 

	21.2	 If a party assigns or transfers all or any of its rights and responsibilities under clause 21.1 it shall
immediately notify the other parties in writing. 

  

	21.3	 Fujifilm may sub-contract all or any of its obligations under this
Agreement provided that in relation to any subcontract manufacture, processing or handling of Product, Fujifilm will obtain the Customer’s written consent (which may be by signature of the relevant SoW(s) which specify that an obligation will
be sub-contracted). 

  

	21.4	 The appointment of any subcontractor shall not relieve the party
sub-contracting from any liability or obligation under this Agreement and the party sub-contracting shall be responsible for all acts and omissions of the subcontractor
to the same extent as if they were its own acts or omissions. 

 22. GENERAL 

 

	22.1	 Entire agreement: This Agreement and the Historic Documents contain all the terms which the parties have
agreed with respect to their subject matter and supersede all previous agreements and understandings between the parties (whether oral or in writing) relating to such subject matter. Each party acknowledges and agrees that it has not been induced to
enter into this Agreement by a statement or promise which it does not contain. Each party confirms that save as otherwise expressly set out in this Agreement and the Historic Documents, the other party gives no warranties either in this Agreement or
elsewhere in connection with the provision of the Programs. Nothing in this clause 22.1 shall exclude or limit a party’s liability for fraud, including fraudulent misrepresentation. 

 

	22.2	 Third party rights: Save as expressly set out in this Agreement, the parties do not intend that any
person who is not a party to this Agreement shall have any right to enjoy the benefit or enforce any of the terms of this Agreement. 

  
 40 

	22.3	 Variations: With the exception of Changes, which shall be subject to clause 13, no variation of this
Agreement shall be valid unless in writing and signed by a duly authorized representative of each of the parties. A party is entitled to assume that a representative of another party is authorized to act on that party’s behalf if that
individual is apparently or seemingly acting in the normal course of the business relationship. An exchange of emails shall not be capable of constituting an agreement to vary this Agreement. 

 

	22.4	 Waiver: No failure or delay by a party to exercise any right or remedy provided under this Agreement or
by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. The single or partial exercise by any party of any right, power or remedy under this
Agreement shall not in any circumstances preclude any other or further exercise of it, or the exercise of any right, power or remedy. A waiver by any party of a breach of any provision of this Agreement shall not be considered as a waiver of a
subsequent breach of the same or any other provision of this Agreement. 

  

	22.5	 Severability: If any provision of this Agreement or a SoW is found by any court or administrative body
of competent jurisdiction to be invalid, illegal or unenforceable in any jurisdiction then it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible that provision shall
be deemed to be omitted from this Agreement or the SoW in so far as this Agreement or that SoW relates to that jurisdiction and the validity and enforceability of that provision in other jurisdictions and the other provisions of this Agreement or
SoW shall not be affected or impaired. 

  

	22.6	 Counterparts: 

 

	 	22.6.1	 This Agreement may be executed in any number of counterparts. Any party may enter into this Agreement by
executing a counterpart and all the counterparts taken together will constitute one and the same agreement. This Agreement shall not be effective until each party has signed one counterpart. 

  
 41 

	 	22.6.2	 Transmission of an executed counterpart of this Agreement (but for the avoidance of doubt not just a signature
page) by email (in PDF, JPEG or other agreed format) shall take effect as delivery of an executed counterpart of this Agreement. 

  

	22.7	 Publicity: The parties anticipate that there may be opportunities for joint or independent press
releases or other announcements relating to the activities contemplated hereby. Notwithstanding the foregoing, no party shall use the name of the other party(ies) or the names of the employees of the other party(ies) nor disclose the terms of this
Agreement or any SoW in any press releases, advertising or sales promotional material or in any publication without prior written permission of such party(ies). Such consent shall not be unreasonably withheld. This provision shall not restrict a
party’s ability to use the other parties names and to disclose the terms of this Agreement or a SoW to the extent, in the reasonable opinion of such party’s legal counsel, required by law or by the requirements of any nationally recognized
securities exchange, quotation system or over-the-counter market on which such party has its securities listed or traded. In the event that such disclosure is required
as aforesaid, the disclosing party shall make reasonable efforts to provide the other parties with at least [***] Business Days’ advance notice and to coordinate reasonably with the other parties with respect to the wording and timing of any
such disclosure, subject to the requirements of such securities laws. 

 23. GOVERNING LAW  

 

	23.1	 The formation, existence, construction, performance, validity and all aspects whatsoever of this Agreement
(including any Scopes of Work) or any term of it and any issues, disputes or claims arising out of or in connection with it (whether contractual or non-contractual in nature) shall be governed by, and
construed in accordance with, the laws of the State of Delaware. 

  
 42 

 IN WITNESS of the above the parties have signed this Agreement on the dates set out next to their
signature. 

  
 43 

 Signature Page 

SIGNED for and on behalf of FUJIFILM DIOSYNTH BIOTECHNOLOGIES TEXAS, LLC: 

 

	
	 Signature: /s/ Gerry Farrell
  

Title:
  

Date: February 13, 2021

 SIGNED for and on behalf of FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC: 

 

	
	 Signature: /s/ Andy Fenny
  

Title:
  

Date: February 12, 2021

 SIGNED for and on behalf of FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED: 

 

	
	 Signature: /s/ Paul Found
  

Title:
  

Date: February 22, 2021

  
 44 

 SIGNED for and on behalf of FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS: 

 

	
	 Signature: /s/ Lars Petersen
  

Title:
  

Date: February 24, 2021

 SIGNED for and on behalf of VIGIL NEUROSCIENCE, INC.: 

 

	
	 Signature: /s/ Ivana Magovcevic-Liebisch
  

Title: President & CEO
  

Date: February 11, 2021

  
 45 

 Schedule 1 Charges 

The Customer will pay to Fujifilm the Charges for the Fujifilm Services in accordance with the Scope of Work and clause 8 (the Fujifilm Services being the
services to be performed by Fujifilm that are described in the relevant Scope of Work which are not Ancillary Services). 
 The Customer will also pay
Charges to Fujifilm in consideration of the research and development and technical consultancy services in relation to the procurement, testing and management of Consumables; Subcontracted Work (including delivery of material to and from such
subcontractors); Process-Specific Equipment (including installation and qualification thereof); Modifications; and Special Waste (the “Ancillary Services”) as calculated in accordance with this Schedule 1. 

 

	1.	 Charges for Consumables in Non-Manufacturing Stage and
Manufacturing Stage  

  

	1.1	 At the time set out in the Scope of Work, or in the course of the Program as mutually agreed in writing by the
parties, the Customer shall pay to Fujifilm an amount in advance in consideration of the Ancillary Services relating to the purchase of Consumables intended to be used during the applicable Non-Manufacturing
Stages and Manufacturing Stages. This will be an amount based upon an estimation of the sums required to purchase Consumables based upon Fujifilm’s historical data from previous manufactures at the applicable scale of production plus [***] of
such sums (the “Consumables Advance Payment”). 

  

	1.2	 On completion of each applicable Non-Manufacturing Stage or
Manufacturing Stage, Fujifilm shall calculate the expenditure incurred in respect of Consumables procured for use during such Non-Manufacturing Stage or Manufacturing Stage and shall add a sum equivalent to
[***] of all such expenditure on to such sum, the aggregate amount being referred to as “Actual Production Expenditure”. 

  
 46 

	1.3	 If the Actual Production Expenditure is greater than the Consumables Advance Payment plus any other amounts
paid under paragraph 1.4, Fujifilm shall issue a further invoice for the Ancillary Services in relation to the Consumables for a sum equivalent to the difference on a monthly basis with a [***] markup. If the Actual Production Expenditure is less
than the Consumables Advance Payment, Fujifilm shall issue a credit note against the earlier invoice for a sum equivalent to the difference to be applied to the Charges for the following Stage upon Completion of reconciliation (if there is one), and
if there is not a following Stage, Fujifilm shall promptly refund such amount. 

  

	1.4	 Each month, Fujifilm may issue an invoice to the Customer in relation to the Ancillary Services regarding any
Consumables used during or procured for use in any Stage during the previous month (or if longer, since the last invoice under this paragraph 1.4 was issued) in amounts which are not covered by the Consumables Advance Payment equivalent to the
expenditure on such additional Consumables during the previous month plus an amount equal to [***] of such expenditure. 

  

	1.5	 For the avoidance of doubt, Process-Specific Consumables paid for by Customer shall be used solely for the
Program 

  

	2.	 Additional Charges in Respect of Subcontracted Work, Process-Specific Equipment, Modifications and
Special Waste 

  

	2.1	 Fujifilm shall invoice the Customer for the Ancillary Services relating to the Subcontracted Work,
Process-Specific Equipment, Modifications and disposal of Special Waste as the case may be in the same amount as the expenditure which Fujifilm incurs in respect of such Ancillary Services plus a sum equivalent to [***] of such expenditure.

  

	2.2	 Fujifilm shall issue invoices for such Ancillary Services either at the time Fujifilm incurs expenditure in
respect of the Subcontracted Work, Process-Specific Equipment, Modifications and/or disposal of Special Waste or as set out in the relevant SoW as the case may be. 

  
 47 

	3.	 Purchase of Process-Specific Consumables and Process-Specific Equipment by the Customer on completion of
the relevant Stage or termination 

  

	3.1	 Subject to: 

  

	 	3.1.1	 clause 10.3; 

  

	 	3.1.2	 the manufacturer’s consent and requirements (if applicable) and subject to the Customer’s warranty
that it will purchase a direct license of any relevant firmware/software required to operate the Process-Specific Equipment; 

  

	 	3.1.3	 and the payment of all relevant Charges, 

 

	3.2	 the Customer shall have an option to purchase from Fujifilm such Process-Specific Equipment and/or
Process-Specific Consumables purchased and paid for by Fujifilm under paragraphs 1 and 2 of this Schedule 1 as remain following completion of the relevant Stage for which such Process-Specific Equipment and/or Process-Specific Consumables were
purchased for consideration of [***] payable, if the work is performed in the UK or USA respectively, at the time of such sale. Fujifilm shall, at Customer’s request and in accordance with Clause 7, deliver to Customer Process-Specific
Equipment and/or Process-Specific Consumables previously paid for by Customer under paragraphs 1 and 2. 

  

	3.3	 The option in paragraph 1.1 shall be exercised within [***] following completion of the relevant Stage under
which such Process-Specific Equipment and/or Process-Specific Consumables were purchased or termination of this Agreement (whichever occurs first). 

  

	3.4	 The Customer shall be responsible for any cost and expense associated with removal/delivery of such
Process-Specific Equipment and/or Process-Specific Consumables and documenting such sale. Such Process-Specific Equipment and/or Process-Specific Consumables shall be delivered Ex Works the Facility (Incoterms 2010). Risk in and title to such
Process-Specific Equipment and/or Process-Specific Consumables shall pass on delivery. 

  

	3.5	 Fujifilm shall be free to use or destroy (at the Customer’s cost) any item(s) of Process-Specific
Equipment or Process-Specific Consumables in respect of which the option referred to in this paragraph 3 is not exercised or for which their assigned expiry date has passed. 

 

	4.	 Product Samples, Cell Banks and other materials on completion or termination

  

	4.1	 Prior to completion of each Program, the Customer shall notify Fujifilm what (if any) samples and/or cell banks
used during the Program the Customer wishes Fujifilm to deliver to the Customer and, subject to clause 10.3, delivery of those samples/cell banks shall take place in accordance with clause 7. If the Customer does not give any such notification to
Fujifilm prior to completion of the Program, Fujifilm may destroy such samples and/or cell banks without further notice at the Customer’s cost. 

  
 48 

	4.2	 Fujifilm shall be entitled, in a manner of its choosing and without further notice to the Customer, to dispose
of any Product, samples, cell banks or other property of the Customer which remains in the possession of Fujifilm in excess of [***] following the effective date of termination. 

5. Batch Cancellation Fees 
  

	5.1	 The Batch Cancellation Fee shall be: 

 

	 	5.1.1	 the applicable percentage of the Batch Fee (in each case as detailed in the SoW) set out in the table below,
which will reflect the period of time between: 

  

	 	(a)	 notice of cancellation of such Batch(es); and 

 

	 	(b)	 the then current date for commencement of the relevant Stage; 

 

	 	5.1.2	 less any sums already received under the SoW for the Fujifilm Services in relation to the cancelled Batch(es)
that have not been performed at the time the Batch Cancellation Fee is calculated. 

  

	5.2	 Percentage of Batch Fee payable: 

 

			
	 Period prior to Commencement of Stage
	  	 Percentage of Batch Fee

	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

 [***] 

  
 49 

	6.	 Program Cancellation Fees 

 

	6.1	 The Program Cancellation Fee shall be: 

 

	 	6.1.1	 the applicable percentage of the total price of the remaining part of the Program (detailed in the SoW(s)) that
is being cancelled set out in the table below, which will reflect the period of time between: 

  

	 	(a)	 notice of cancellation of the Program; and 

 

	 	(b)	 the then current date for commencement of the Manufacturing Stage(s) 

 

	 	6.1.2	 less any sums already received under the SoW(s) for the Fujifilm Services in relation to the cancelled element
of the Program that have not been performed at the time the program Cancellation Fee is calculated. 

  

	6.2	 Percentage of total price of the Program payable: 

 

			
	 Period prior to Commencement of the Manufacturing
Stage(s)
	  	 Percentage of remaining total Program price

	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

  

	6.3	 [***]For the avoidance of doubt the Customer will not be expected to pay both Batch Cancellation Fees and
Program Cancellation Fees and the Program Cancellation Fee for Non-Manufacturing Program are the fees described in clause 14.3.1. 

  
 50 

 Schedule 2 Addresses for Notice 

 

			
	 FDBK:
 Contact: Chief Operating
Officer
  
 Address: Fujifilm Diosynth Biotechnologies, Belasis Avenue, Billingham, TS23
1LH, England
  
 Nominated email address: [***]
	  	 Copied to:
  

Contact: Legal Counsel
  

Address: Fujifilm Diosynth Biotechnologies, Belasis Avenue, Billingham, TS23 1LH, England

 
 Nominated email address: [***]

		
	 FDBT:
  

Contact: Chief Operating Officer
  

Address: FUJIFILM Diosynth Biotechnologies Texas, LLC, 3939 Biomedical Way, College Station, TX 77845

 
 Nominated email address: [***]
	  	 Copied to:
  

Contact: Legal Department
  

Address: FUJIFILM Holdings America Corporation, 200 Summit Lake Drive, Valhalla, NY 10595.

 
 Nominated email address: [***]

		
	 FDBU:
  

Contact: Chief Operating Officer
  

Address: FUJIFILM Diosynth Biotechnologies U.S.A., Inc., 101 J. Morris Commons Lane, Morrisville, NC 27560

 
 Nominated email address: [***]
	  	 Copied to:
  

Contact: Legal Department
  

Address: FUJIFILM Holdings America Corporation, 200 Summit Lake Drive, Valhalla, NY 10595.

 
 Nominated email address: [***]

		
	 FDBD:
  

Contact: [***]
  

Address: Biotek Alle 1, 3400 Hillerød, Denmark
  

Nominated email address: [***]
	  	 Copied to:
  

Contact: Legal Counsel
  

Address: FUJIFILM Diosynth Biotechnologies, Belasis Avenue, Billingham, TS23 1LH, England

 
 Nominated email address: [***]

		
	 Customer: Vigil Neuroscience, Inc.
  

Contact: [***]
  

Address: 300 Technology Square, 8th floor, Cambridge MA 02139

 
 Nominated email address: [***]
	  	 Copied to:
  

Contact: [***]
  

Address: 300 Technology Square, 8th floor, Cambridge MA 02139

 
 Nominated email address: [***]

  
 51

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]